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ABSTRACT 
Cyclooxygenase (COX) can metabolize dihomo-γ-linolenic acid (DGLA) and 
arachidonic acid (AA) through free radical-mediated lipid peroxidation to form the anti-
carcinogenic 1-series of prostaglandins and pro-carcinogenic 2-series of prostaglandins, 
respectively. Our previous studies had demonstrated that in ovine COX-mediated DGLA and AA 
peroxidation, there are common and exclusive free radicals formed through different free radical 
reactions. However, it was still unclear whether the differences are associated with the 
contrasting bioactivity of DGLA vs. AA. In order to investigate the possible association between 
cancer cell growth and the exclusive free radicals generated from COX/DGLA vs. COX/AA, we 
refined our combined spin-trapping/LC/MS method with solid phase extraction to characterize 
free radicals in their reduced forms in the human colon cancer cell line HCA-7 colony 29, which 
has a high COX-2 expression. For the first time, we were able to profile free radical formation in 
the experimental settings in which cell proliferation (via MTS assay) and cell cycle distribution 
(via PI staining) could be assessed. Our results showed that DGLA- and AA-derived exclusive 
free radicals, rather than prostaglandins, were closely associated with the opposing bioactivities 
of DGLA vs. AA. 
Due to rapid conversion from DGLA to AA via Δ-5 desaturase (D5D), the anti-
proliferative effect of DGLA on cancer cell growth was limited. Thus, double doses of DGLA 
and D5D inhibitor were introduced. Among DGLA, double-dose DGLA, and combined 
DGLA/D5D inhibitor treatments, the latter exerted the most anti-proliferative effect on cancer 
cell growth and caused significant cell G2/M arrest. D5D knockdown cells (via siRNA 
transfection) were used to further investigate the possible mechanism underlying the anti-
proliferative effect of DGLA on cancer cell growth. In addition, the combined DGLA/D5D 
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inhibitor treatment increased the susceptibility of cancer cells to the chemotherapy drug 5-
fluorouracil. In D5D knockdown cells, DGLA and 5-fluorouracil exerted greater effects on cell 
growth inhibition and cytotoxicity due to synergism. 
In summary, increasing DGLA and concurrently decreasing AA in cells could be a novel 
approach to controlling the development of AA-dependent cancer. Our study allowed us to 
directly study the free radical-associated PUFA bioactivity, thus improving our understanding of 
COX-catalyzed lipid peroxidation in cancer biology. 
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CHAPTER 1. INTRODUCTION 
1.1. Polyunsaturated Fatty Acids, Eicosanoids and Inflammation-Related Diseases 
1.1.1. Metabolism of dietary polyunsaturated fatty acids 
Fatty acids that contain more than one double bond in their carbon atom chain are 
referred to as polyunsaturated fatty acids (PUFAs) [1-5]. The nutritionally important PUFAs are 
classified as ω-6 and ω-3 on the basis of the position of the first double bond counting from the 
methyl end of the molecule [1-5]. For example, dihomo-γ-linolenic acid (20:3, ω-6) has twenty 
carbon atoms and three double bonds, with the first double bond at the sixth carbon atom 
counted from the methyl end of the acyl chain. ω-6 PUFAs include linoleic acid (LA, 18:2), γ-
linolenic acid (GLA, 18:3), dihomo-γ-linolenic acid (DGLA, 20:3), and arachidonic acid (AA, 
20:4), and ω-3 PUFAs include α-linolenic acid (ALA, 18:3), eicosapentaenoic acid (EPA, 20:5), 
and docosahexenoic acid (DHA, 22:6) [1-5]. 
Plant seed oils are frequently rich in PUFAs. Sunflower, safflower, corn and soybean oil 
all contain high amounts of LA [3-5]. Evening primrose oil, borage oil, black currant oil, and 
hemp seed oil contain substantial amounts of GLA [6, 7]. Although meat and egg yolks are direct 
dietary sources of AA [8], dietary LA is considered to be the main source of tissue AA [9]. 
Canola oil, perilla oil, flaxseed oil, linseed oils and walnuts contain abundant ALA [6]. EPA and 
DHA are mostly found in oil from deep, cold water fatty fish [10, 11]. In the absence of fish oil, 
ALA is the principle source of dietary ω-3 PUFAs [12]. 
LA and ALA are considered to be essential fatty acids, which must be obtained from the 
diet because mammals lack the ability to introduce double bonds into fatty acids beyond carbons 
9 and 10 counted from the carboxyl end [3-5]. LA is the precursor of the ω-6 PUFAs and ALA is 
the precursor of the ω-3 PUFAs. Once consumed, LA and ALA can be metabolized to their 
2 
down-stream PUFAs by the combined action of desaturation and elongation enzymes [2]. 
Desaturation enzymes introduce a new double bond in the carbon atom chain and elongation 
enzymes introduce two new carbon atoms. LA (18:2) is converted into GLA (18:3) by Δ-6 
desaturase (D6D), followed by a two carbon atom chain elongation through a fatty acid elongase, 
elongation of very long chain fatty acid protein 5 (ELOVL5), to form DGLA (20:3) and finally 
undergoing desaturation by Δ-5 desaturase (D5D) to generate AA (20:4). Using the same series 
of enzymes as those used to metabolize ω-6 PUFAs, ALA is converted into EPA (20:5). Further 
conversion of EPA into DHA (22:6) involves two elongation steps to form docosapentaenoic 
acid (22:5) and tetracosapentaenoic acid (24:5), respectively; then desaturation to form 
tetracosahexaenoic acid (24:6) and removal of two carbons by β-oxidation to yield DHA [3] 
(Scheme 1). Among the series of elongation and desaturation steps in the metabolism of ω-6 and 
ω-3 PUFAs, D6D and D5D control the rate-limiting steps [13]. D6D and D5D are expressed in 
the majority of human tissues, with the highest levels being found in the liver, brain and heart 
[14]. 
PUFAs are important constituents of all cell membranes. PUFA esterified in the cell 
membrane’s phospholipid is released by the action of several phospholipase enzymes 
(predominantly Phospholipases A2, PLA2). The fatty acids released by this hydrolysis 
subsequently undergo enzymatic or non-enzymatic lipid peroxidation to form various lipid 
mediators (Scheme 2). Cyclooxygenase (COX), lipoxygenase (LOX) and the cytochrome P450s 
(CYP450) are three major enzymes which could metabolize PUFA to prostaglandins (PGs), 
thromboxanes (TXs), leukotrienes (LTs), monohydroxy fatty acids and epoxy fatty acids[15, 16]. 
Isoprostanes, isoleukotrienes, and other peroxidized fatty acid products are formed non-
enzymatically [16]. 
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Scheme 1. The structure and metabolism of ω-6 and ω-3 PUFAs. 
The number before the colon denotes the number of carbon atoms and the number following 
refers to the number of double bonds. The omega (ω) designation is used to describe the position 
of a double bond from the methyl end. The delta (Δ) nomenclature is used to assign the position 
of an individual double bond counting from the carboxyl group carbon. 
The lipid mediators derived from 20-carbon PUFAs are collectively known as 
eicosanoids (Greek eicosa = 20). AA is the main eicosanoid precursor in cells [9]. AA-derived 
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eicosanoids include the 2-series of PGs, the 2-series of TXs formed by COX; the 4-series of TXs, 
15- and 12-hydroxyeicosatetraenoic acids (HETEs) formed by LOX; and the epoxy 
eicosatrienoic acids (EETs) and 20-HETE formed by CYP450 [15]. DGLA and EPA are also the 
substrates for COXs (constitutive isoform COX-1 and inducible isoform COX-2) and various 
LOXs (5-LOX, 12-LOX, and 15-LOX). DGLA is the precursor of the 1-series of PGs, the 1-
series of TXs and 15-hydroxyeicosatrienoic acid (15-HETrE) [17]. EPA is the precursor of the 3-
series of PGs, the 3-series of TXs and the 5-series of LTs [18]. Those eicosanoids are 
synthesized de novo as required and act in an autocrine or paracrine manner on target cells [19]. 
The compositions of dietary PUFAs vary among countries. The typical western diet is 
considered to be a high fat, high energy diet but with low fiber intake [20, 21]. As a consequence 
of the increased intake of LA-enriched vegetable oils in the Western diet [22, 23], the ratio ω-
6:ω-3 in the Western diet is around 10:1 to 20:1, while the recommended ratio is 1:1 to 4:1 [24-
26]. Over the last few decades, epidemiological studies have suggested that the increased dietary 
intake of ω-6 PUFAs is associated with an increase in the incidence of diseases involving 
inflammatory processes such as cardiovascular diseases, rheumatoid arthritis, inflammatory 
bowel diseases, and cancer [2, 20, 27, 28]. On the other hand, dietary intakes of ω-3 PUFAs 
could ameliorate the symptoms of chronic inflammation and decrease cancer incidence [2, 11, 29, 
30]. Eskimos and Japanese fisherman who have a high consumption of ω-3 PUFAs from fish and 
marine mammals have low rates of breast and colon cancers [23, 31]. Interestingly, some studies 
showed that DGLA may be an exceptional ω-6 PUFA which actually possesses anti-
inflammatory and anti-cancer activities [32-34]. 
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1.1.2. AA-derived eicosanoids and inflammation related diseases 
As a result of the high intake of ω-6 PUFAs in Western diets, AA is the predominant 
PUFA in most cell membranes. AA is the precursor of the 2-series of PGs, the 2-series of TXs, 
and the 4 series of LTs. In general, the actions of eicosanoids derived from AA are more pro-
inflammatory. Chronic inflammation is believed to be associated with an increase in cancer 
incidence. One of the strongest associations between chronic inflammation and cancer is the 
increased risk of colon cancer in individuals with inflammatory bowel diseases [35, 36]. 
Inflammation also plays an important role in the development of other cancers, e.g. prostate, 
bladder, pancreatic, and breast cancers [37-39]. Inflammation in the tumor microenvironment is 
now recognized as one of the hallmarks of cancer. Chronic inflammation causes the up-
regulation of a number of pro-inflammatory cytokines including interleukin (IL)-1, IL-6 and 
tumor necrosis factor (TNF)-α. Nuclear factor kappa B (NFκB) is a transcriptional factor which 
has a variety of pro-tumorigenic activities. The pro-inflammatory cytokine-induced activation of 
NFκB leads to increased cell proliferation, stimulation of angiogenesis, and resistance to 
apoptosis [40, 41]. NFκB is the key mediator of inflammation-induced carcinogenesis and 
evidence directly links the NFκB pathway to increased tumor formation and inflammation in 
experimental mouse models of intestinal cancer [42, 43]. Because NFκB regulates COX-2 
expression at the transcriptional level, COX-2 expression is increased, and higher levels of 
inflammatory PGE2 are formed [44-46]. Thus, inflammation and enhanced metabolism of AA by 
COX-2 are linked to the increased risk of cancer. Higher PG levels, mainly PGE2, are observed 
in various tumors [47, 48]. In addition to regulation by COX, the PGE2 level is also determined 
by 15-prostaglandin dehydrogenase (15-PGDH), a prostaglandin degradation enzyme. 15-PGDH 
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oxidizes the active PGE2 into biologically inactive 15-keto PGE2. The expression of 15-PGDH 
was reduced in many tumors, which also contributes to the increase of PGE2 [49-51]. 
The biological effect of PGs is mediated by a family of G-protein coupled receptors, 
designated EP for PGE2 receptors, FP for PGF2α receptors, TP for the thromboxane receptor, and 
IP for PGI2 receptors [52]. Some PGs are also ligands for nuclear receptors such as peroxisome 
proliferator-activated receptors (PPARs). For example, PGI2 is a natural ligand for PPAR δ [53]. 
Due to the high concentrations of PGE2 in tumors, EP receptors have been extensively studied 
[52]. Four subtypes of EP receptors have been identified, designated as EP1, EP2, EP3, and EP4 
[52, 54-57]. The signaling pathways of the EP receptor subtypes are significantly different. The 
EP1 receptor couples to phospholipase C/inositol triphosphate via a Gq-protein, leading to 
increased intracellular calcium concentration. The EP2 and EP4 receptors couple to adenylate 
cyclase (AC) via a Gs-protein, resulting in increases in intracellular levels of cyclic 3’, 5’-
adenosine monophosphate (cAMP). The EP4 receptor couples to a Gi protein, leading to the 
reduction of intracellular cAMP [54]. Both EP2 and EP4 expression are up-regulated in 
azoxymethane-induced colorectal cancer tissue compared with adjacent normal mucosa [55]. 
The mRNA levels of the EP2 and EP4 receptors also increased in APCΔ716 mouse small 
intestinal and colonic polyps [56]. Activation of EP2 and EP4 receptors via PGE2 has been 
linked to cell proliferation, invasion, apoptosis, and angiogenesis [57]. Signaling through EP2 
leads to GSK-3 phosphorylation via a protein kinase A (PKA)-dependent mechanism, while the 
activation of EP4 also leads to GSK-3 phosphorylation, but via a phosphatidylinositol 3-kinase-
dependent pathway [58, 59]. PGE2 can also transactivate the epidermal growth factor receptor 
(EGFR) [60] and the PPAR δ receptor [61]. 
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Numerous epidemiological, clinical, and animal and cell culture studies have documented 
that the use of COX inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) is effective at 
decreasing the incidence and mortality of colorectal cancer [62, 63]. Apart from colorectal 
cancer, NSAIDs have also been associated with a reduced risk of many other cancers, for 
example, breast, stomach, bladder, ovary, and lung cancers [48, 64, 65]. Despite the efficacy of 
NSAIDs as chemopreventive agents, the precise molecular mechanisms underlying the 
protective effects of NSAIDs are not well understood. One possible mechanism for their anti-
cancer properties has been attributed to the altered metabolism of AA. Inhibition of COX leads 
to the reduced conversion from AA to the pro-inflammatory prostaglandins. 
1.1.3. DGLA-derived eicosanoids and inflammation related diseases 
Increasing evidence suggests that DGLA might be an exception among the ω-6 PUFA 
family members in its potential ability to suppress tumor growth and metastasis [66-68]. DGLA 
is shown to inhibit the motility and invasiveness of human colon cancer cells via increasing the 
expression of E-cadherin, a cell-to-cell adhesion molecule which suppress metastasis [66, 67]. In 
addition, DGLA reduces tumor-endothelium adhesion, a key factor in the establishment of 
distant metastases, partly by improving gap junction communication within the endothelium [66, 
68]. 
Because DGLA and AA are competing for the lipid-peroxidizing enzymes such as COX 
and LOX, an increase in DGLA relative to AA is able to attenuate the biosynthesis of AA-
derived eicosanoids, e.g. the 2-series of PGs and the 4-series of LTs, and exert an anti-
inflammatory effect [69]. Depending on the cell type, DGLA is converted to members of the 1-
series of PGs (mainly PGE1) and/or 15-HETrE [27]. These two DGLA-derived eicosanoids have 
shown clinical efficacy in a variety of diseases, including suppression of chronic inflammation, 
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vasodilation and lowering of blood pressure, inhibition of smooth muscle cell proliferation 
associated with atherosclerotic plaque development, inhibition of cancer cell growth and the 
differentiation of tumor cells [70-73]. 
In comparison with PGE2, PGE1 may possess distinct anti-inflammatory and anti-
proliferation action. GLA and DGLA supplementation studies conducted in humans and mouse 
models have shown that the synthesis of 1-series PGs, rather than the 2-series PGs, is selectively 
elevated by either GLA or DGLA [17, 74]. Although the increases in the tissue levels of PGE1 
after DGLA supplementation are modest relative to those of PGE2, effects are noteworthy 
because select biological properties of PGE1 are about 20 times stronger than those of PGE2 [75]. 
In particular, PGE1 triggers a series of intracellular responses by binding to select EP receptors 
and/or the IP receptor [76]. The EP2 and EP4 receptors couple to adenylate cyclase via a Gs-
protein, and receptor activation results in increases in intracellular levels of cAMP. Elevation of 
cAMP stimulates the expression of numerous genes through the PKA-mediated phosphorylation 
of the nuclear cAMP response element binding proteins (CREB). Through this mechanism, PGE1 
has been shown to inhibit vascular smooth muscle cell proliferation in vitro [32, 77], reducing 
the migration and proliferation of vascular SMC which, in turn, arrests the formation of typical 
atherosclerotic plaque [78, 79]. Whether PGE1 and PGE2 act on the same or different receptors 
was still not clear. Some studies demonstrate that PGE1 could compete with PGE2 through 
binding to the same receptors, EP2 and EP4 [80-82]. 
Several diseases may benefit from GLA or DGLA administration [17, 83]. It is reported 
that GLA and DGLA suppress human synovial cell proliferation by increasing PGE1 synthesis 
and intracellular cAMP levels [84]. In addition, administration of GLA or DGLA is capable of 
suppressing human T-cell proliferation [83, 85]. Recent studies demonstrated that DGLA 
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produced by GLA feeding decreased the Th2 cytokine and immunoglobulin G1 antibody 
responses. GLA and DGLA was also able to induce T-regulatory cell activity, e.g., transforming 
growth factor (TGF)-beta-producing T cells, and was able to reduce proinflammatory IL-1 and 
TNF-α production [86], indicating that the immunity mechanism is likely to participate in the 
anti-tumor effect. 
However, the mechanism of DGLA-mediated effects has not been fully elucidated. It is 
worth noticed that in both in vivo and in vitro studies, the cellular content of AA, even after 
significant enrichment with DGLA, was still 2.5 ± 3.0-fold higher than DGLA, mainly due to the 
effective desaturation of DGLA to AA by D5D [74, 87, 88]. For example, dietary 
supplementation of GLA or DGLA as ethyl esters or triglycerides leads to only a small increase 
in GLA or DGLA content in cell membrane lipids, often accompanied by a very significant 
increase in AA content. Moreover, the cellular ratio of PGE1/PGE2 in animals fed with GLA-
enriched oils was shown to be substantially lower than the ratio of DGLA/AA [17, 74]. Similarly, 
in mouse fibrosarcoma cells treated with exogenous DGLA, the ratio of PGE1/PGE2 was 
considerably smaller than the cellular ratio of DGLA/AA [87, 89]. 
Therefore, an effective solution to accumulate DGLA is inhibiting the further conversion 
from DGLA to AA by D5D inhibitors. Sesame, curcumin and CP-24879 (a mixed D5D/D6D 
inhibitor) (Scheme 3) have been verified to exert anti-proliferative or anti-cancer effects via their 
ability to enhance the concentration of DGLA [74, 88, 90, 91]. The addition of GLA or DGLA 
together with CP-24879 inhibited D5D activity and blocked the biosynthesis of AA from DGLA. 
This led to a very substantial increase in the accumulation of DGLA from 2.3% to almost 12% of 
total fatty acids without a change in the level of AA in cells [74]. In addition, because addition of 
DGLA bypasses a rate-limiting enzymatic step (D6D desaturation) that controls the metabolism 
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of ω-6 PUFAs, it may generate a systemic decline in Δ6 desaturation. A reduced capacity to 
convert LA to DGLA has been associated with various physiological and pathophysiological 
states, including diabetes, atopic dermatitis, rheumatoid arthritis, cardiovascular disease and 
cancer [17, 33, 92]. Therefore, supplementation of DGLA with inhibitors of D5D may be 
valuable in alleviating some of the symptoms of these diseases. The biosynthesis of DGLA-
derived eicosanoids is dependent primarily on the abundance of free DGLA, so increasing the 
administration of DGLA and/or targeting the D5D may be a good strategy to treat some 
inflammation diseases. 
 
Scheme 3. Structure of tested D5D inhibitors. 
The typical Western diet enriched in ω-6 PUFAs has been suggested to be associated 
with an increased risk of cancer and other inflammation-related diseases. However, DGLA might 
be an exceptional ω-6 which may have anti-cancer and anti-inflammatory effects. As the most 
abundant ω-6 PUFA in mammalian cells, AA is metabolized to the pro-carcinogenic and pro-
inflammatory 2-series of PGs through COX. DGLA, the upstream fatty acid of AA, is also a 
substrate of COX and is converted to the anti-carcinogenic and anti-inflammatory 1-series of 
PGs. The PUFA-derived eicosanoids such as the PGs have been extensively studied. However, 
eicosanoids are not the only metabolites generated from COX-catalyzed PUFA peroxidation. 
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Many other lipid mediators have been discovered, such as the PUFA-derived free radical 
metabolites and the degradation end products. 
1.2. Lipid Peroxidation and Lipid Mediators in Inflammatory Diseases 
PUFAs with methylene-interrupted double bonds are highly susceptible to oxidative 
decomposition, or what is commonly known as lipid peroxidation. LOX and COX are two lipid-
peroxidizing enzymes that metabolize dietary and membrane lipids (PUFAs) through a series of 
free radical reactions [93-95]. The lipid metabolites generated from both LOX- and COX-
catalyzed peroxidation of PUFAs, such as LA (18:2, ω-6), AA (20:4, ω-6), EPA (20:5, ω-3), and 
DHA (22:6, ω-3), have been of great interest due to their potent and diverse biological activities. 
Lipid peroxidation and PUFA metabolites are implicated in tumor growth, angiogenesis, and 
metastasis by the change in expression of various LOXs (5-LOX, 12-LOX, and 15-LOX) and 
COX-2 (inducible COX isoform) in a variety of cancers [96-99]. 
COX-/LOX-catalyzed PUFA peroxidation is a well-known free radical chain reaction 
consisting of three major steps-initiation (reaction 1), propagation (reactions 2-3), and 
termination (reactions 4-5): 
L-H + X● → L● + XH         (Reaction 1) 
L● + O2 → LOO●          (Reaction 2) 
LOO● + LH→ LOOH + L●         (Reaction 3) 
L● + L● → non-radical products        (Reaction 4) 
L● + LOO●→ non-radical products        (Reaction 5) 
Here L-H represents a lipid molecule, e.g. PUFA; L● represents a carbon-centered lipid 
(PUFA) radical, and X● represents radicals from oxidants, e.g. hydroxyl radical, ferryl and 
perferryl species, and oxidative species in activated COX/LOX enzymes. The weakest carbon-
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hydrogen bonds, at the bis-allylic methylene position of PUFAs, are typically vulnerable to 
oxidation since they have a much lower dissociation energy (~75 kcal/mol) than that of a typical 
alkyl C-H bond (101 kcal/mol [100, 101]). During propagation (reactions 2-3), peroxyl radical 
(LOO●, propagator) forms from the reaction of L● with oxygen, and further attacks another lipid 
or PUFA molecule. Peroxyl radical can also be converted into other types of free radicals 
through H-abstraction, Fe2+-mediated Fenton-type reactions, and β-scission (Scheme 4) [2, 93, 
102]. 
 
Scheme 4. An overview of free radical reactions in LA peroxidation. 
Adapted from Qian et al. [102]. 
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Apart from eicosanoids, lipid peroxidation products are the most investigated bioactive 
molecules of PUFA metabolism. Through lipid peroxidation, many highly reactive lipid radicals 
are produced and degraded to a series of lipid peroxidation end products including 
malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE) [103-105]. These end products of 
lipid peroxidation participate in the signal transduction cascade and in control of cell 
proliferation and differentiation, as well as in apoptosis pathways [106-108]. 
MDA is the most mutagenic degradation product of PUFA peroxidation. Dietary intake 
of PUFAs increases intestinal MDA production in vivo [109]. MDA then reacts with the guanine 
in DNA to form a cyclic pyrimido [1,2α] purin-10(3H)-one (M1dG) adduct, which is the major 
MDA-DNA adduct detected in human and rodent tissues. If the DNA repair system does not 
replace the M1dG with a normal DNA base, cells will undergo apoptosis, or genetic mutation 
will be induced. M1dG genetic mutation is one of the possible reasons for the carcinogenic 
features of MDA. MDA together with 4-HNE also forms adducts with elongation factor two in 
ribosomes, consequently disturbing or reducing protein synthesis, which has often been observed 
during ageing and cancer development [110]. 
The MDA level is significantly elevated in colitis, an inflammatory and preneoplastic 
state of colorectal cancer, and antioxidants decrease the MDA concentration in animal models 
and ameliorate the severity of colitis [111]. Increased plasma or urine MDA concentration has 
also been observed in many other cancers, such as skin, breast and also colorectal cancer [112]. 
In patients with advanced colorectal cancer, the serum MDA concentration is much higher than 
in those with primary colorectal cancer [113]. Surinenaite et al. [114] found that the serum MDA 
level was more elevated in stage III than stage II colorectal cancer patients. After the tumor 
tissue was removed by surgery, the serum MDA level was significantly decreased [115]. These 
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observations suggest a close correlation between MDA and colorectal cancer carcinogenesis and 
progression, and MDA is thus a potential biomarker for clinical prognosis and use as an index of 
surveillance of treatment effects. On the other hand, increased levels of reactive oxygen species 
and MDA lead to mitochondrial dysfunction. This cytotoxic effect may be attributed to the 
inhibitory effect of PUFAs in colorectal cancer cell growth [116]. 
Recently, increasing evidence from animal and in vitro studies suggests that unlike the 
other ω-6 PUFAs and their lipid mediators, which generally possess pro-inflammatory and pro-
cancer activity, DGLA might inhibit carcinogenesis [70]. A supplement of DGLA significantly 
increased the formation of free radicals and lipid peroxides in tumor cells and induced apoptosis 
[117, 118], suggesting that DGLA-derived free radicals and lipid peroxides may be responsible 
for its anti-tumorigenic effect by influencing apoptosis and genes/oncogenes that regulate the 
apoptotic process [117]. Previous studies have shown that under certain conditions some PUFAs 
were able to induce apoptosis of tumor cells with little or no cytotoxic action on normal cells 
[117, 119, 120]. It was observed that among all the tested fatty acids, DGLA was the most 
effective in selectively killing tumor cells [117]. These results suggested that DGLA shows 
selective tumoricidal action in vitro. Through suppressing the expression of oncogenes Her-2/neu 
and Bcl-2 and enhancing p53 activity, DGLA could induce apoptosis of tumor cells [119, 121-
123]. Further study found that the COX inhibitor and anti-oxidants had opposite effects on the 
anti-tumorigenic action of DGLA. It was found that COX inhibitors blocked the tumoricidal 
action of DGLA on human cervical carcinoma, whereas anti-oxidants inhibited the cytotoxic 
action of DGLA on human breast cancer cells [124-126]. These results suggested that the COX 
metabolism of DGLA may play a role in the anti-cancer effect of DGLA. 
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In some cancer cells, GLA or DGLA led to only a partial inhibition of cancer cell growth 
in the presence of a COX inhibitor, which indicates that PGE1, the COX product of DGLA, 
cannot completely account for its anti-tumor effect [17, 33, 74]. Recent research revealed that 
free radicals and lipid peroxidation are related to the cytotoxicity of PUFAs on cancer cells, 
which could be completely arrested by anti-oxidants such as vitamin E and superoxide 
dismutase. On the other hand, it has been reported that vitamin E only partially arrests the growth 
inhibition of cancer cells mediated by PUFAs [122, 127]. The different experimental results may 
be because of the use of various cell lines. Another reason is that almost all the cytotoxic effects 
against cancer cells depend on the concentration of the metabolic products from PUFAs. 
Therefore, it is possible that DGLA exerts its anti-tumor cytotoxic effects via a combination of 
the free radicals, lipid peroxidation and the non-radical metabolites, which probably inhibit cell 
proliferation, promote apoptosis and even make cancer cells differentiate and mature. 
Through a series of free radical reactions, various bioactive lipid mediators were 
generated from COX-catalyzed PUFA peroxidation, among which the role of the free radical 
metabolites in inflammatory diseases was still not clear. AA and DGLA are both substrates of 
COX. Due to the differences in their structures and the substrate-enzyme conformations in the 
active site, COX may catalyze AA and DGLA’s peroxidation through different free radical 
reactions, thus resulting in different free radical metabolites [171, 173]. 
1.3. The Catalytic Mechanism of COX 
COX (also referred as prostaglandin endoperoxide H) is a lipid peroxidizing enzyme that 
catalyzes the committed step in prostaglandin biosynthesis. There are two COX isoforms: COX-
1 and COX-2 [128]. COX-1 is constitutively expressed in most mammalian tissues. The 
prostaglandins produced by COX-1 in response to hormone stimulation play a housekeeping role 
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in normal physiological processes, including the regulation of renal water and sodium 
metabolism, stomach acid secretion, parturition, and hemostasis [19, 129]. COX-2 is induced by 
various cytokines, growth factors, inflammation mediators and tumor promoters, and is involved 
in cell replication and differentiation [19]. COX-1 and COX-2 are therapeutic targets for 
NSAIDs, including aspirin, ibuprofen, and the specific COX-2 inhibitors [48, 130-132]. NSAIDs 
inhibit the production of lipid metabolites through COX, reduce inflammation, fever, and pain, 
and lower the risk of mortality from cardiovascular disease and various cancers [48, 130-133]. 
COX converts fatty acids, e.g. DGLA and AA, to PGH in two reactions: 1) its 
prostaglandin H synthase activity (the cyclooxygenase activity) incorporates two oxygen 
molecules into DGLA and AA to generate PGG and 2) its peroxidase activity, generally coupled 
with a reducing agent, reduces PGG to form PGH, which can be further converted to a second 
series of PGs (PGD, PGE, and PGF) (Scheme 5). 
Scheme 5. COX-catalyzed DGLA and AA peroxidation. 
DGLA is converted to AA via D5D. 
These two reactions occur at distinct but structurally and functionally interconnected sites. 
The cyclooxygenase catalysis requires the enzyme to be activated first, a process which is 
peroxide-dependent [134-136]. In contrast, the peroxidase activity is independent of the 
cyclooxygenase [134-136]. At the cyclooxygenase site, the reaction begins with abstraction of 
the 13-pro-S-hydrogen from AA by a tyrosyl radical positioned on Tyr-385; this step is the rate-
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determining step and generates an AA radical [3, 134]. The tyrosyl radical is formed due to 
oxidation of the heme group at the peroxidase site of the enzyme [134]. 
Although there are some subtle kinetic differences between COX-1 and COX-2 in terms 
of hydroperoxide activator requirements and substrate and inhibitor specificities [137, 138], the 
two isoforms are closely related structurally and mechanistically. Both isoforms are signal 
peptides with different lengths. COX-1 contains 576 amino acids and COX-2 contains 587 amino 
acids [134, 135, 137, 138]. COX-1 and COX-2, which are encoded by separated genes, showed a 
60%-65% sequence identity in the same species, and individual isoforms from different species 
showed an 85%-90% sequence identity. The crystal structures of COX isoforms are structurally 
homologous and superimposable[134, 135, 137, 138]. Each monomer consists of three domains: 
an epidermal growth factor (EGF) domain of about 50 amino acids in length at the N terminus, a 
neighboring membrane binding domain (MBD) of about 50 amino acids in length, and a large C-
terminal globular catalytic domain of about 460 amino acids in length. The EGF domain is 
essential for folding [134, 135, 137, 138]. The MBDs of COX contain four amphipathic helices, 
the last of which merges into the catalytic domain [134, 135, 137, 138]. These helices surround 
an opening into the COX active site through which fatty acid substrates and NSAIDs are 
believed to enter[134, 135, 137, 138]. The globular catalytic domain has a hydrophobic channel 
protruding into the core of this domain [134, 135, 137, 138]. 
Both COX-1 and COX-2 are located on the lumenal surfaces of the ER and of the inner 
and outer nuclear membranes [137, 138]. COX-2 appears to be relatively more concentrated 
within the nuclear membrane thus the products formed through COX-2 may have greater access 
to the nucleoplasm to influence nuclear events via nuclear receptors [137, 138]. 
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X-ray crystallographic studies indicate that the COX catalysis occurs in a hydrophobic 
channel which extends from the MBD of the enzyme into the core of the globular domain [139]. 
The fatty acid substrate, such as AA or DGLA, is positioned in this site in an extended L-shaped 
conformation [139, 140]. Crystallographic [139] and mutagenic [141, 142] analyses of the 
interaction of AA within the COX active site assigned active site residues to functional 
categories [141, 142] as follows: (a) Tyr-385 residues directly involved in abstraction of the 13-
pro-S-hydrogen (Tyr-385); (b) residues essential for positioning C-13 for hydrogen abstraction 
(Tyr-348 and Gly-533); (c) residues essential for the high binding affinity of AA (Arg-120); and 
(d) residues critical for positioning AA such that following abstraction of the 13-pro-S-hydrogen 
the AA radical is converted to PGG2 at the cyclooxygenase active site (Val-349, Trp-387, and 
Leu-534). 
Most studies of COX activities have utilized AA as the substrate. Although AA is the 
preferred substrate, both COX isoforms will oxygenate ω-3 and ω-6 C18, C20, and C22 fatty 
acids in vitro with catalytic efficiencies in the range of 0.05–0.7 that of AA [143]. Some of these 
alternative substrates, including DGLA, are also oxygenated via COX activity when added 
exogenously to intact cells [74]. Substrates other than AA typically have higher Km values than 
AA [143] but can compete with AA for the COX active site, thereby inhibiting formation of the 
2-series PGs. 
A mutational and crystallographic analysis of the interaction of DGLA with the COX 
active site identified the active site residues that determine COX fatty acid substrate specificity 
[140]. DGLA binds in the COX active site channel in an extended L-shaped conformation 
generally similar to that seen for AA [140]. Despite their similar L-shaped conformations in the 
COX active site, the positions of the carboxyl halves of the DGLA and AA molecules differ 
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significantly [139, 140]. The locations for C-3, C-4, and C-6 through C-8 of DGLA in the COX 
active site are the two regions showing the largest deviations from AA [140]. Specifically, the 
relative positions of C-2 through C-10 differ considerably between AA and DGLA due to the 
absence of the C-5/C-6 double bond in DGLA [140]. 
The differences in the catalytic mechanism of COX-mediated DGLA and AA 
peroxidation suggested that there may be different free radical metabolites formed through 
different free radical reactions. However, due to their high activity and short lifetimes, the free 
radical metabolites had not been identified and characterized until recently [171, 173], not to 
mention their association with PUFA’s bioactivity. The development of an appropriate technique 
for characterization of PUFA-derived radicals during lipid peroxidation greatly advances the 
understanding of COX and PUFA peroxidation in inflammatory diseases. 
1.4. PUFA-Derived Free Radical’s Detection and Characterization 
1.4.1. Electron spin resonance and spin-trapping 
The most common and traditional technique to measure free radicals is electron spin 
resonance (ESR), also known as electron paramagnetic resonance (EPR). ESR is designed to 
detect chemical species containing unpaired electron(s), which are detected in a magnetic field as 
they transition between different energy levels [144]. The ESR spectrum gives the distinctive 
ESR parameters of each radical, hyperfine couplings and g values, which give information about 
the structures of radicals. 
Unfortunately, in living systems, almost all free radicals that are generated are very 
reactive and have very short lifetimes. The short lifetimes of free radicals make them 
undetectable by ESR due to poor signal-to-noise. In order to overcome this problem, the ESR 
spin trapping technique was developed in the late 1960’s [145-147]. In this technique, primary 
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and short-lived free radicals in a living system could react with either a nitrone or nitroso 
compound (spin trapping agent) to form spin adducts or radical adducts (reaction 6) that have a 
much longer lifetime and can be measured by ESR. 
Free Radical + Spin Trap → Radical Adduct (Spin Adduct)                   (Reaction 6) 
Three classic and common spin trapping agents are listed in Scheme 6: 2-methyl-2- 
nitrosopropane (MNP), α-[4-pyridyl 1-oxide]-N-tert-butyl nitrone (POBN), and 5, 5-dimethyl-1- 
pyrroline N-oxide (DMPO). MNP and POBN are spin trapping agents that preferentially trap 
carbon-centered free radicals [148-152]. DMPO has more trapping flexibility since it can trap 
different types of unstable free radicals, including oxygen-centered, carbon-centered, and sulfur-
centered free radicals [153-155]. These spin traps had all been broadly used to assist ESR 
measurement of PUFA-derived radicals formed from many chemical and biological systems 
[156-159]. 
N
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CH NCH2(CH3)3
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Scheme 6. The structures of three classic and common spin traps. 
Due to its good spin trapping ability and appropriate solubility in biological media, the 
nitrone compound POBN has been widely used in many ESR studies to detect PUFA-derived 
free radicals formed from in vitro and in vivo lipid peroxidation. It has so far been the most 
successful spin trap used to trap PUFA-derived free radicals in both cellular peroxidation and in 
vivo peroxidation [101, 160-162]. However, like all other spin trapping agents used with the 
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traditional ESR method, POBN has its shortcomings and limitations that restrict its use in 
biological systems. As shown in the structure of the POBN radical adduct in the spin trapping 
reaction (reaction 7), both magnetic nuclei near the radical, i.e., the N and H atoms, originate 
from POBN instead of from the free radicals (R●) to be trapped. These are the two atoms in the 
spin adduct that contribute the hyperfine couplings (aN ≈ 14.4-16.1 G; aH ≈ 2.2-2.8 G [148]) in 
ESR spectra, thus many POBN adducts share identical or almost identical six-line signals (Fig. 
1). 
N
O
H
C RN
O
N
O
CHN
O
R
(H3C)3C (H3C)3C
 
               POBN                     Free Radical                   POBN Adduct       (Reaction 7) 
Therefore, with the traditional ESR method, POBN cannot provide comprehensive 
structural information, particularly when many different types of radicals are generated in a 
complicated reaction system such as PUFA peroxidation (Scheme 4). For example, a total of five 
different carbon-centered radicals could be generated from linoleic acid peroxidation (Scheme 4), 
and there are many more if we count their possible isomers. As all of their adducts produce 
similar hyperfine couplings, all these radicals can be trapped by POBN and show the same six 
line ESR spectrum (Fig. 1). 
Unlike other comprehensive methods for molecule identification, e.g. NMR and MS, 
ESR alone cannot provide unambiguous molecular structures and identities from the hyperfine 
coupling constants, particularly those from spin adducts. In addition, hyperfine coupling can vary  
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aH
 
Fig. 1. Typical ESR spectrum of POBN radical adduct. 
Note, aN ≈ 14.4-16.1 G; aH ≈ 2.2-2.8 G. 
with many factors such as solvent, temperature, and even the individual ESR instrument. Thus, 
in most previous studies, PUFA-derived free radicals had never been structurally identified with 
the traditional ESR method. Their structures were either proposed based on the presumed 
mechanism or ambiguously termed PUFA-derived free radicals. 
1.4.2. Development of the combined HPLC/ESR/MS and spin-trapping technique 
In order to characterize individual PUFA-derived free radicals generated from 
complicated lipid peroxidation, many researchers had combined ESR with high-performance 
liquid chromatography (HPLC) as well as mass spectrometry (MS) and/or tandem MS (MS2). A 
typical combination system is displayed in Scheme 7, in which spin trapped free radicals with the 
same and/or similar spectra (e.g. the six-line spectrum of the POBN adduct) were separated by a 
chromatography column according to their polarities, monitored by ESR, and collected and/or 
directly eluted to the MS detector for structure identification. 
In the on-line ESR system, instead of running a magnetic field scan to get a six-line ESR 
spectrum for POBN adduct(s), a time scan would be conducted with the magnetic field fixed on 
the top of the first or third line of the POBN adduct spectrum. In this way one would observe a 
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number of absorption peaks vs. retention time, with each peak representing a POBN adduct with 
a different structure and/or a different isomer. 
 
Scheme 7. LC/ESR/MS combined technique. 
Spin trapped radical adducts that have identical or similar ESR spectra are separated with an 
HPLC column, detected by on-line ESR under a time scan model with a fixed magnetic field, 
and then identified by MS. The dashed line represents an LC/MS refinement that offers much 
higher detection sensitivity and reliability since all three redox forms of a radical adduct can be 
measured. 
In the late 1980’s, Iwahashi et al. made great efforts to develop an LC/ESR and LC/MS 
combination to characterize free radicals formed from PUFA peroxidation, epoxidation and β-
scission hydroperoxidation [163, 164]. However, since many technologies, e.g., the fast 
resolution LC column and the soft ionization MS analyzer, were unavailable or not yet used in 
research, several problems were encountered in the characterization of free radicals via a 
combination of LC/ESR and LC/MS: (1) although HPLC was used to separate POBN adducts in 
an LC/ESR on-line system, the UV chromatogram of the analyte had never been reported due to 
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very poor chromatography resolution; (2) the ESR-active LC fractions (e.g. POBN radical 
adducts) were not detected as the corresponding m/z ions. The product ions of the reduced forms 
of spin adducts were detected for ESR-active peaks, which raised questions about the method’s 
reliability; (3) some POBN radical adducts, particularly the radicals with -COOH (~pKa 5.0), 
had very poor retention behavior due to the pH range (5-6) of the mobile phase (ammonium 
acetate) used for chromatographic separation; (4) a semi-preparative LC column and very large 
amounts of samples were required for these experiments, thus it was not a suitable protocol for 
most biological reactions, in which analytical sampling and performance are demanded [74-75]; 
and (5) a serious ESR tuning problem was encountered due to poor chromatograph resolution 
and low sensitivity arising from interface issues between the LC and ESR. The ESR tuning 
problem often creates artificial on-line ESR peak(s) during LC/ESR detection, thus also raising 
the question of the method’s reliability. 
Benefiting from many new developments and improvements in LC and MS technology in 
the early 2000’s, Qian et al. finally made a breakthrough in combining the LC/ESR and LC/MS 
methods to characterize PUFA-derived free radicals in many biological systems [156, 165]. The 
interface issues present in the combination of the HPLC, ESR, and MS techniques (Scheme 7) 
were dealt with, and most problems encountered in previous applications have been resolved. 
This refined combination of LC/ESR and LC/MS [165-167] was able to optimize several aspects 
of the chromatography and MS conditions: (1) adding 1.0 - 0.01% acetic acid (HOAc) into the 
mobile phase to maintain a weakly acidic pH greatly improved the retention behavior of all types 
of POBN adducts; (2) replacing the classic ODS column with a rapid resolution Eclipse column 
not only achieved the best chromatographic resolution and sensitivity, but also allowed 
experiments to be conducted with analytic sampling and performance; (3) applying soft MS 
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ionization to allow all ESR-active peaks to be detected as the corresponding m/z ions 
significantly improved the method’s reliability; and (4) adding a very small amount of 
tetrahydrofuran (THF) in the mobile phase improved LC resolution. In fact, THF can also 
stabilize the ESR tuning during HPLC/ESR measurement [165-167], perhaps due to its low 
dielectric constant. However, due to its corrosiveness, which could potentially damage the 
instrument, THF was not used as a mobile phase component in later combination LC/ESR and 
LC/MS systems [168-173]. The current combination of spin trapping, LC/ESR and LC/MS 
refined by Qian et al. not only greatly improves the reliability of radical identification, but also 
optimizes the method’s sensitivity and resolution. 
1.4.3. Detection of free radical from COX-catalyzed AA and DGLA peroxidation via spin-
trapping and LC/ESR/MS 
Using the refined combination technique (Scheme 7), Qian et al. have recently 
characterized the carbon-centered radicals formed from ovine COX-catalyzed DGLA and AA 
peroxidation in vitro [171, 173]. These studies suggested that both similar and different free 
radical reactions occur in the COX-catalyzed peroxidation of AA vs. DGLA. Due to the common 
structural moiety (C-8 to C-20) in DGLA and AA, COX can catalyze their free radical 
peroxidation by the same pathway, i.e., C-15 oxygenation, to form the same or similar free 
radicals and non-radical metabolites. The different structural moiety (C-1 to C-7) in DGLA 
forms distinctive free radicals and non-radical products from its unique C-8 oxygenation. 
In the study of COX-catalyzed AA peroxidation, three major types of radical adducts 
(from β and β′-scission) with numerous isomers were observed [171], including three isomers of 
POBN/●C14H21O4 (m/z 448), two isomers of POBN/●C6H13O (m/z 296), etc. The radical 
species·●C14H21O4 (as m/z 448 for the radical adduct) is a novel double-bonded carbon-centered 
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radical that is derived (special β′-scission) from PGF2 during COX/AA peroxidation via C-15 
oxygenation. Two isomers of POBN/●C6H13O (m/z 296) also form from the same special β′-
scission. However, a normal β-scission of PGF2-type alkoxyl results in formation of the ●C6H11 
radical as an m/z 266 ion. The special β′-scission (forming two radicals instead of one) was 
found to be preferred over β-scission in COX/AA peroxidation [171]. 
Just as in AA, β-scission also takes place in COX/DGLA via C-15 oxygenation, but only 
forms two isomers of POBN/●C6H13O (m/z 296). The carbon double-bond radical was not 
generated, most likely due to this β′-scission taking place during PGH synthesis instead of during 
PGF1 synthesis [173]. In addition, two exclusive radicals are generated from C-8 oxygenation in 
COX-catalyzed DGLA peroxidation, radical products of m/z 324 as POBN/●C7H13O2 and m/z 
354 as POBN/●C8H14O3. This successful characterization of novel and exclusive free radicals 
from similar and different radical reactions between COX-catalyzed peroxidation of AA and 
DGLA laid a foundation for our new investigations of COX biology and the role of PUFAs in 
inflammatory diseases, especially in cancer. 
1.4.4. Refining the approach to ESR spin-trapping and LC/MS to detect free radicals under 
normal biological conditions. 
COX can metabolize DGLA and AA through free radical-mediated lipid peroxidation to 
form the 1-series and 2-series of PGs, respectively. Unlike the pro-carcinogenic and pro-
inflammatory PGs2, the PGs1 may possess anti-carcinogenic and anti-inflammatory activity. Our 
previous studies have demonstrated that in ovine (cell-free) COX-mediated DGLA and AA 
peroxidation, there are similar free radicals formed through similar reactions (hereafter called 
common) and different ones formed through different free radical reactions (hereafter called 
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exclusive). However, it was still unclear whether the differences are associated with the 
contrasting bioactivity of AA vs. DGLA. 
The overall objective of the present research was to identify AA and DGLA-derived free 
radical metabolites and also elucidate their roles in colon cancer progression and/or prevention. 
We hypothesized that the differences in COX-catalyzed free radical peroxidation between 
DGLA vs. AA correspond to a conflict between the bioactivities of DGLA and AA; and that 
maintaining a balanced and/or beneficial ratio of DGLA vs. AA in the culture medium could 
control and slow the growth and progression of colon cancer cells. 
In order to investigate the possible association between cancer cell growth and exclusive 
free radicals generated from COX/AA vs. COX/DGLA, we refined our combined spin-
trapping/LC/MS method to include solid phase extraction (SPE) in order to characterize free 
radicals in their reduced forms (hydroxylamines) in the human colon cancer cell line HCA-7 
colony 29, which has a high expression of COX-2. For the first time, we were able to profile free 
radical formation in the experimental settings in which cell proliferation (via the MTS assay) and 
cell cycle distribution (via PI staining) could also be assessed. We identified and characterized 
both common and exclusive free radicals as their reduced forms in cellular COX-catalyzed AA 
vs. DGLA peroxidation. Our results showed that DGLA- and AA-derived exclusive free radicals, 
rather than PGE1 and PGE2, were more consistent with the opposing bioactivities of DGLA vs. 
AA. 
Due to rapid conversion from DGLA to AA via D5D, the anti-proliferative effect of 
DGLA in our treatments was limited. Thus, double doses of DGLA and D5D inhibitors were 
introduced. Treatment with double doses of DGLA or the co-treatment of DGLA with D5D 
inhibitors increased the DGLA levels in cells and further increased the formation of DGLA-
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derived exclusive free radicals. The increased DGLA competed with AA at the enzyme site, thus 
controlling the generation of AA-derived exclusive free radical metabolites. Among DGLA, 
double-dose DGLA, and combined DGLA/D5D treatments, the latter exerted the most anti-
proliferative effect on colon cancer cell growth. Co-treatment of DGLA with D5D inhibitors 
greatly limited the formation of exclusive AA-derived free radicals and increased the exclusive 
DGLA-derived free radicals, thus causing significant cell G2/M arrest and inhibition of cell 
proliferation. HCA-7 colony 29 transfected with siRNA to silence the expression of D5D was 
used to further investigate the possible mechanism underlying the anti-proliferative effect of 
DGLA on cell growth. According to the Western blot analysis, D5D expression was completely 
blocked. Our results suggested that targeting D5D was able to reciprocally alter the levels of 
DGLA and AA in cells, resulting in a profound increase in anti-proliferative DGLA-derived free 
radical metabolites and a simultaneous decrease in the pro-proliferative AA-derived free 
metabolites. In addition, the combined treatment with DGLA and D5D inhibitors increased the 
susceptibility of colon cancer cells to the chemotherapy drug 5-fluorouracil (5-FU). In the D5D 
knockdown cells, the synergistic effects of DGLA and 5-FU on growth inhibition and 
cytotoxicity were even greater. 
In summary, our refined LC/MS technique along with SPE allowed us for the first time to 
characterize free radicals in cells under normal growth conditions in which cell response, i.e., 
proliferation and cell cycle distribution, could also be assessed. Our results suggest that the 
exclusive free radical metabolites correspond to the contrasting effects of AA vs. DGLA on 
cancer cell growth. Increasing DGLA levels (by double doses of DGLA or targeting D5D) and 
concurrently decreasing AA in cells could be a novel approach to controlling AA-dependent 
cancer development. Our study allowed us to directly study free radical-associated PUFA 
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bioactivity, thus improving our understanding of COX-catalyzed lipid peroxidation in cancer 
biology.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1. Chemicals and Reagents 
High-purity POBN was purchased from Alexis Biochemicals (San Diego, CA, USA). 
Deuterated POBN (d9-POBN, Scheme 8) was synthesized by the core synthesis facility at North 
Dakota State University.  
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Scheme 8. Synthesis of d9-POBN. 
Under three equivalents of potassium permanganate, the d9-tert-butylamine was oxidized to d9-2-
methyl-2-nitropropane, which was then subjected to a controlled reduction (with Al-Hg as 
reductant) to form N-tert-butylhydroxylamine. The final product, d9-POBN, was obtained from a 
dehydration reaction between N-tert-butylhydroxylamine and 4-pyridinecarboxaldehyde-1-oxide. 
The overall yield of the current d9-POBN synthesis is ~ 30%. 
OmniPur® 10× Phosphate Buffered Saline (PBS) Liquid Concentrate was purchased from 
EMD Millipore (Billerica, MA, USA). AA and DGLA were purchased from Nu-Chek-Prep 
(Elysian, MN, USA). Ethanol (200 proof, for molecular biology) was purchased from Sigma-
Aldrich (St. Louis, MO, USA). Heptanoic acid, 1-hexanol and 8-hydroxyoctanoic acid were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
CP-24879, sesamin and curcumin were purchased from Cayman Chemicals (Ann Arbor, 
MI, USA). 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide 
(DMSO) was purchased from Alfa Aesar (Ward Hill, MA, USA). 
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Acetonitrile (ACN, HPLC grade), water (H2O, HPLC grade), methanol and ethyl alcohol 
pure (200 proof) were purchased from EMD Chemicals (Gibbstown, NJ, USA). Ammonium 
hydroxide (NH4OH, 5.0 N) and glacial acetic acid (HOAc) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). NH4OH (5 %) was freshly prepared by diluting the 5.0 N solution with 
deionized water. 
TRIS (base) was purchased from J.T. Baker (Phillipsburg, NJ, USA). Hydrogen chloride 
(HCl, 12.1 N) was purchased from EMD Chemicals (Gibbstown, NJ, USA). Sodium chloride 
(NaCl) was purchased from VWR International (West Chester, PA, USA). cOmplete Protease 
Inhibitor Cocktail Tablets were purchased from Roche Applied Science (Indianapolis, IN, USA). 
Triton® X-100, glycerol and DL-dithiothreitol (DTT) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). 
Bovine serum albumin solution (2.0 mg/mL) was purchased from Thermo Scientific 
(Rockford, IL, USA). The DCTM BCA protein assay, glycine, Sodium dodecyl sulfate (SDS), and 
Precision Plus Protein™ Kaleidoscope Standards were purchased from Bio-Rad Laboratories 
(Hercules, CA, USA). Acrylamide/bis-acrylamide (30 % solution), 2-mercaptoethanol and CAPS 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ammonium persulfate (APS) was 
purchased from AMRESCO (Solon, OH, USA). TEMED was purchased from Research 
Organics (Cleveland, OH, USA). Tween® 20 was purchased from G-Bioscience (St. Louis, MO, 
USA). Bromophenol was purchased from EMD Chemicals (Gibbstown, NJ, USA). Sodium 
hydroxide (NaOH) was purchased from J.T. Baker (Phillipsburg, NJ, USA). 
Polyclonal anti-COX-2 antibody produced in rabbits was purchased from Abcam 
(Cambridge, MA, USA). Polyclonal anti-FADS1 antibody produced in rabbits and monoclonal 
Anti-Actin antibody produced in mice were purchased from Sigma-Aldrich (St. Louis, MO, 
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USA). Horseradish peroxidase-conjugated goat anti-rabbit IgG and horseradish peroxidase-
conjugated goat anti-mouse IgG were purchased from Cayman Chemicals (Ann Arbor, MI, 
USA). Pierce ECL Western Blotting Substrate was purchased from Thermo Scientific (Logan, 
UT, USA). 
CellTiter 96® AQueous One Solution Cell Proliferation Assay was purchased from 
Promega (Madison, WI, USA). Ribonuclease A from bovine pancreas (RNase A, 30 mg/mL) 
was purchased from Sigma-Aldrich (St. Louis, MO, USA). Propidium iodide (PI, 10 mg/mL) 
was purchased from Life Technologies (Grand Island, NY, USA). 
Opti-MEM® Reduced Serum Medium (GlutaMAX™), Lipofectamine™ RNAiMAX 
reagent, Silencer® Select siRNA (5 nmol) for FADS1 and negative control #1 (5 nmol) were 
purchased from Life Technologies (Grand Island, NY, USA). 
2.2. Cell Culture 
The human colon cancer cell line HCA-7 colony 29 was purchased from the European 
Collection of Cell Cultures (Porton Down, Salisbury, UK). Fetal bovine serum (FBS) and 0.25% 
trypsin-EDTA was obtained from Thermo Scientific (Logan, UT, USA). DMEM high glucose 
medium (phenol-red free) was obtained from ScienCell Research Laboratories (Carlsbad, CA, 
USA). Cells were grown in DMEM high glucose medium (phenol red-free) supplemented with 
10% FBS in an incubator containing a 95% humidified atmosphere of 5% CO2 at 37°C. Cells 
were sub-cultured at a ratio of 1:5 after they had reached ~90% confluency. Final concentrations 
of all treatments including controls were prepared with an appropriate volume of cell culture 
medium to attain a concentration of 0.1% (v/v) ethanol or DMSO. 
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2.3. Preparation of Reaction Solution 
2.3.1. Stock solutions 
Stock solutions of POBN and d9-POBN (500 mM) were freshly prepared in PBS buffer. 
Stock solutions of AA and DGLA (100 mM) were prepared in ethanol. PGE2, PGE1, 
PGE2-d9, PGE1-d4, AA-d8, DGLA-d6 were purchased from Cayman Chemicals (Ann Arbor, MI, 
USA). Stock solutions of the PGE2, PGE1, PGE2-d9, PGE1-d4, AA-d8, and DGLA-d6 (100 ng/µL) 
were prepared in ethanol. 
Stock solutions of heptanoic acid, 1-hexanol and 8-hydroxyoctanoic acid (500 µM) were 
prepared in ethanol. All of the stock solutions were stored in in aliquots at -80 °C. A series of the 
corresponding working solutions was freshly prepared by diluting the stock solutions with 
ethanol. 
Stock solutions of CP-24879 (50 mM), sesamin (100 mM), curcumin (50 mM) and 5-FU 
(1.0 M) were prepared in DMSO. All of the stock solutions were stored in in aliquots at -80 °C. 
A series of corresponding working solutions was freshly prepared by diluting the stock solutions 
with DMSO. 
2.3.2. Cell lysis buffer 
HCl (10.0 N) was prepared by transferring 1 mL of HCl to a 15 mL centrifuge tube. 11.1 
mL of deionized water was added and the solution vortexed to mix completely. The volume was 
then made up to 12.1 mL with deionized water. 
NaCl (5.0 M) was prepared by transferring approximately 14.6 g of NaCl to a 50 mL 
centrifuge tube. 45 mL of deionized water was added and the solution vortexed to dissolve it 
completely. The volume was made up to 50 mL with deionized water. 
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The protease inhibitor (5× stock solution) was prepared by transferring 9.0 mL of ice cold 
deionized water to a 15 mL centrifuge tube. One tablet of cOmplete Protease Inhibitor Cocktail 
was added and the solution vortexed to dissolve it completely. 1.0 mL aliquots were stored at -
20 °C. 
DTT (1.0 M) was prepared by transferring approximately 1.5 g of DTT to a 15 mL 
centrifuge tube. 9.0 mL of deionized water was added and vortexed to dissolve it completely. 
The volume was made up to 10 mL. 1.0 mL aliquots for each were stored at -20 °C. 
Tris buffer (1.0 M, pH 7 .4) was prepared by transferring approximately 12.1 g of Tris 
base into a 100 mL reagent bottle. 90 mL of deionized water was added and stirred to dissolve 
completely. The pH was adjusted to 7.4 ± 0.05 with HCl (10.0 N) and the volume made up to 
100 mL with deionized water. 
The cell lysis buffer was prepared on ice by transferring 1.0 mL of deionized water to a 
15 mL centrifuge tube. 216 µL of 5.0 M NaCl solution, 1.8 mL of protease inhibitor stock 
solution, 9.0 µL of 1.0 M DTT, 4.5 mL of 1.0 M Tris buffer (pH 7.4), 900 µL of glycerol and 
450 µL of Triton® X-100 were added. The volume was made up to 10 mL with deionized water. 
The contents were mixed by vortexing and 1.0 mL aliquots stored at -20 °C. 
2.3.3. Protein assay 
Protein standard solutions: Bovine serum albumin solution (2 mg/mL) was diluted with 
deionized water to prepare a series of protein standard solutions of 0.25, 0.5, 0.75, 1, 1.5 to 2.0 
mg/mL. 1.0 ml aliquots of the standard solutions were stored at -20 °C. 
Coloring reagent (a mixture of DCTM BCA protein assay reagents A and S) was prepared 
fresh just before use. 1.0 mL of protein assay reagent A and 20 µL of protein assay reagent S 
were mixed in a 1.5 mL centrifuge tube. 
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2.3.4. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Reagents for gel preparation: APS (10%) was freshly prepared by dissolving 
approximately 0.1 g of APS in 1 mL deionized water. SDS (10%) was prepared by dissolving 
approximately 1.0 g of SDS in 10 mL deionized water. 
Tris buffer (1.5 M, pH 8.8) was prepared by transferring approximately 18.2 g of Tris 
base into a 100 mL reagent bottle. 90 mL of deionized water was added and stirred to dissolve 
completely. The pH was adjusted to 8.8 ± 0.05 with HCl (10 N). The volume was made up to 
100 mL with deionized water. 
Tris buffer (1.0 M, pH 6.8) was prepared by transferring approximately 12.1 g of Tris 
base into a 100 mL reagent bottle. 90 mL of deionized water was added and stirred to dissolve 
completely. The pH was adjusted to 6.8 ± 0.05 with concentrated HCl (10 N). The volume was 
made up to 100 mL with deionized water. 
Reagents for PAGE: NaOH (10 N) was prepared by transferring approximately 100.0 g 
of NaOH to 100 mL reagent bottle. 200 mL of deionized water was added and stirred to dissolve 
completely. The volume was made up to 250 mL with deionized water. 
Tris buffer (0.5 M, pH 6.8) was prepared by transferring approximately 6.1 g of Tris base 
into a 100 mL reagent bottle. 90 mL of deionized water was added and stirred to dissolve 
completely. The pH was adjusted to 6.8 ± 0.05 with HCl (10 N). The volume was made up to 
100 mL with deionized water. 
Sample buffer (4× stock solution) was prepared by transferring 20 mL of 0.5 M Tris 
buffer (pH 6.8) into a 50 mL centrifuge tube. 20 mL glycerol, 2.0 g SDS, 2 mL 2-
mercaptoethanol, and approximately 16.0 mg bromophenol blue were added and vortexed to 
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dissolve and mix the contents completely. The volume was made up to 50 mL with deionized 
water. 1.0 mL aliquots were stored at -20 °C. 
Electrophoresis buffer (10× stock solution) was prepared by transferring approximately 
30.3 g of Tris base into a 1000 mL reagent bottle. Approximately 144.0 g glycine, 10.0 g SDS 
and 900 mL of deionized water were added and stirred to dissolve completely. The volume was 
made up to 1000 mL with deionized water and stored at 4 °C. 
Running buffer (1× working solution) was prepared by transferring 100 mL of 10× 
electrophoresis buffer into a 1000 mL reagent bottle. The volume was made up to 1000 mL with 
deionized water and stored at 4 °C. The buffer was reused three times. 
Transfer buffer (10× stock solution) was prepared by transferring approximately 22.1 g of 
CAPS into a 1000 mL reagent bottle. 900 mL of deionized water was added and stirred to 
dissolve completely. The pH was adjusted to 11.0 ± 0.05 with NaOH (10 N). The volume was 
made up to 1000 mL with deionized water and stored at 4 °C. 
Transfer buffer (1× working solution) was prepared by transferring 100 ml of 10× buffer 
to a 1000 mL reagent bottle. 200 mL methanol was added. The volume was made up to 1000 ml 
with ice cold deionized water and stored at 4 °C. The buffer was reused three times. 
Tris buffered saline (TBS, 10× stock solution) was prepared by transferring 
approximately 12.1 g of Tris base to a 1000 mL reagent bottle. 87.7 g of NaCl and 900 mL of 
deionized water was added and stirred to dissolve, and the pH adjusted with HCl (10 N) to 
7.6.±.0.05. The volume was made up to 1000 mL with deionized water and stored at 4 °C. 
Washing Buffer (TBS-T, 1× working solution) was prepared by transferring 100 mL of 
10× TBS in a 1000 mL reagent bottle. 1 mL Tween-20 was added. The volume was made up 
1000 mL with deionized water and stored at 4 °C. 
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Blotting buffer (reusable) was prepared by transferring approximately 5.8 g of Tris base 
and 2.9 g of glycine in a 1000 mL reagent bottle. 700 mL deionized water was added and stirred 
to dissolve completely. 200 mL methanol was added. The volume was made up to 1000 mL with 
deionized water. 
Blocking Solution (5% Non-fat Dry Milk) was prepared by transferring approximately 5 
g of non-fat dry milk in a 100 mL reagent bottle. 90 mL of 1× TBS-T was added and stirred to 
dissolve and the volume made up to 100 mL with 1× TBS-T. It was used fresh. 
2.3.5. Immunoblotting 
Incubation Solution (for dilution of primary and secondary antibodies) was prepared by 
transferring 1 mL of blocking solution in a 15 mL centrifuge tube. The volume was made up to 
10 ml with 1× TBS-T. Use it fresh. Polyclonal anti-COX-2 antibody produced in rabbit was used 
at a 1: 600 dilution. Polyclonal anti-FADS1 antibody produced in rabbit was used at a 1:400 
dilution and monoclonal Anti-Actin antibody produced in mouse was used at a 1:4000 dilution. 
Horseradish peroxidase-conjugated goat anti-rabbit IgG and Horseradish peroxidase-conjugated 
goat anti-mouse IgG were used at a 1:4000 dilution. 
2.3.6. Cell cycle distribution 
RNase A (10 mg/mL stock solution) was prepared by transferring 1.0 mL Rnase A (30 
mg/mL) to 1.5 mL centrifuge tube. 2.0 mL deionized water was added and vortexed to mix 
completely. 200 µL aliquots were stored at -20 °C. 
PI (50 µg/mL working solution) was prepared by transferring 40 µL PI (10 mg/mL) to 15 
mL centrifuge tube. 8.0 mL deionized water was added and vortexed to mix completely. PI was 
prepared away from light and used fresh. 
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2.3.7. Transfection with siRNA 
FADS1 siRNA and negative control #1 (100 µM stock solution) was prepared by 
centrifuging the tube to ensure that the dried siRNA was at the bottom of the tube. 100 µL of 
Nuclease-free Water was added and vortexed to dissolve completely. 10 µL aliquots were stored 
at -20 °C. 
2.4. Spin-Trapping Experiments in Cell-PBS Suspension 
To measure ESR-active free radical spin adducts, HCA-7 colony 29 cells at ~90% 
confluency were trypsinized, harvested, and suspended in PBS at ~108 cells/mL. POBN and 
PUFAs at final concentrations of 50 and 1.0 mM, respectively, were then added to 200 µL of 
cell-PBS suspension to start the peroxidation and spin-trapping reaction. This complete reaction 
mixture was then incubated at 37°C in the absence of light. After a 30 min incubation, the 
reaction was stopped by mixing with ACN (1:1, v/v). The reaction mixture was centrifuged for 
15 min at 14,000 rpm using a Microfuge® 22R Centrifuge (Beckman Coulter) and the 
supernatant was collected. The supernatant was condensed by removing ACN via a Vacufuge® 
5301 Centrifugal Vacuum Concentrator (Eppendorf) for later offline ESR, LC/ESR and LC/MS 
analysis. 
2.5. Spin-Trapping Experiments under Normal Cell Growth Conditions 
Cells were seeded at the density of 4×106 cells per 100 mm petri dish to obtain 30 ~ 40% 
confluency. After a one-night incubation that allowed the cells to attach to the dish, the cell 
culture medium was replaced with fresh, and then POBN and PUFAs at final concentrations of 
20 mM and 100 µM, respectively, were added to start the peroxidation and spin-trapping 
reaction. 
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Unlike the overdosing with POBN and PUFA in the spin-trapping experiments performed 
in cell-PBS suspension, which could cause cell death in as short a time as just over 30 min, much 
lower concentrations of POBN and PUFA were introduced into the cell culture medium in our 
refined spin-trapping experiment. Instead of detecting the ESR-active POBN radical adduct, the 
reduced POBN radical adducts (hydroxylamines) were measured since they are a more stable 
redox form and could accumulate during incubation. After 0.5, 2, 4, 8, 12, 24 and 48 h of 
treatment, both the cell culture medium and cell homogenate (cells were scrubbed and 
homogenized with a Sonifier 150, Branson Ultrasonics) were collected. The reaction was 
stopped by adding ACN (1:1, v/v) into the mixture of the cell culture medium and cell 
homogenate. Then the mixture was vortexed and centrifuged for 15 min at 3000 rpm. The 
supernatant (4.0 mL) was subjected to SPE, followed by LC/MS and LC/MS2 analysis. 
In the spin-trapping experiments when dual spin traps (a mixture of d0- and d9-POBN, 
50:50, v/v) were used to confirm the structural assignments of the hydroxylamines, all reaction 
conditions were the same as in the corresponding POBN spin-trapping reaction system. 
2.6. Extraction and Analysis of Hydroxylamines 
A mixed-mode anion exchange (MAX) SPE cartridge (Oasis®, Waters) was employed to 
separate the hydroxylamine from the supernatant obtained from spin-trapping experiments under 
normal cell growth conditions. The sorbent of the MAX cartridge (N-vinylpyrrolidone-DVB 
copolymer, -CH2N(CH3)2C4H9+) could interact with negatively charged groups (Scheme 9), e.g., 
the pyridyl-oxide group in POBN’s structure and the carboxyl and/or hydroxyl groups in the 
structures of PUFA-derived radicals. This highly selective interaction enabled the separation of 
hydroxylamines from the matrices. The MAX SPE cartridge was preconditioned with 2.0 mL 
methanol and 2.0 mL water and then 4.0 mL supernatant was loaded. The MAX SPE cartridge 
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was washed with 1.0 mL 5% NH4OH and 1.0 mL methanol, and then hydroxylamines were 
eluted with 2 mL ACN:methanol (60:40, v/v, 2% formic acid). The elution was condensed to 
dryness with a concentrator and reconstituted in 100 µL methanol:water (10:90, v/v) for LC/MS 
and LC/MS2 analysis. 
CH2N C4H9
CH3
CH3
MAX sorbent
Mixed-mode anion exchange
NHC
R (COO-)
NHO
C(CH3)3
O
Hydroxylamine
Scheme 9. Hydroxylamine-sorbent interactions on Oasis MAX sorbent. 
MAX is a strong mixed-mode anion exchange, water-wettable, polymeric sorbent stable from pH 
0-14. SPE procedures using MAX sorbent enable separation of hydroxylamines from complex 
matrices including biological fluids. 
2.7. Spin-Trapping of Hydroxyethyl Radical (Test of POBN’s Trapping Ability) 
In our refined spin-trapping experiment, the reaction was performed for days under 
normal cell growth conditions. To determine whether POBN would still be able to trap radicals 
under such conditions, we tested POBN’s trapping ability for hydroxyethyl radicals (●C2H4OH) 
for up to 48 h. POBN in DMEM high glucose medium (phenol-red free) was put in an incubator 
containing a 95% humidified atmosphere of 5% CO2 at 37°C. After 2, 4, 24 and 48 h, the POBN 
in cell culture medium was mixed with ethanol and an Fe2+ stock solution (1.0 mM, prepared 
from ferrous ammonium sulfate in redistilled water, with the pH kept around 2.5 [174]. The final 
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concentrations of POBN, ethanol and Fe2+ in the reaction mixture were 20 mM, 1.0 mM and 0.1 
mM, respectively. The reaction mixture was used directly for offline ESR analysis with an ESR 
flat cell for magnetic field scans. 
2.8. Extraction and Analysis of PUFAs and PGEs in Cell Culture Medium 
Cells were seeded at a density of 4×106 cells per 100 mm petri dish to obtain 30 ~ 40% 
confluency. After a one-night incubation that allowed the cells to attach to the dish, the cell 
culture medium was replaced with fresh, and then PUFAs at final concentrations of 100 µM 
were added to start the peroxidation reaction. After 0.5, 2, 4, 8, 12, 24 and 48 h of treatment, the 
cell culture media were collected. PUFAs and PGs in cell culture medium were extracted via 
SPE. Two mL of cell culture medium was collected after treatment and the internal standards 
(PGE1-d4, PGE2-d9, AA-d8 and DGLA-d6) were added. Then the medium was mixed with 
methanol and water to make a total of 3 mL of 15% methanol solution and vortexed for 1 min. 
The mixture was set on ice for 30 min and centrifuged for 15 min at 3000 rpm. The supernatant 
was collected and transferred to a new tube. After the pH was adjusted to 3.0 using 0.2 N HCl, 
the supernatant was loaded on a reverse phase SPE cartridge (SampliQ Silica C18 ODS, Agilent, 
preconditioned with 2 mL methanol and 2 mL water). The reverse phase SPE cartridge was 
washed with 1 mL of water, and then PUFAs and PGEs were eluted with 2 mL ethyl acetate. The 
elution was condensed by concentrator to dryness and reconstituted with 100 µL ethanol for 
LC/MS analysis. 
2.9. Offline ESR 
For the complete reaction system and relevant control experiments, reaction solutions 
(after mixing with ACN, 50% v/v) were transferred to the same ESR flat cell for magnetic field 
scans. ESR spectra were recorded with a Bruker EMX spectrometer equipped with a super high 
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Q cavity operating at 9.78 GHz at room temperature. Other ESR spectrometer settings were 
magnetic field center, 3497.4 G; magnetic field scan, 70 G; modulation frequency, 100 kHz; 
microwave power, 20 mW; modulation amplitude, 1.0 G; receiver gain, 5.0×104; time constant, 
0.655 s; and conversion time, 0.164 s. 
2.10. LC/MS and LC/MS2 
2.10.1 LC/MS and LC/MS2 for identification of free radical adducts and hydroxylamines 
The LC/MS system consisted of an Agilent 1200 series HPLC system and an Agilent 
LC/MSD SL ion trap mass system. The outlet of the UV detector in LC was connected to the MS 
system with red PEEK HPLC tubing (0.005 i.d.). LC separations were performed on a C18 
column (Zorbax Eclipse-XDB, 4.6×75 mm, 3.5 μm) equilibrated with 90% A (H2O-0.1% HOAc) 
and 10% B (ACN-0.1% HOAc). A forty microliter condensed sample from a spin-trapping 
experiment in a cell-PBS suspension or under normal cell growth conditions was injected into 
the HPLC system by autosampler and eluted at a 0.8 mL/min flow rate with a combination of 
gradient and isocratic elution: (i) 0-5 min, 90 to 73% A and 10 to 27% B; (ii) 5-25 min (isocratic), 
73% A and 27% B; (iii) 25-40 min, 73 to 30% A and 27 to 70% B; (iv) 40-43 min, 30 to 5% A 
and 70 to 95% B; and (v) 43-50 min (isocratic), 5% A and 95% B. The LC flow rate (0.8 
mL/min) into the MS inlet was adjusted to 60 μL/min via a splitter. Electrospray ionization in 
positive mode was used for all LC/MS measurements. Total ion current (TIC) chromatograms in 
full mass scan mode (m/z 50 to m/z 600) were performed to profile all products formed in the 
reaction of COX-catalyzed AA/DGLA in the presence of POBN. Other MS settings were 
capillary voltage, -4500 V; nebulizer press, 20 psi; dry gas flow rate, 8 L/min; dry temperature, 
60 °C; compound stability, 20%; and number of scans, 50. An extracted ion current 
chromatogram (EIC) from the above full scan experiment was obtained to acquire the MS profile 
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of the individual POBN trapped radical adduct. Normally an isolation width of ±0.5 Da was 
selected for EIC. 
LC/MS2 analysis in multiple reactions monitoring (MRM) mode was performed to 
confirm the structural assignment of hydroxylamine. A four-Da width was typically used to 
isolate parent ions of interest. Other settings of the MS were: mass range, m/z 50-600; capillary 
voltage, -4500 V; nebulizer press, 20 psi; dry gas flow rate, 8 L/min; dry temperature, 60°C; 
compound stability, 20%; and number of scans, 5.The LC/MS2 studies of reduced products of d9-
POBN radical adducts were performed to confirm the structures of reduced products of POBN 
radical adducts. All reactions for the POBN and the d9-POBN spin trap systems were performed 
under identical conditions. 
2.10.2. LC/MS for quantification of hydroxylamine 
LC/MS settings for quantification were identical to the above full scan methods. A small 
and known amount of d9-POBN was used purely as an internal standard in LC/MS quantification. 
Unlike the above LC/MS2 procedure in which d9-POBN was used as a spin trap for purposes of 
radical detection and structure identification, here it was not added until the mixture of cell 
culture medium and cell homogenate was mixed with blocking agent (1:1, v/v) to stop the 
reaction. Based on the average abundance of several types of POBN radical adducts observed in 
our reaction system and publications [169, 170], we chose 2.0 µg/ml as the quantity of internal 
standard d9-POBN to add to the ACN-sample mixture. To quantify the abundance of molecule 
ions of interest, the integrated EIC peak of m/z 204 for d9-POBN was always used as the 
standard. 
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2.10.3. LC/MS for PUFAs and PGEs detection and quantification 
Five microliters of sample was injected into the HPLC system and eluted with a 
combination of gradient and isocratic elution: (i) 0-12 min (isocratic), 68% A and 32% B; (ii) 12-
14 min, 68 to 44% A and 32 to 56% B; (iii) 14-28 min (isocratic), 44% A and 56% B; (iv) 28-30 
min, 44 to 14% A and 56 to 86% B; (v) 30-38 min, 14 to 4% A and 86 to 95% B; and (vi) 38-44 
min (isocratic), 5% A and 95% B. Electrospray ionization in negative mode was used for all 
LC/MS measurements. Other MS settings were nebulizer press, 15 psi; dry gas flow rate, 5 
L/min; dry temperature, 325 °C. 
For quantification, m/z 351, 360, 353, 357 305, 303, 311 were used for measuring PGE2, 
PGE1, AA, DGLA, PGE1-d4, PGE2-d9, AA-d8 (m/z 311) and DGLA-d6 (m/z 311), respectively. 
The concentrations of PUFAs in the samples were calculated by comparing the ratios of the peak 
areas of the compounds to those of the internal standards using the internal standard curve. The 
standard curve was constructed from a series of concentrations of PGE2, PGE1, AA, DGLA and 
the same concentrations of PGE1-d4, PGE2-d9, AA-d8 and DGLA-d6, which were added into the 
cell culture medium. 
2.11. Transfecting HCA-7 Colony 29 Cells with FADS1 siRNA 
HCA-7 colony 29 cells were transfected with FADS1 siRNA according to the 
manufacturer’s protocol. Cells were seeded at 2×105 cells per well in a 6-well plate. After a 12 h 
incubation to allow the cells to attach, the cell culture medium was removed and cells were 
washed with PBS. Then the transfection mix was generally prepared and added. Briefly, for each 
well to be transfected, FADS1 siRNA stock solution (100 µM, in RNase free water) was diluted 
in 250 µL Opti-MEM reduced serum medium (Invitrogen) to final concentrations of 50, 100 and 
150 nM and mixed with 15 µL of each transfection reagent (Lipofectamine™ RNAiMAX) pre-
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diluted in 250 µL Opti-MEM. After a 5 min incubation at room temperature, the transfection 
mixes were added to the cells in a final volume of 2.5 mL medium. The cells were incubated for 
48 hours at 37°C in a CO2 incubator until ready to assay for gene knockdown. Cells transfected 
with a non-target control siRNA were used as controls. The gene knockdown results were 
evaluated by Western blot. 
This procedure was used to reverse transfect siRNA into HCA-7 colony 29 cells in a 6-
well format. For cells transfected in different cell culture formats, e.g. a 96-well plate or a 100 
mm petri dish, the amounts of Lipofectamine™ RNAiMAX, siRNA, cells, and medium were 
scaled up or down according to Table 1. 
Table 1. Scaling Up or Down Transfections. 
Culture Vessel Multiplication Factor 
96-well plate 0.04× 
6-well plate 1× 
100 mm petri dish 2.2× 
The multiplication factor in the table was used to scale the volumes for transfection experiments. 
The factor is based on the relative surface area of a single well from a 6-well plate. 
If the volume of Lipofectamine™ RNAiMAX was too small to dispense accurately, 
Lipofectamine™ RNAiMAX was pre-diluted 10-fold in Opti-MEM® I Reduced Serum Medium, 
and a 10-fold higher amount was dispensed (at least 1.0 μL per well). 
2.12. Western Blot Analysis 
Preparation of cell lysate: Cell lysis buffer was placed on ice and all steps carried out at 
4 °C. 150 µL of cell lysis buffer was added to each well of the Petri dish. Cells in the whole area 
of the Petri dish were scraped with a plastic scraper.  The lysate was collected in 1.5 mL 
centrifuge tubes, passed through a syringe (25 gauge, BD) 5-6 times to make the lysate 
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homogeneous, and then centrifuged at 2000 rpm for 2 min at 4 °C.  The supernatant was 
collected and stored at -80 °C for further analysis. 
Protein quantification: The protein concentration in the cell lysates was measured using a 
DCTM protein assay kit according to the manufacturer’s instructions. Briefly, 5 uL of protein 
standard or diluted cell lysate and the DCTM protein assay reagents were added into each well in 
a 96-well plate. Solutions were incubated at room temperature for 15 min in the dark. The optical 
density was then read at 750 nm using a Microplate Reader (SpectraMax M5, Molecular 
Devices). The protein amount in each sample was calculated by the standard curve. 
Preparation of samples for loading: Each sample was normalized to the same concentration and 
then the sample prepared to load onto the gel by mixing with the sample buffer (sample:4× 
sample buffer = 3:1). Samples were vortexed and spun down, denatured at 95 °C for 5 min, and 
stored at -20 °C for further analysis. 
Preparation of gel: The required concentrations of resolving gel and stacking gel were 
prepared according to Table 2, avoiding any bubble formation in the wells. 
Table 2. Volume of components required to cast gels. 
 Resolving Gel (10%) Stacking Gel (4%) 
 
2 mL 
1.5 M Tris buffer (pH 8.8) 
1.25 mL 
1.0 M Tris buffer (pH 6.8) 
H2O 7.8 mL 7.55 mL 
acrylamide/bis-acrylamide 
(30 % solution) 
4 mL 1 mL 
10% SDS 160 µL 100 µL 
10 % APS 160 µL 100 µL 
TEMED 16 µL 10 µL 
Total 16 mL 10 mL 
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Running the gel after sample loading: Samples (maximum 40 µL) were loaded in the 
wells and run at constant voltage, first at 90 V, while the samples passed by the stacking gel, 
then increasing the voltage to 120 V. The voltage was switched off just before the blue line 
reached the bottom to prevent overrun. 
Transferring: Sponges and filter paper were soaked in blotting buffer for 15 min. The 
Immobilon-P transfer membrane (PVDF, Millipore) was first soaked in methanol (activation step) 
for 15 min and then in blotting buffer. The proteins were transferred electrophoretically to the 
PVDF membrane at constant voltage (80 V) for 2 h on ice. 
Blotting: Membranes were blocked for non-specific binding by rocking gently in 5% non-fat dry 
milk (diluted in 1× TBS-T) for 1 h and washed for 5 min in 1% non-fat dry milk (diluted in 1× 
TBS-T), then incubated with primary antibody for 1 hr at room temperature or overnight at 4°C 
(with dilution in incubation solution as required) with continuous rocking. 
Membranes were washed 3 times for 5 min each in 1× TBS-T and twice for 5 min each in 
1% non-fat dry milk (diluted in 1× TBS-T). The secondary antibody was added (diluted in 
incubation solution as required) and incubated for 1 h at room temperature, with continuous 
rocking. 
Membranes were washed 3 times for 5 min each in 1× TBS-T, incubated in ECL western 
blot substrates (Pierce) for 1 min, and exposed to X-ray film (Phoenix Research), taking care that 
all the chemiluminiscent exposure should be as fast as possible to avoid loss of signal. 
Luminescent signals were captured on a Mini-Medical Automatic Film Processor (Imageworks). 
2.13. Cell Proliferation Assay via MTS 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay is a colorimetric 
method for determining the number of viable cells in proliferation or cytotoxicity assays. The 
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CellTiter 96® AQueous One Solution Reagent contains a novel tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; 
MTS] and an electron coupling reagent (phenazine ethosulfate; PES). PES has enhanced 
chemical stability that allows it to be combined with MTS to form a stable solution. The MTS 
tetrazolium compound is bioreduced by cells into a colored formazan product that is soluble in 
tissue culture medium. This conversion is presumably accomplished by NADPH or NADH 
produced by dehydrogenase enzymes in metabolically active cells. The quantity of formazan 
product as measured by the absorbance at 490nm is directly proportional to the number of living 
cells in culture. 
A cell proliferation assay was performed according to the manufacturer's instructions. 
Briefly, cells were seeded at 5000 cells per well into 96-well plates. After overnight incubation 
to allow the cells to attach, different treatments were added. The cells were incubated in an 
incubator containing a 95% humidified atmosphere of 5% CO2 at 37°C for 48 h and then 20 µL 
per well of CellTiter® 96 Aqueous One Solution Reagent was added into each well. After the 
plate was incubated for 4 h in an incubator, the absorbance at 490 nm was recorded with a 96-
well plate reader. Values were normalized to the value in the control group. 
2.14. Cell Cycle Distribution Analysis via PI Staining 
PI is a fluorescent dye that binds specifically to DNA. This property has led to its 
common use in evaluation of cell cycle, aneuploidy and apoptosis by flow cytometry. When 
excited by a laser light at 488 nm, PI emits a signal that can be monitored by the red wavelength 
detector typically reserved for phycoerythrin (usually FL2).  
The effect of different treatment on cell cycle distribution was determined by flow 
cytometry after staining the cells with PI. Briefly, 4×106 cells were seeded, allowed to attach by 
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overnight incubation, and exposed to different treatments for 8 and 24 h. Cells were trypsinized, 
washed with PBS and fixed in ice-cold 70% ethanol at 1×106 cells/mL for 30 min at 4 °C. The 
cells were then treated with 10 µL ribonuclease A (10 mg/mL) and 400 µL PI (50 μg/mL) for 30 
min and measured on a Cell Lab Quanta™ SC (Beckman Coulter, CA). The percentage of cells 
in different phases of the cell cycle was computed using Flow Jo (TreeStar, OR). At least 10,000 
cells were analyzed. 
2.15. Statistics 
Data were expressed as mean ± standard deviation (SD). Statistical differences between 
the mean values for two groups (at least three experiments per group for all experiments) were 
evaluated by analysis of variance (ANOVA) and Tukey’s post hoc test. Correlation relationships 
were determined by correlation/regression analysis in which P values less than 0.05 were 
considered statistically significant. 
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CHAPTER 3. DETECTION AND IDENTIFICATION OF FREE RADICALS FORMED 
FROM CELLULAR COX-CATALYZED AA AND DGLA PEROXIDATION 
3.1. Introduction 
The major ω-6 PUFA found in tissues is AA, which is converted from dietary LA 
through a series of desaturation and elongation enzymes ([2] Scheme 1). LA (18:2) is converted 
into GLA by D6D, followed by a two-carbon-atom chain elongation by ELOVL5 to form DGLA, 
and finally undergoing desaturation by D5D to generate AA. Both AA and its upstream fatty acid, 
DGLA, are substrates of COX, one of the most studied mammalian oxygenases. COX catalyzes 
the lipid peroxidation of PUFAs to form PGHs, the precursors of such bioactive lipid mediators 
as PGs (PGE, PGD, and PGF, Scheme 2). COX has two isoforms, the constitutive isoform COX-
1 and the inducible isoform COX-2 [94]. Unlike COX-1, which is expressed in nearly all 
mammalian tissues, COX-2 is often up-regulated at the inflammation site and in various tumor 
tissues, thus it has received much research attention in connection with inflammation-related 
diseases including cancer [19, 175-178]. It was reported that COX-2 is overexpressed by ~40% 
in human adenomas and ~80% in adenocarcinomas relative to normal mucosa in colon tissues 
[179, 180]. 
COX catalyzes AA peroxidation to the pro-inflammatory and pro-carcinogenic PGs2. 
PGE2, one form of PGs2, is the major COX product that could stimulate colorectal 
carcinogenesis by activating elements of the pro-survival signaling pathway such as the 
extracellular-signal-regulated kinases (ERK), cAMP/PKA and EGFR [181-183]. Unlike its 
downstream product AA, DGLA may be the exceptional ω-6 PUFA which may perform anti-
inflammatory and anti-cancer activities by increasing PGs1 through COX. For example, PGE1, 
one form of PGs1, was reported to inhibit vascular smooth muscle cell proliferation, reduce 
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vascular cell adhesion, and attenuate the development of atherosclerosis [32, 76, 184]. PGE1 also 
exerted an inhibitory effect on the growth of melanoma cells and HeLa cells [70, 185-187]. 
It is well-known that COX catalyzes PUFAs to PGs through a series of free radical 
reactions [134]. As the most reactive intermediates, however, the PUFA-derived free radicals 
formed during COX-catalyzed peroxidation have never been identified and characterized due to 
the lack of appropriate methodology. Thus, the possible role of these free radical metabolites in 
inflammation related diseases including cancer are still not clear. Recently, the novel technique 
of combined LC/ESR/MS and spin-trapping allowed us to detect and characterize the free 
radicals formed from COX-catalyzed AA and DGLA peroxidation (ovine COX in a cell-free in 
vitro system [171, 173]). Our previous studies suggested that both similar and different free 
radical reactions occurred in COX-catalyzed peroxidation of AA vs. DGLA ([171, 173] Scheme 
10 and 11). For example, COX can catalyze their free radical-mediated peroxidation through the 
same pathways, e.g. C-15 oxygenation, to form the same or similar free radicals and non-radical 
metabolites due to the common structural moiety (C-8 to C-20) in AA and DGLA. In contrast, 
the different structural moiety (C-1 to C-7) in DGLA generated exclusive free radicals and non-
radical products via its unique C-8 oxygenation pathway. This unique C-8 oxygenation in the 
COX/DGLA reaction may be attributed to the different relative positions of C-2 through C-10 in 
DGLA compared to AA due to the absence of the C-5/C-6 double bond in DGLA [188]. 
In the study of COX-catalyzed AA peroxidation, three types of POBN radical adducts 
with numerous isomers were observed [171], including three isomers of POBN/●C14H21O4 (m/z 
448), two isomers of POBN/●C6H13O (m/z 296) and ten isomers of POBN/●C20H34O5 (m/z 548) 
(Scheme 10). The radical species POBN/●C14H21O4 (m/z 448) contains a novel carbon-carbon 
double bond radical (●C=C) that is derived from the special β′-scission PGF2 type alkoxyl radical 
53 
during COX/AA peroxidation via C-15 oxygenation (Scheme 10). Two isomers of 
POBN/●C6H13O (m/z 296) also form from the same special β′-scission. This special β′-scission 
(breaking the carbon bond on the opposite side of the normal β-scission) was found to be 
preferred over the normal β-scission in COX/AA peroxidation ([171], Scheme 10). 
Scheme 10. Proposed mechanism of COX-catalyzed AA peroxidation. 
Free radical reactions including formation of C-13 radicals, C-9/C-11 endoperoxide bridging 
(adding the first O2 via the cyclooxygenase activity of COX), C-8 and C-12 cyclization, and C-15 
oxygenation (adding the second O2 via the peroxidase activity of COX). A total of four types of 
free radicals, ●C5H11, ●C6H13O, ●C14H21O4 and ●C20H34O5, were formed and trapped by POBN as 
m/z 266, 296, 448 and 548 ions. 
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Similarly, β′-scission also takes place in COX/DGLA via C-15 oxygenation, but two 
isomers of POBN/●C6H13O (m/z 296) were formed without detection of their co-products; i.e., 
●C=C was not generated [173]. Such a pattern probably results because this β′-scission takes 
place in the PGH1-type alkoxyl radical instead of the PGF1-type alkoxyl radical ([173], Scheme 
11). Another radical adduct of POBN/●C5H11 (m/z 266) from β-scission in the C-15 oxygenation 
pathway was observed [173]. In addition, two exclusive DGLA-derived free radicals are 
generated from C-8 oxygenation in COX-catalyzed DGLA peroxidation (cell-free), radical 
products of m/z 324 as POBN/●C7H13O2 (from β-scission) and m/z 354 as POBN/●C8H14O3 
(from β′-scission, Scheme 11). 
In order to confirm whether those radicals were actually formed from cellular COX 
peroxidation and thus to assess the association between those novel free radical metabolites and 
cell growth, we made the first effort in this study to characterize free radicals formed from 
cellular COX-catalyzed AA and DGLA peroxidation using the human colon cancer cell line 
HCA-7 colony 29, a cell line with high COX-2 expression. Our refined LC/MS method along 
with SPE allowed us for the first time to detect and characterize free radicals as the reduced form 
(hydroxylamines) derived from the cellular COX metabolism of AA and DGLA in an 
experimental setting in which cell growth responses such as proliferation and cell cycle 
distribution could also be assessed. Therefore, our new protocol should allow us to further study 
the free radical-based mechanism associated with PUFA bioactivity and improve our knowledge 
of COX in cancer biology. 
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Scheme 11. Proposed mechanisms of COX-catalyzed DGLA peroxidation. 
(A) Free radical reaction, e.g. C-15 oxygenation (similar to that of COX/AA), formed two free 
radicals, ●C5H11 and ●C6H13O, which were trapped by POBN as m/z 266 and 296 adducts. (B) 
Free radical reaction, e.g., C-8 oxygenation (another way to add the second O2, occurring after 
formation of the C-13 radical and C-9/C-11 endoperoxide bridge), formed two exclusive free 
radicals, ●C7H13O2 and ●C8H15O3, which were trapped by POBN as the m/z 324 and m/z 354 ions. 
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3.2. Results and Discussion 
3.2.1. COX-2 expression in HCA-7 colony 29 cells 
The human colon carcinoma cell line HCA-7 colony 29 (a subpopulation isolated from 
the HCA-7 cell line) is a new addition to the colorectal collection. Due to its higher expression of 
COX-2, the HCA-7 colony 29 cell line is very useful for studying COX-catalyzed PUFA 
peroxidation. In our study, the expression of COX-2 in HCA-7 colony 29 was evaluated by 
Western blot analysis as described in Chapter 2, after cells were treated with 0.1% ethanol 
(control), 100 µM of DGLA or 100 µM of AA. HCA-7 colony 29 cells showed a strong COX-2 
expression that was not altered by treatment with DGLA and AA (Fig. 2). The unchanged COX-
2 expression indicated that the substrates did not affect the enzyme expression; thereby AA- and 
DGLA-derived metabolites through COX were comparable. 
 
Fig. 2. Western blot analysis of COX-2 expression with PUFA treatment. 
HCA-7 colony 29 cells were treated with 0.1% ethanol, 100 µM of AA or 100 µM of DGLA, 
respectively, for 24 h. Ten micrograms of protein per sample was separated by SDS-PAGE, 
transferred to PVDF membrane, and immunoblotted using a COX-2 specific antibody. Beta-actin 
served as the loading control. 
3.2.2. Offline ESR detection of free radicals 
Free radicals generated and spin-trapped by POBN from COX-catalyzed PUFA 
peroxidation in HCA-7 colony 29 cells were measured by offline ESR. In the control experiment 
in the absence of PUFA in cell-PBS suspension, no ESR signal of POBN radical adducts was 
COX-2 
Beta-actin 
      Control     AA       DGLA 
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observed (Fig. 3A). A typical six-line ESR signal of POBN radical adducts with hyperfine 
coupling constants of aN ≈ 15.69 G and aH ≈ 2.68 G (Fig. 3B and 3C) was observed after cells 
were incubated with 1.0 mM of AA or DGLA. Although AA is generally considered to be the 
more favored substrate for COX, the ESR signal of POBN radical adducts between AA and 
DGLA treatment did not show any significant difference in G value or signal height. 
3465 3480 3495 3510 3525
A. Spin-trapping in Cell-PBS suspension
B. Spin-trapping in Cell-PBS suspension with AA
 Magnetic Field (G)
C. Spin-trapping in Cell-PBS suspension with DGLA
 
Fig. 3. Offline ESR spectra of spin-trapping experiments in cell-PBS suspensions. 
(A) ESR spectra of spin-trapping experiments in cell-PBS suspension without PUFA. (B) ESR 
spectra of spin-trapping experiments in cell-PBS suspension with a supplement of 1.0 mM of AA. 
(C) ESR spectra of spin-trapping experiments in cell-PBS suspensions with a supplement of 1.0 
mM of DGLA. ESR field scans were performed with an ESR flat cell and the hyperfine 
couplings of the spectra were aN≈15.69 G and aH≈2.68 G. 
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However, this offline ESR measurement can provide only an overall signal intensity of 
POBN radical adducts, not specific information in terms of types, numbers, and structures, 
because many of the POBN spin adducts tend to have the same or similar aN and aH hyperfine 
couplings [146]. 
Although this experiment demonstrated the generation of free radicals formed from 
cellular COX-catalyzed PUFA peroxidation, it must be performed in the presence of a large 
excess of cells (>108), and high concentrations of POBN (> 50 mM) as well as PUFA (> 1 mM) 
in PBS for very short incubation time (< 30 min). 
3.2.3. LC/ESR/MS identification of free radicals in cell-PBS suspension 
In order to obtain detailed structural information for the individual POBN radical adducts 
from COX-catalyzed PUFA peroxidation in cell-PBS suspensions, samples were subjected to 
LC/ESR and LC/MS analysis. Although no ESR-active peak was observed in online LC/ESR 
chromatograms (data not shown), almost all radical adducts including isomers observed in the 
cell-free system [171, 173] in our previous publications were detected in cells via LC/MS (Fig. 
4). 
For example, the EIC chromatogram of four protonated molecular ions of m/z 266, m/z 
296, m/z 448 and m/z 548 could be projected from the full MS scan (m/z 50 to m/z 600, Fig. 4A) 
of the cellular COX/AA spin-trapping reaction. The EIC peak of the m/z 266 ion corresponded to 
the POBN radical adduct of the pentyl radical, which was the product of the β-scission occurring 
away from the double bond (POBN/●C5H11, tR ≈ 24.0 min, Fig. 4A, Scheme 10). The EIC peaks 
of the m/z 296 ion corresponded to the POBN radical adduct of two isomers of hexanol radicals 
(POBN/●C6H13O, tR ≈ 12.4 min and 17.8 min, Fig. 4A). The EIC peaks of the m/z 448 ion 
corresponded to the POBN radical adducts of three isomers of POBN/●C14H21O4 (tR ≈ 11.9 min,  
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Fig. 4. LC/MS chromatogram (EICs) of POBN adducts formed from cellular COX-
catalyzed AA and DGLA peroxidation. 
Spin-trapping experiments in cell-PBS suspension with a supplement of 50 mM POBN and 1.0 
mM PUFA for 30 min. (A) EICs of m/z 296, m/z 448, m/z 266 and m/z 548 as POBN/●C5H11, 
POBN/●C6H13O, POBN/●C14H21O4 and POBN/●C20H34O5 formed from C-15 oxygenation of 
COX/AA. (B) EICs of m/z 266 and m/z 296 as POBN/●C5H11 and POBN/●C6H13O formed from 
C-15 oxygenation of COX/DGLA. (C) EICs of m/z 324 and m/z 354 as POBN/●C7H13O2 and 
POBN/●C8H15O3 from C-8 oxygenation of COX/DGLA. 
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14.8 min and 23.3 min, Fig. 4A). POBN/●C6H13O and POBN/●C14H21O4 were derived from a 
special β-scission labeled ‘β′’in Scheme 10, where β-scission occurred toward the double bond 
near the PGF ring. All three radicals were generated from the C-15 oxygenation of COX/AA 
peroxidation and spin-trapped by POBN (Scheme 10). POBN/●C20H34O5 (m/z 548, tR ≈ 26.2 min, 
Fig. 3A) was formed from the rearrangement of a PGF2-type alkoxyl radical (Scheme 10). 
Due to the shared structural moiety (C8-C20) of AA and DGLA, cellular COX-catalyzed 
DGLA peroxidation undergoes the same C-15 oxygenation pathway (Scheme 11A). Thus, the 
EIC peaks of the m/z 266 ion (POBN/●C5H11, tR ≈ 24.0 min, Fig.4B) and the m/z 296 ion 
(POBN/●C6H13O, tR ≈ 12.4 min and 17.8 min, Fig. 4B) were both observed. However, the 
formation of ●C=C as the second radical of the β′-scission in addition to ●C6H13O was not 
observed in COX/DGLA peroxidation. The β′-scission appears to preferentially occur at the 
PGH1 stage, which results in the rearrangement of the ●C=C to form an oxygen-centered radical 
that could not be trapped by POBN [171]. C-8 oxygenation in COX-catalyzed DGLA 
peroxidation also formed two exclusive free radicals corresponding to the protonated molecule 
ions of m/z 354 and m/z 324 (Fig. 4C). The EIC of m/z 354 was projected at tR ≈ 7.5 min and 8.4 
min, and appeared to be two isomers of POBN/●C8H15O3 that formed from the β′-scission of a 
DGLA-derived alkoxyl radical with a carboxyl end (Scheme 11B). The molecule at m/z 324 (tR ≈ 
9.1 min) was the POBN radical adduct of the ●C7H13O2 radical with the carboxyl end formed 
from the β-scission of the DGLA-derived alkoxyl radical as proposed in Scheme 11B. 
When a lower concentration of POBN (20 mM) as well as PUFA (100 µM) was used, the 
signal intensity of the offline ESR was significantly decreased and not all the POBN radical 
adducts were observed in the LC/MS chromatogram (data not shown). 
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Although our Fig. 4 demonstrated radical identification in cellular COX-catalyzed AA 
and DGLA peroxidation for the first time, its biological application was problematic for several 
reasons: (1) in order to observe the EIC peaks of POBN adducts as in Fig. 4, peroxidation and 
spin-trapping experiments must be conducted with a large number of cells (>108/mL); (2) an 
excessive amount of POBN (> 50 mM) as well as PUFA (> 1 mM) must also be introduced, even 
though such high doses of supplements could lead to cell death within 1 h, and (3) the spin-
trapping and peroxidation were taking place in PBS instead of cell culture medium and the 
incubation time was very short (< 30 min). All these facts indeed restrict the biological 
application of the detection method in Fig. 4, since common parameters of cell growth, e.g. 
proliferation, apoptosis, and cell cycle distribution, must be assessed after a long incubation time. 
3.2.4. Assessment of POBN’s trapping ability 
Due to its appropriate solubility in biological fluids, POBN has been widely used in many 
lipid peroxidation studies to detect free radicals formed in vivo and in vitro. POBN has normally 
been administered via acute injection in animal models and the samples analyzed by ESR after a 
short period of time (~ 0.5 to 1 h) [168, 189]. For in vitro studies, the time of the reaction in the 
presence of POBN was also very short (less than 0.5 h) [169-173]. Whether POBN is able to trap 
free radicals after a days-long incubation in complete growth medium has never been studied. 
Methods for evaluating a cell population's response to external factors such as cell 
proliferation and apoptosis usually require a long incubation time, varying from hours to days, 
when cells are cultured under normal growth conditions (cells grown in a recommended 
complete growth medium in an incubator containing a 95% humidified atmosphere of 5% CO2 at 
37°C). In order to investigate the possible association between PUFA-derived free radical 
metabolites and cell growth, the free radical formation from cellular COX-catalyzed PUFA  
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Fig. 5. POBN’s trapping ability and stability in cell culture medium. 
POBN in culture medium was mixed with ethanol and Fe2+ stock solution and subjected to 
offline ESR measurement. The final concentrations of POBN, ethanol and Fe2+ in the reaction 
mixture were 20 mM, 0.1 mM and 0.1 mM, respectively. (A) Offline ESR spectra of 
POBN/●C2H4OH, (B) Trapping ability of POBN in cell culture medium after 2, 4, 24 and 48 h 
incubation, (C) Concentration of POBN in cell culture medium after 2, 4, 24 and 48 h incubation. 
ESR field scans were performed with an ESR flat cell and the hyperfine couplings of the spectra 
were aN≈15.71 G and aH≈2.62 G. 
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peroxidation should be assessed under the same conditions as the cell proliferation and apoptosis 
assays (i.e., a long incubation time such as 24 or 48 h is normally needed). 
Thus, we investigated the potency of POBN as a spin trap after 2, 4, 24 and 48 h of 
incubation in a complete culture medium. At the end of each time point, ethanol and Fe2+ were 
added to a POBN/medium solution to start the spin-trapping reaction, and the reaction mixture 
was immediately subjected to off-line ESR analysis. Ethanol was oxidized to hydroxyethyl 
radical (●C2H4OH) in the present of Fe2+ and trapped by POBN to form POBN/●C2H4OH. A six-
line spectra of POBN/●C2H4OH (aN ≈ 15.71 G and aH ≈ 2.62 G) was detected via offline ESR 
(Fig. 5A). The signal intensity of POBN/●C2H4OH quickly decreased to ~50% after a 4 h 
incubation and remained at around the same level up to 48 h (Fig. 5B). 
This result suggested that POBN was able to continually and effectively trap radicals 
after incubations lasting up to several days. POBN’s concentration was also measured via 
LC/MS. Interestingly, the concentration of POBN in the medium was almost unchanged during 
the 48 h incubation. 
3.2.5. LC/MS and dual spin-trapping in detection of free radicals as hydroxylamines 
Since POBN is able to trap free radicals under cell culture conditions for up to 48 h, we 
conducted the peroxidation and spin-trapping reactions with lower concentrations of POBN (20 
mM) as well as PUFA (100 µM); cells were cultured in complete growth medium in an incubator 
containing a 95% humidified atmosphere of 5% CO2 at 37°C. After a 30 min incubation, the 
supernatant was extracted through a MAX SPE cartridge and subjected to offline ESR as well as 
LC/ESR analysis. 
Although no offline ESR signal was observed in offline ESR spectra and no ESR-active 
peak was detected via LC/ESR (data not shown), we proposed that the ESR-active POBN radical 
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adducts could be readily reduced to their ESR-silent forms as hydroxylamines due to the cellular 
reducing environment, e.g. the presence of the antioxidant GSH and the antioxidant enzymes 
GSH peroxidase, GSH reductase and superoxide dismutase [190, 191]. 
Hydroxylamines are more stable redox forms than the related radical forms of POBN 
adducts, and they could accumulate during incubation to a concentration that is detectable by 
LC/MS (Scheme 12). The reduction of any given POBN adduct corresponded to the structural 
changes +1 Da for the protonated molecules during MS ionization. For example, ●C6H13O was 
trapped by POBN as the m/z 266 ion, thus the corresponding reduced POBN adduct 
(hydroxylamine) was the m/z 297 ion (+1 Da). 
Scheme 12. Reduction of POBN-trapped radical adducts and detection of hydroxylamines 
by LC/MS. 
The reduced radical adducts (e.g. hydroxylamines) in dual spin-trapping experiments in cells 
were able to accumulate and be singled out in LC/MS as 9-Da ion pairs. Note that R: free 
radicals. 
In order to characterize AA- and DGLA-derived free radicals formed under normal cell 
growth conditions, we examined the reduced forms of the adducts. In cellular COX-catalyzed 
AA peroxidation, one isomer of POBN/●C6H13O’s reduced form was projected at tR ≈ 14.5 min 
as a molecule ion of m/z 297 (Fig. 6A). In fact, m/z 297 was the only reduced POBN radical 
adduct that was observed after 30 min of incubation. After an 8 h incubation, in addition to 
POBN/●C6H13O, another reduced POBN radical adduct was observed, which corresponded to  
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Fig. 6. LC/MS chromatogram (EICs) of hydroxylamines formed from cellular COX-
catalyzed PUFA peroxidation. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions in the presence of 20 
mM POBN and 100 µM PUFA. (A) EIC of m/z 297 from cells treated with AA for 30 min. (B) 
EIC of m/z 297 from cells treated with DGLA for 30 min. (C) EIC of m/z 297 and m/z 449 from 
cells treated with AA for 8 h. (D) EIC of m/z 297, m/z 325 and m/z 355 from cells treated with 
DGLA for 12 h. (*) m/z 449 was the hydroxylamine generated from COX/AA peroxidation. 
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one isomer of POBN/●C14H21O4’s reduced form as a protonated molecular ion of m/z 449. The 
EIC chromatography of m/z 449 was projected at tR ≈ 9.6 min (Fig. 6C). The signal intensity of 
m/z 297 increased from 0.5 to 8 h and the appearance of m/z 449 after 8 h suggests that POBN 
radical adducts were reduced to their corresponding hydroxylamine products and accumulated 
during incubation. However, the signal intensity of m/z 449 was much lower than that of m/z 297. 
In cellular COX-catalyzed DGLA peroxidation, similar to what we observed in the 
COX/AA reaction, one isomer of POBN/●C6H13O’s reduced form as a molecule ion of m/z 297 
was projected at tR ≈ 14.5 min (Fig. 6B), and m/z 297 was the only reduced POBN radical adduct 
observed after 30 min of incubation. When the incubation time was extended to 12 h, two more 
hydroxylamine products were observed: POBN/●C7H13O2 and POBN/●C8H15O3’s reduced form 
as protonated molecular ions of m/z 325and m/z 355 were profiled at tR ≈ 6.1 min and tR ≈ 7.1 
min, respectively (Fig. 6D). There was an increase of the signal intensity of m/z 297 from 0.5 to 
12 h, and m/z 297 was still the major hydroxylamine that was detected after a 12 h incubation 
compared to m/z 325 and m/z 355. Interestingly, m/z 449, the reduced POBN adduct of the 
special ●C=C derived from the COX/AA reaction, was also observed at 12 h, which indicated 
that DGLA was converted to AA in cells. 
3.2.6. LC/MS, LC/MS2 and dual spin-trapping in characterization of hydroxylamines 
Because the POBN radical adducts were reduced to the ESR-silent hydroxylamines in 
cells, ESR no longer served as a detector. In order to confirm the structural assignment of 
hydroxylamines, the dual spin trap technique (d0 and d9-POBN) was applied. Dual spin-trapping 
experiment along with LC/MS detection [170-173] was used for recognition and also 
identification of a number of isomers of radical adducts and their structures. In this technique, 
the nine hydrogen atoms on the tert-butyl group were replaced by deuterium in d9-POBN. The 
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commercially unavailable spin trap d9-POBN has been recently synthesized starting from 
commercially available d9-tert-butylamine (Scheme 8). When a 50:50 mixture of POBN and d9-
POBN was applied in a cellular spin-trapping experiment, hydroxylamine could be singled out in 
LC/MS as an ion pair with a 9-Da difference (Scheme 12), and then the corresponding d0/d9-
POBN fragmentation should be observed by LC/MS2. 
The dual spin-trapping experiments were performed with a 12 h incubation because at 
that time all four reduced products, POBN/●C6H13O, POBN/●C14H21O4, POBN/●C7H13O2 and 
POBN/●C8H15O3, were observed. Under the same chromatographic conditions, the polarity and 
molecular differences between the structures of the reduced products of d0- and d9-POBN radical 
adducts resulted in a shorter retention time for the reduced d9-POBN adduct than for the reduced 
d0-POBN adduct, as shown in Figs. 7A, 8A, 9A and 10A. 
In the cellular COX/AA reaction using dual spin traps, two ion pairs of m/z 306/297 and 
m/z 458/449 were observed. The ion pair of m/z 297/306 (tR ≈ 14.5 min and tR ≈ 13.8 min) 
represented d0/d9-POBN/●C6H13O’s reduced products (Fig. 7A). LC/MS2 studies confirmed these 
assignments by showing a unique fragmentation pattern of m/z 179 and m/z 209 ions from 
POBN/●C6H13O (Fig. 7B). LC/MS analysis of m/z 188 and m/z 209 from d9- POBN/●C6H13O 
further verified the assignments (Fig. 7C). 
Another ion pair of m/z 449/458 (tR ≈ 9.6 min and tR ≈ 9.3 min) represented d0/d9-
POBN/●C14H21O4’s reduced products (Fig. 8A). LC/MS2 studies confirmed these assignments by 
showing a unique fragmentation pattern of m/z 179, m/z 342, m/z 360 and m/z 431 ions from 
POBN/●C14H21O4 (Fig. 8B). LC/MS analysis of m/z 179, m/z 342, m/z 360 and m/z 440 from d9- 
POBN/●C14H21O4 further verified the assignments (Fig. 8C). 
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Fig. 7. LC/MS chromatogram (EICs) and LC/MS2 analysis of m/z 306 and m/z 297 in dual 
spin-trapping experiment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions in the presence of 20 
mM d0/d9-POBN and 100 µM AA for 12 h. (A) EIC of m/z 306 and m/z 297 from cells treated 
with AA. (B and C) LC/MS2 of m/z 297 and m/z 306 from cells treated with AA. Each 
chromatographic fraction with m/z 297 in the POBN experiment had a counterpart in the d9-
POBN spin-trapping experiment (a′, b′, c′, and d′ ions). 
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Fig. 8. LC/MS chromatogram (EICs) and LC/MS2 analysis of m/z 458 and m/z 449 in dual 
spin-trapping experiment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions in the presence of 20 
mM d0/d9-POBN and 100 µM AA for 12 h. (A) EIC of m/z 458 and m/z 449 from cells treated 
with AA. (B and C) LC/MS2 of m/z 449 and m/z 458 from cells treated with AA. Each 
chromatographic fraction with m/z 449 in the POBN experiment had a counterpart in the d9-
POBN spin-trapping experiment (a′, b′, c′, and d′ ions). 
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In a cellular COX/DGLA reaction using dual spin traps, the ion pair of m/z 306/297 was 
also observed and the results of EICs and LC/MS2 analysis was similar to that observed in the 
COX/AA reaction (data not shown). Another two ion pairs of m/z 325/234 and m/z 355/264 
were observed as shown in Figs. 9A and 10A. The ion pair of m/z 325 /334 represented d0/d9-
POBN/●C7H13O2’s reduced product. The LC/MS2 studies confirmed these assignments by 
showing a unique fragmentation pattern of m/z 122 and m/z 237 ions from POBN/●C7H13O2 (Fig. 
9B). LC/MS analysis of m/z 122 and m/z 237 from d9- POBN/●C7H13O2 further verified the 
assignments (Fig. 9C). The ion pair of m/z 355/364 represented d0/d9-POBN/● C8H15O3’s 
reduced product. LC/MS2 studies confirmed these assignments by showing a unique 
fragmentation pattern of m/z 138, m/z 179, m/z 250 and m/z 266 ions from POBN/● C8H15O3 
(Fig. 10B). LC/MS analysis of m/z 138, m/z 188, m/z 250 and m/z 266 from d9- POBN/● 
C8H15O3 further verified the assignments (Fig. 10C). 
However, under the same chromatographic conditions, the ion pairs of m/z 325/234 and 
m/z 355/264 were not observed as double peaks because the retention times of these ion pairs 
were too short (tR ≈ 6 min) as shown in Figs. 9A and 10A. In fact, when we changed the 
chromatographic conditions and extended the retention time of the analytes, the double peaks of 
m/z 325 and m/z 334 (tR ≈ 12.6 and 13.0 min) as well as m/z 355 and m/z 364 (tR ≈ 14.9 and 15.2 
min) were both detected as shown in the inset of Figs. 9A and 10A. 
In conclusion, our refined LC/MS method along with the SPE allowed us to detect and 
characterize free radicals formed from cellular COX metabolism of AA and DGLA as their 
reduced form (hydroxylamines). Since hydroxylamines were accumulated products, they could 
be detected under the experimental setting in which cell growth response such as proliferation 
and cell cycle distribution could also be assessed. Thus, for the first time, common and exclusive  
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Fig. 9. LC/MS chromatogram (EICs) and LC/MS2 analysis of m/z 334 and m/z 325 in dual 
spin-trapping experiment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions in the presence of 20 
mM d0/d9-POBN and 100 µM DGLA for 12 h. (A) EIC of m/z 334 and m/z 325 from cells 
treated with DGLA. (B and C) LC/MS2 of m/z 325 and m/z 334 from cells treated with DGLA. 
Each chromatographic fraction with m/z 325 in the POBN experiment had a counterpart in the 
d9-POBN spin-trapping experiment (a′, b′, c′, and d′ ions). The inset in Fig. 9A was the EIC of 
m/z 334 and m/z 325 under different chromatographic condition: (i) 0-40 min, 0 to 60% B; (ii) 
40-43 min, 60 to 95% B; and (iii) 43-50 min (isocratic), 5% A and 95% B. 
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Fig. 10. LC/MS chromatogram (EICs) and LC/MS2 analysis of m/z 364 and m/z 355 in dual 
spin-trapping experiment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions in the presence of 20 
mM d0/d9-POBN and 100 µM DGLA for 12 h. (A) EIC of m/z 364 and m/z 355 from cells 
treated with DGLA. (B and C) LC/MS2 of m/z 355 and m/z 364 from cells treated with DGLA. 
Each chromatographic fraction with m/z 355 in the POBN experiment had a counterpart in the 
d9-POBN spin-trapping experiment (a′, b′, c′, and d′ ions). The inset in Fig. 10A was the EIC of 
m/z 364 and m/z 355 under different chromatographic conditions: (i) 0-40 min, 0 to 60% B; (ii) 
40-43 min, 60 to 95% B; and (iii) 43-50 min (isocratic), 5% A and 95% B. 
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free radicals as the reduced form were identified and characterized in COX-catalyzed AA vs. 
DGLA peroxidation in cells. The ●C6H13O was the common free radical generated from both 
COX/AA and COX/DGLA peroxidation. The ●C14H21O4 was the exclusive free radical from 
COX/AA and the ●C7H13O2 and ●C8H14O3 were exclusive free radicals from COX/DGLA. 
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CHAPTER 4. THE ASSOCIATION BETWEEN AA-/DGLA-DERIVED FREE RADICAL 
METABOLITES AND COLON CANCER CELL GROWTH 
4.1. Introduction 
AA, the major ω-6 PUFA in mammalian cells, has been associated with the enhancement 
of tumorigenesis and metastasis in the development of various cancers [72, 192-196]. 
Interestingly, increasing evidence from animal and in vitro studies suggests that DGLA, the 
upstream fatty acid of AA, may possess anti-inflammatory and anti-carcinogenetic activity [70-
73]. Previous studies have showed that under certain conditions some PUFAs were able to 
induce apoptosis of tumor cells with little or no cytotoxic action on normal cells [117, 119, 120]. 
It was observed that among all the tested fatty acids, DGLA was the most effective in selectively 
killing tumor cells [117]. These results suggested that DGLA shows selective tumoricidal action 
in vitro. Through suppressing the expression of oncogenes Her-2/neu and Bcl-2 and enhancing 
p53 activity, DGLA could induce apoptosis of tumor cells [119, 121-123]. Further study found 
that the COX inhibitor and anti-oxidants had opposite effect on the anti-tumorigenic action of 
DGLA. It was found that COX inhibitors blocked the tumoricidal action of DGLA on human 
cervical carcinoma, whereas anti-oxidants inhibited the cytotoxic action of DGLA on human 
breast cancer cells [124, 125]. These results suggested that the COX metabolism of DGLA may 
play a role in the anti-cancer effect of DGLA. 
COX catalyzes AA and DGLA peroxidation to form PGE2 and PGE1, respectively. PGE2 
and PGE1 are well-known lipid signaling molecules that participate in various physiological and 
pathological actions by activating the PKA signaling pathway through EP receptors. In general, 
PGE2 and PGE1 were believed to be associated with the opposing effects of AA vs. DGLA. 
However, the structures of PGE2 and PGE1 are similar, with PGE1 only missing one double bond 
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in the structure. If both of them bind to the same receptors, it was hard to believe that PGE2 and 
PGE1 could exert opposing activities. In COX-catalyzed PUFA peroxidation, in addition to 
PGEs, several free radicals, the most reactive intermediate metabolites, were formed. However, 
due to their highly reactive nature, the individual free radicals have not been characterized in 
cells and the role of those novel free radical metabolites in cancer progression and prevention 
still remains a mystery. Our new method has allowed us to study the exclusive free radical 
products of COX/AA vs. COX/DGLA for the first time, which may open a new door to 
advancing COX biology. 
In our previous results (Chapter 3), free radicals formed in common from COX/AA and 
COX/DGLA peroxidation and those formed exclusively from one or the other were identified 
and characterized in colon cancer cell HCA-7 colony 29. We further investigated the association 
between the individual free radicals and the contrasting bioactivity of AA vs. DGLA. In this 
chapter, we profiled free radical products derived from the cellular COX metabolism of AA and 
DGLA under normal cell growth conditions and tested their association and effects on cell 
growth. Our results suggested that the free radical metabolites may be a better indicator for the 
opposite effects of AA vs. DGLA on cancer cell proliferation than PGE2 vs. PGE1. DGLA may 
attenuate colon cancer cell proliferation via its exclusive free radical metabolites through COX 
metabolism, and regulating DGLA, and its metabolites in cells could be used as a new approach 
to controlling colon cancer cell growth. 
4.2. Results and Discussion 
4.2.1. Quantification of hydroxylamines as free radicals in a single dose of PUFA treatment 
In order to find a possible association between free radical metabolites generated from 
COX-catalyzed PUFA peroxidation and cell growth, the time course of hydroxylamine (the 
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reduced form of POBN trapped radical adducts) formation was quantified for up to 48 h with d9-
POBN as an internal standard rather than a spin trap for radical identification. For this purpose, a 
small measured amount of d9-POBN was added, but only after the mixture of cell culture 
medium and cell homogenate was mixed with ACN (1:1, v/v) to stop the peroxidation and spin-
trapping reaction. The same amount of d9-POBN was added to each sample and the 
concentration of each hydroxylamine was calculated by comparing their integrated peak areas in 
EICs to the peak area of the internal standard of d9-POBN (m/z 204, tR ≈ 3.6 min) with a known 
concentration at 2.0 µg/mL. The final concentrations of hydroxylamines were normalized to cell 
numbers and expressed as [hydroxylamines] per 2×106 cells. 
Hydroxylamines in cells treated with a single dose of AA: In cells treated with AA, the 
m/z 297 ion, as the reduced product of POBN/●C6H13O, was observed at all the time points (from 
0.5 to 48 h). The concentration of the m/z 297 ion gradually increased and reached its peak 
concentration of ~ 68.0 nM at 12 h, then slightly decreased at 24 h and 48 h (Fig. 11A), possibly 
due to decreased POBN trapping ability after one day of the experiment. Before 8 h, the m/z 297 
ion was the only hydroxylamine that was detected. The reduced product of POBN/●C14H21O4, as 
the m/z 449 ion, was detected starting at 8 h (Fig. 11B). Its concentration increased from 8 to 12 
h, followed by a decrease from 12 to 48 h. The peak concentration of the m/z 449 ion was ~ 7.0 
nM, which was about 1/10 that of the m/z 297 ion. 
Hydroxylamines in cells treated with a single dose of DGLA: In cells treated with DGLA, 
the m/z 297 ion was also observed from 0.5 to 48 h (Fig. 12A). From 0.5 to 12 h, its 
concentration increased to a peak of ~ 79.2 nM and decreased afterwards at 24 and 48 h. The 
reduced products of POBN/●C7H13O2 and POBN/● C8H15O3 as the m/z 325 and m/z 355 ions 
were observed at 8 h and clearly detected from 12 h to 48 h (Fig. 12B). At 24 h, the ions of m/z 
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Fig. 11. Profiles of hydroxylamines with a single dose of AA treatment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions for 0.5, 2, 4, 8, 12, 24 
and 48 h in the presence of 20 mM POBN and 100 µM AA. (A) Profile of common radical 
product (m/z 297) in cells treated with AA. (B) Profile of exclusive radical product (m/z 449) in 
cells treated with AA. Hydroxylamines were quantified with d9-POBN (2 µg/mL). Data are 
expressed as means ± SD from n≥3. 
325 and m/z 355 reached their peak concentrations at ~ 5.8 nM and 8.5 nM, respectively. The 
concentration of the m/z 325 ion did not show a significant difference from 12 h to 48 h. For the 
ion of m/z 355, there was a substantial increase from 12 h to 24 h and afterwards a decrease. 
Interestingly, the hydroxylamine of the m/z 449 ion (asterisked in Fig. 12B), which was the 
exclusive product from COX/AA peroxidation, was also observed in cells treated with DGLA. 
Its peak concentration (~6.4 nM) was observed at 12 h. 
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Fig. 12. Profiles of hydroxylamines with single dose of DGLA treatment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions for 0.5, 2, 4, 8, 12, 24 
and 48 h in the presence of 20 mM POBN and 100 µM. (A) Profile of common radical product 
(m/z 297) in cells treated with DGLA. (B) Profiles of exclusive radical products (m/z 325 and 
mm/z 355) in cells treated with DGLA. Hydroxylamines were quantified with d9-POBN (2 
µg/mL). (*) m/z 449 was the exclusive radical product generated from COX/AA peroxidation. 
Data are expressed as means ± SD from n≥3. 
The concentration of the m/z 297 ion in cells treated with DGLA showed a trend similar 
to what we observed in cells treated with AA, but continued to become higher as the incubation 
time increased. At 0.5 and 2 h, the concentrations of the m/z 297 ion in COX/DGLA and 
COX/AA were at about the same level. From 4 to 48 h, it was higher in cells treated with DGLA. 
It is worth noticing that the peak concentration of the m/z 449 ion in cells treated with DGLA 
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was close to the level of that at 24 h and 48 h in cells treated with AA, which indicates a rapid 
conversion from DGLA to AA. 
The most abundant hydroxylamine accumulated during a 48 h incubation in both the AA 
and DGLA treatments was the m/z 297 ion, whose concentration was about 10-fold greater than 
the m/z 449, m/z 325 and m/z 355 ions. In fact, in cell-free in vitro systems where ovine COX 
catalyzed AA and DGLA peroxidation [171, 173], the m/z 296 ion as POBN/●C6H13O was also 
the most abundant radical adduct in both reactions. It has been reported that the POBN adducts 
of the m/z 448 ion (POBN/●C14H21O4) showed very low MS efficiencies compared to their ESR 
and UV detection during online separation due to the steric hindrance of protonation of the 
POBN. Similarly, the reduced product of POBN/●C14H21O4 as the m/z 449 ion may have the 
same very low MS efficiencies as m/z 448. 
In COX-catalyzed DGLA peroxidation, the free radicals were generated from two distinct 
pathways: C-15 oxygenation and C-8 oxygenation. The hydroxylamine, the m/z 297 ion as the 
reduced product of POBN/●C6H13O, was generated from the C-15 oxygenation pathway (Scheme 
11), while the ions of m/z 325 and m/z 355, as the reduced products of POBN/●C7H13O2 and 
POBN/● C8H15O3, were generated from C-8 oxygenation (Scheme 11). However, which was the 
preferred DGLA peroxidation pathway was still unknown. The high abundance of the m/z 297 
ion and the low abundance of the m/z 325 and m/z 355 ions suggest that maybe the C-15 
oxygenation pathway is the preferred one. As a result, m/z 325 and m/z 355 will have 
accumulated more slowly than m/z 297 and would be detected later. Another reason for the low 
abundance of m/z 325 and m/z 355 was the rapid conversion of DGLA to AA in cells. COX 
competed with D5D for DGLA, and as the available substrate decreased, the radical formation 
would subsequently decrease. 
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4.2.2. Profile of PUFAs and PGEs in a single dose of PUFA treatment 
The presence of the hydroxylamine of the m/z 449 ion in the cellular spin-trapping 
experiment with a supplement of DGLA suggested that DGLA could be rapidly converted to AA 
in cells (by D5D). In order to verify our hypothesis and learn more about the metabolism of 
PUFA in cells, we used LC/MS to examine the time course of the concentrations of PUFAs and 
prostaglandins in cell culture medium after AA or DGLA treatment. The concentrations of AA, 
DGLA, PGE2 and PGE1 were quantified by the commercially available deuterated internal 
standards AA-d8, DGLA-d6, PGE2-d9 and PGE1-d4. The same amounts of internal standards with 
known concentrations were added to each sample and the concentrations of AA, DGLA, PGE2 
and PGE1 were calculated according to the standard curves. 
AA and PGE2 in cells treated with a single dose of AA: When cells were incubated with 
AA, the concentration of AA in the cell culture medium gradually decreased in the first 4 h and 
significantly dropped at 8 h, almost reaching the control level after 24 h (Fig. 13A). In the 
meantime, a substantial production of PGE2 was observed at 0.5 h, and the concentration of 
PGE2 reached a peak at 8 h (~ 101.5 nM) and slightly decreased afterwards (Fig. 13B). 
PUFAs and PGEs in cells treated with a single dose of DGLA: In the DGLA-treated cells, 
the trends of the uptake of DGLA and the formation of PGE1 (Fig. 14) were similar to those 
observed in AA-treated cells. The uptake of DGLA was significantly higher at both 8 and 12 h 
and almost depleted in the medium at 48 h (Fig. 14A). The peak concentration of PGE1 was ~ 
81.3 nM at 8 h (Fig. 14B). As expected, AA was also detected in DGLA-treated cells and 
reached a peak (~ 4.0 nM) at 8 h (Fig. 14A), almost the same level as in AA-treatment at 12 h 
(Fig. 13A). The concentration of the metabolite of AA through COX metabolism, PGE2, 
constantly increased from 0.5 to 48 h and the ratio of [PGE1]:[PGE2] decreased from ~ 1:6 to 1:1. 
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Fig. 13. Profiles of AA and PGE2 with single doses of AA treatment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions for 0.5, 2, 4, 8, 12, 24 
and 48 h with a supplement of 100 µM of AA. (A) Profile of AA in cell culture medium, (B) 
Profile of PGE2 in cell culture medium. AA and PGE2 were quantified with the internal standards 
AA-d8 and PGE2-d9, respectively. Data are expressed as means ± SD from n≥3. 
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Fig. 14. Profiles of DGLA, AA, PGE1 and PGE2 with a single dose of DGLA treatment. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions for 0.5, 2, 4, 8, 12, 24 
and 48 h with a supplement of 100 µM of DGLA. (A) Profiles of DGLA and AA in cell culture 
medium, (B) Profiles of PGE1 and PGE2 in cell culture medium. DGLA, AA, PGE1 and PGE2 
were quantified with the internal standards DGLA-d6, AA-d8, PGE1-d4 and PGE2-d9, respectively. 
Data are expressed as means ± SD from n≥3. 
The profiles of PUFAs in cell culture medium showed the rate of uptake of the 
exogenous PUFA by cells. The formation of PGEs as the end non-radical metabolites in COX-
catalyzed PUFA peroxidation was closely related to the formation of the free radical metabolites 
and indicated the availability of the free fatty acid at the enzyme site in cells. The pattern of PGE 
formation was consistent with the formation of the free radical metabolites in this study. The 
significant drop of both AA and DGLA in the cell medium was observed at 8 h and 12 h, and the 
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maximum production of PGEs also occurred at 8 h. As observed in the time course of 
hydroxylamine formation, 8 h and 12 h are two critical time points at which the hydroxylamines 
reached their peak concentrations or started to show up. 
In DGLA-treated cells, the detection of AA and PGE2 confirmed the conversion from 
DGLA to AA. The appearance of AA in the cell culture medium was probably due to the 
diffusion of the free fatty acid through the membrane. Although AA concentration peaked at 8 h 
and decreased afterwards, there was a steady increase in PGE2 up to 48 h. The production of 
PGE2 did not decrease after 8 h but kept increasing, suggesting that the DGLA continuously 
converted to AA with the maximum conversion occurring at 8 h, and AA (converted from 
DGLA) even reached the same level as in the AA-treatment at 12 h. 
The exogenous PUFA could be esterified into the phospholipid of the cell membrane. 
Due to the high concentration of PUFAs in the cell culture medium, the exogenous PUFA could 
also diffuse into the cells without being incorporated into the cell membrane. According to the 
results, the dramatic drop of AA and DGLA in the cell culture medium suggested that more than 
90% of the uptake of the supplemental AA and DGLA was achieved by 12 h, which meant at 12 
h, all the exogenous PUFA was either incorporated into the cell membrane’s phospholipids or 
diffused into the cells as the free fatty acid. Those free AA and DGLA were subsequently 
metabolized to their corresponding metabolites (including PGEs and the free radical metabolites). 
The free DGLA also served as the substrate of D5D (the enzyme converting DGLA to AA) and 
was continuously converted to AA. As the pool of exogenous PUFA was exhausted at 12 h, the 
formation of PUFA-derived metabolites started to decrease (not increasing due to the decreased 
POBN trapping ability) because now the source of PUFA came from the membrane’s 
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phospholipids and needed to be released into the cells as the free acid formed by the action of 
cPLA2. 
4.2.3. Effect of PUFAs on cell proliferation and cell cycle distribution 
We have successfully characterized and profiled the common and exclusive free radical 
products generated from COX/AA and COX/DGLA peroxidation in HCA-7 colony 29 cells. In 
order to make a possible association between these novel free radical metabolites and the 
opposing bioactivity of AA vs. DGLA, first of all, the effects of PUFA on the proliferation of 
HCA-7 colony 29 were evaluated via the MTS assay. 
The effect of AA or DGLA on cell growth was evaluated via the MTS assay. After a 48 h 
incubation, the cells supplemented with AA showed a slight increase in cell proliferation 
compared to the control treatment (Table 3). The DGLA-treated cells showed a similar pro-
proliferation effect (Table 3), which was expected as we hypothesized. The DGLA should 
exhibit an inhibitory effect on cell growth compared to AA, but the constant conversion from 
DGLA to AA may abolish this effect because of the pro-proliferation effect of the exclusive AA-
derived free radical metabolites (●C=C). 
Table 3. Effect on cell proliferation and cell cycle distribution from PUFAs. 
HCA-7 
Colony 29 
treated w/ 
Cell Cycle Distribution Cell Proliferation 
% in G1 Phase % in G2/M Phase % viability 
8 h 24 h 8 h 24 h 48 h 
Control 
(0.1 % ethanol) 
37.4 
± 2.4 
41.3 
± 3.5 
22.1 
± 1.2 
20.9 
± 0.9 100 
AA 
(100 µM) 
40.2 
± 7.2 
41.6 
± 3.8 
22.3 
± 2.7 
23.8 
± 2.1 
112.1* 
± 3.9 
DGLA 
(100 µM) 
43.6* 
± 9.6 
42.7 
± 2.3 
29.4* 
± 2.1 
23.6 
± 1.6 
109.1* 
± 5.7 
HCA-7 colony 29 cells treated with 0.1% ethanol, 100 µM AA or 100 µM DGLA. Data 
represent the mean ± SD derived from three separate experiments with triplicate wells per 
condition. Cell viability (%) was compared with the control group. Control cells were incubated 
with 0.1% ethanol (final concentration). (*) P˂0.01, significantly different from control. 
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Fig. 15. Effect of PUFA on cell cycle distribution. 
(A-B) HCA-7 colony 29 cells were treated with 0.1% ethanol for 8 and 24 h, respectively, (C-D) 
HCA-7 colony 29 cells were treated with 100 µM AA for 8 and 24 h, respectively, (E-F) HCA-7 
colony 29 cells were treated with 100 µM DGLA for 8 and 24 h, respectively. 
To further confirm our hypothesis, PI staining was performed to evaluate the effects of 
AA and DGLA on cell cycle distribution at 8 and 24 h (Table 3 and Fig. 15). At 8 h, when most 
of the DGLA was not converted to AA, cells treated with DGLA induced a significant cell G2/M 
phase arrest (~ 40% compared to control and AA-treated cells ~ 30% Table 3). The DGLA 
mediated G2/M phase cell cycle arrest was accompanied by a G1 delay (Table 3). However, both 
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G1 and G2/M arrests were almost completely recovered at 24 h as AA accumulated in cells and 
competed with DGLA for the COX to form the pro-proliferative metabolites. 
The G2/M checkpoint is an important cell cycle checkpoint that insures that cells do not 
initiate mitosis before they have a chance to repair damaged DNA after replication. Several 
mechanisms have been reported whereby free radicals could cause various DNA damage, such as 
oxidized bases, abasic sites, DNA-DNA intrastrand adducts, DNA strand breaks and DNA-
protein cross-links [197, 198]. In addition, substantial evidence suggests that the highly reactive 
free radicals could cause DNA lesions that up-regulate the apoptotic genes p53 and p21 to induce 
cell apoptosis [199, 200]. The increased p53 was correlated to the accumulation of G2/M arrest in 
cells [201-203]. Thus a possible mechanism for the inhibitory effect of DGLA-derived free 
radical metabolites is through the activation of the tumor suppressor p53. 
4.2.4. Comparison of effects of free radical metabolites and PGEs on cell growth 
The effect of PGEs on cell growth was also evaluated since PGEs are the most studied 
COX metabolites, which are believed to be involved in regulating cancer cell growth through the 
down-stream signaling pathways. Cells were treated with PGE2 and PGE1 at the same 
concentration as that of the radical derivatives. However, as shown in Fig. 16, both PGE2 and 
PGE1 slightly increased cell proliferation compared to the control treatment, with little difference 
as the concentration increased. As the concentration of PGE2 increased from 0.01 to 1 µM, the 
cell viability increased by ~8.4%, while for PGE1, the cell viabilities were not significantly 
altered at any of the three concentrations (Fig. 16). 
It was surprising that the PGE1, which was considered to be the anti-inflammatory PGE, 
not only did not inhibit colon cancer cell growth as reported [70, 186], but on the contrary, 
promoted proliferation in HCA-7 colony 29 cells. PGE1 has been used to treat chronic 
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Fig. 16. Effect of PGEs on colon cancer cell growth. 
HCA-7 colony 29 cells were treated with PGEs at concentrations of 0.01, 0.1 and 1 µM for 48 h. 
Data represent the mean ± SD derived from three separate experiments with triplicate wells per 
condition. Cell viability (%) was compared with a control group. Control cells were incubated 
with 0.1% ethanol (final concentration). 
inflammatory diseases in vascular tissues. An increase in PGE1 might contribute to the 
attenuation of the development of atherosclerosis via the inhibition of the adhesion molecules in 
vascular smooth muscle cells and endothelial cells [76]. Increasing evidence suggested that PGE1 
also possesses anti-cancer activity; it was able to inhibit cancer cell growth in vitro. A high dose 
of PGE1 (30 µg/mL) inhibited the proliferation of HeLa cells [185]. The proliferative activity of 
murine B16-F10 melanoma cells was found to be particularly affected by PGE1: B16-F10 cells’ 
proliferation decreased by about 40% after 48 and 72 h of treatment with 10 µg/mL of PGE1 [70]. 
PGE1 only showed this inhibitory effect at a high concentration (more than 10 µg/mL), while a 
low dose of PGE1 (3 µg/mL) may fail to alter cell proliferation or even increase cell growth 
[185]. That would explain why PGE1 did not show an inhibitory effect on cell growth in HCA-7 
colony 29 cells. According to our results in the cell proliferation assay, the highest dose of PGE1 
used to treat HCA-7 colony 29 cells was 1 µM, which equals ~0.35 µg/mL, much lower than the 
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effective concentration for inhibition. Our results were also consistent with the observations in 
[185] that a lower concentration of PGE1 increased cell proliferation, although the underlying 
mechanism was not yet clear. However, under physiological conditions, the level of PGE1 could 
never achieve a concentration as high as 1 µM. In our results (Fig. 14), the highest concentration 
of PGE1 with a direct treatment of 100 µM of DGLA was only around 0.1 µM. 
The same issues were raised in the research targeting the pro-proliferation effect of PGE2. 
The elevated COX-2 expression observed in colon cancer cells resulted in a high concentration 
of AA-derived PGs, in particular PGE2. PGE2 has been shown to stimulate the growth of cancer 
cells. The growth of the colon cancer cells (HT-29) was stimulated by a range of PGE2 
concentrations (from 0.1 up to 10 µM), e.g., PGE2 (0.5 µM) increased cell yield by ~19% over 
control levels and cell numbers were ~45% greater than control levels with 10 µM PGE2 [204]. 
The cell growth increased as the level of PGE2 increased. In addition, the expression of vascular 
endothelial growth factor, one of the major regulators for angiogenesis, was induced by PGE2 at 
a concentration of 0.5 µM in LS-174T cells [205], suggesting that PGE2 signaling may exert pro-
oncogenic actions that play a critical role in colorectal carcinogenesis. However, the 
concentration of PGE2 that was used in those experiments was higher than what could be 
achieved under physiological conditions. 
In order to detect a possible association between these novel free radical metabolites and 
the opposing bioactivity of AA vs. DGLA, the effects of free radical metabolites on the 
proliferation of HCA-7 colony 29 were evaluated via the MTS assay. Because PUFA-derived 
free radicals cannot be synthesized in order to test them on cells due to their very short lifetimes, 
various concentrations (from 0.01 to 1 µM) of the selected derivatives of free radicals (the 
corresponding alcohol form) were used to assess their effect on colon cancer cell proliferation. 
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Table 4. The tested free radical derivatives (metabolites). 
Radical Derivatives Radicals Resources 
1-Hexanol OH  
C-15 oxygenation of COX/AA 
& COX/DGLA 
8-Hydroxyoctanoic acid COOHHO  C-8 oxygenation of COX/DGLA 
Heptanoic acid COOH  C-8 oxygenation of COX/DGLA 
To be made and studied 
HO
HO
COOH
 
C-15 oxygenation of COX/AA 
The corresponding derivatives of ●C6H13O, ●C7H13O2 and ●C8H15O3 were hexanol, 
hepotanoic acid and 8-hydroxyoctanoic acid, respectively (Table 4). The ●C6H13O was the 
common free radical that was observed in both COX/AA and COX/DGLA peroxidation, and the 
corresponding spin adduct was m/z 296 (POBN/●C6H13O). Two more free radicals, ●C7H13O2 
and ●C8H15O3, were exclusive free radical metabolites from COX/DGLA and corresponded to 
the spin adducts of m/z 324 (POBN/●C7H13O2) and m/z 354 (POBN/●C8H15O3). Among the three 
radical derivatives, both hexanol and 8-hydroxyoctanoic acid inhibited cell proliferation at 
concentrations from 0.01 to 1.0 µM, while 8-hydroxyoctanoic acid had the most inhibitory effect 
(decreasing the cell viability to ~ 80% compared to the control group) and the hexanol had a 
moderately inhibitory effect (Fig. 17). The heptanoic acid did not inhibit cell proliferation (Fig. 
17). 
Among the four types of free radicals that were characterized and profiled in both 
COX/AA and COX/DGLA peroxidation, the derivatives of ●C6H13O, ●C7H13O2 and ●C8H15O3 
were tested on cell growth via the MTS assay (Fig. 17). The only one not tested was the 
exclusive radical ●C=C (●C14H21O4) from COX/AA peroxidation. The ●C14H21O4 radical does 
not have commercially available derivatives. We believed that this special radical should be 
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closely related to the pro-carcinogenic effect of AA. The radical derivative of ●C14H21O4 will be 
synthesized and studied for its potential role on colon cancer cell growth in the future. 
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Fig. 17. Effect of free radical derivatives on colon cancer cell growth. 
HCA-7 colony 29 cells were treated with free radical derivatives at concentrations of 0.01, 0.1 
and 1.0 µM for 48 h. 1-hexanol was derived from ●C6H13O. Heptanoic acid was derived from 
●C8H15O3. 8-hydroxyoctanoic acid was derived from ●C7H13O2. Data represent the mean ± SD 
derived from three separate experiments with triplicate wells per condition. Cell viability (%) 
was compared with the control group. Control cells were incubated with 0.1% ethanol (final 
concentration). (*) P˂0.01, significantly different from control. 
The exclusive free radicals generated from COX-catalyzed DGLA showed an inhibitory 
effect on colon cancer cell growth, while we believed that the exclusive free radicals (●C=C) 
generated from COX-catalyzed AA should have the opposite effect. Because the effect of the 
●C=C on cell growth was not able to be tested due to the lack of corresponding derivatives, we 
tested the effect of the precursor instead. We had proved that the PUFA-derived free radical 
metabolites rather than PGEs were the critical player in the proliferation of colon cancer cell 
growth. Thus, if AA and DGLA exerted different effects on colon cancer cell growth, the 
difference should be attributed to their exclusive free radical metabolites. 
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Among the tested free radical derivatives, those from the exclusively DGLA-derived free 
radicals showed an inhibitory effect on HCA-7 colony 29’s growth, while the PGE1 did not. 
Taken together, our results suggest that these free radical metabolites may play a more important 
role in regulating colon cancer cell growth than PGEs. 
4.2.5. Study of double doses of PUFA treatment 
DGLA has a potential inhibitory effect on colon cancer cell growth via free radical 
metabolites through COX peroxidation. But the rapid conversion from DGLA to AA in cells 
decreased the DGLA levels while concurrently increasing AA levels, which abolished the 
inhibitory effect of DGLA on cell growth as shown in Table 3. We expected that the increased 
availability of DGLA in cells after a second dose would subsequently increase DGLA-derived 
radicals and restore the inhibitory effect of DGLA on cell growth. 
In order to determine the formation of free radical products after the second dose of 
PUFA was introduced, radical formation with double doses of PUFA treatment was profiled, 
with the second dose administered 24 h after the first. The concentrations of hydroxylamines 
after the second dose were profiled at 36 and 48 h, which was equivalent to the time points of 12 
and 24 h after the first dose. 
Hydroxylamines in cells treated with double doses of DGLA: In cells treated with double 
doses of DGLA, the common ion of m/z 297 as the reduced adduct of POBN/●C6H13O and the 
exclusive ions of m/z 325 and m/z 355 from COX/DGLA as the reduced adducts of 
POBN/●C7H13O2 and POBN/● C8H15O3, respectively, all increased at 36 and 48 h after the 
introduction of the second dose compared to that at 12 and 24 h (Fig. 18). There was a small 
increase in the concentrations of the m/z 297 ions from ~ 79.2 nM at 12 h to 84.1 nM at 36 h and 
from 65.7 nM at 24 h to 73.6 nM at 48 h (Fig. 18A). The concentrations of the m/z 325 ions 
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increased by about 25 % from ~7.8 nM at 12 h to 9.8 nM at 36 h and by about 40% from 8.6 nM 
at 12 h to 12.2 nM at 24 h (Fig. 18B). The concentrations of the m/z 355 ions increased 
substantially, by around 83% from ~7.1 nM at 12 h to 13.0 nM at 36 h, but at 24 and 48 h the 
levels stayed about the same (12.4 and 13.8 nM, respectively, Fig. 18B). 
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Fig. 18. Profile of hydroxylamines with double doses of DGLA treatment. 
HCA-7 colony 29 cells were treated with 100 µM of DGLA for 24 h and the second dose was 
added after another 24 h of incubation. The hydroxylamines were profiled at 12, 24, 36 and 48 h. 
(A) Profile of common radical product (m/z 297) in cells treated with DGLA. (B) Profile of 
exclusive radical products in cells treated with DGLA. The exclusive radical products in 
COX/DGLA peroxidation were m/z 325 and m/z 355. Hydroxylamines were quantified with d9-
POBN. (*) m/z 449 was the hydroxylamine generated from COX/AA peroxidation. Data are 
expressed as means ± SD from n≥3. 
Hydroxylamines in cells treated with double doses of AA: In cells treated with double 
doses of AA, there was a slight increase in the hydroxylamine of the m/z 297 ion (the reduced 
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adduct of POBN/●C6H13O) at 36 and 48 h (~72.1 and 66 .1 nM) as compared to those observed at 
12 and 24 h (~68.0 and 55.8 nM) (Fig. 19A). The m/z 449 ion as the reduced adduct of 
POBN/●C14H21O4 showed a slight increase at 36 h compared to 12 h (from ~7.0 to 8.0 nM) and 
had accumulated much more at 48 h (around a 50% increase) than at 24 h (from ~5.7 to 8.7 nM) 
(Fig. 19B). 
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Fig. 19. Profile of hydroxylamines with double doses of AA treatment. 
HCA-7 colony 29 cells were treated with 100 µM of AA for 24 h and the second dose was added 
after 24 h incubation. The hydroxylamines were profiled at 12, 24, 36 and 48 h. (A) Profile of 
common radical product (m/z 297) in cells treated with AA. (B) Profile of exclusive radical 
product (m/z 449) in cells treated with AA. Data are expressed as means ± SD from n≥3. 
In cells treated with double doses of DGLA, the trend of the m/z 297 ion’s formation was 
similar to that observed in cells treated with AA. Most interestingly, the exclusive free radical 
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product of m/z 449 from COX/AA peroxidation remained at the same level after the second dose 
of DGLA as compared to that at 12 and 24 h (Fig. 18B), suggesting that the increased DGLA in 
cells indeed competed with AA for COX and suppressed the formation of AA-derived pro-
proliferation free radical metabolites, while at the same time it increased the formation of the 
DGLA-derived anti-proliferation free radical metabolites. 
We have observed in the single dose PUFA treatments that both the formation of free 
radical metabolites and the PGEs decreased from 12 to 24 h (Figs. 11-14). These decreases were 
assumed to be due to the decreased pool of free fatty acids in cells. In the double dose PUFA 
treatment, it is worth noticing that at 36 and 48 h, equivalent to the time points of 12 and 24 h 
after the first dose, the free radical metabolites were increased rather than decreased. To address 
this interesting outcome, we profiled the PUFA and PGEs in the double dose treatment. 
PUFAs and PGEs in cells treated with double doses of DGLA: After the second dose was 
introduced, the concentration of AA was a little bit higher at 36 h and 48 h compared to that at 
12 h and 24 h (Fig. 20A). Due to the conversion from DGLA to AA, a very small increase in the 
concentration of AA was observed. Compared to the small increase of the concentration of PGE2, 
the production of PGE1 increased significantly after the second dose to ~ 123.4 nM at 48 h (Fig. 
20B), which successfully brought the ratio of [PGE1]:[PGE2] up to around 3:1 from the 1:1 ratio 
we observed in the single dose treatment at 48 h (Fig. 20B). 
AA and PGE2 in cells treated with double doses of AA: The profiles of AA and PGE2 in 
the cell culture medium with double doses of AA are shown in Fig. 21. When the second dose of 
AA was introduce to the cell culture 24 h after administration of the first dose, the uptake pattern 
of AA was similar to the one we observed in treatment with double doses of DGLA (Fig. 21A). 
95 
For the generation of PGE2, the second dose of AA continued to increase the production of PGE2 
up to the peak concentration at ~ 144.8 nM after 48 h (Fig. 21B). 
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Fig. 20. Profile of DGLA, AA, PGE1 and PGE2 with double doses of DGLA treatment. 
HCA-7 colony 29 cells were treated with 100 µM of DGLA for 24 h, with the second dose added 
after a 24 h incubation. The levels of AA and DGLA, as well as their metabolites PGE1 and 
PGE2, were evaluated after 12, 24, 36 and 48 h. (A) Profiles of DGLA and AA in cell culture 
medium, (B) Profiles of PGE1 and PGE2 in cell culture medium. DGLA, AA, PGE1 and PGE2 
were quantified with the internal standards DGLA-d6, AA-d8, PGE1-d4 and PGE2-d9, respectively. 
Data are expressed as means ± SD from n≥3. 
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Fig. 21. Profiles of AA and PGE2 with double doses of AA treatment. 
HCA-7 colony 29 cells were treated with 100 µM of AA for 24 h and the second dose was added 
after a 24 h incubation. The levels of AA and PGE2 were evaluated after 12, 24, 36 and 48 h. (A) 
The concentration of AA in cell culture medium; (B) The concentration of PGE2 in cell culture 
medium. AA and PGE2 were quantified with the internal standards AA-d8 and PGE2-d9, 
respectively. Data are expressed as means ± SD from n≥3. 
The formation of PGEs verified the formation of the free radical metabolites in the 
double dose-PUFA treatment. In cells treated with double doses of AA, the peak concentrations 
of PGE2 (Fig. 21B) and the exclusive free radical product of ●C14H21O4 from COX/AA (Fig. 19B) 
were observed at 48 h. Similarly, the peak concentrations of PGE1 (Fig. 20B) and the exclusive 
free radical products of ●C7H13O2 and ● C8H15O3from COX/DGLA (Fig. 18B) were observed at 
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48 h in cells treated with double doses of DGLA. The large amount of available DGLA 
overwhelmed AA at the COX site in cells, thus increasing the DGLA-derived metabolites 
(including the anti-proliferation free radical metabolites and the non-radical PGE1) and 
suppressing the formation of AA-derived metabolites (including the pro-proliferation free radical 
metabolites and PGE2). 
Comparison of effects of single dose vs. double doses of PUFA treatment on cell growth: 
The effect of double doses of AA and DGLA was also evaluated via the MTS assay. DGLA 
showed an inhibitory effect on cell proliferation compared to AA (Fig. 22). Compared to the 
single dose treatment, double doses of DGLA decreased cell proliferation. The cell viability 
decreased from 109.0 % to 102.5 % (Fig. 22). On the other hand, double doses of AA 
significantly increased cell proliferation (the cell viability was increased from 112.4 % to 
132.9 %, Fig. 22). 
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Fig. 22. Effects of single dose vs. double dose treatment of DGLA or AA on cell 
proliferation. 
HCA-7 colony 29 cells were treated with a single dose (100 µM) or double doses (2×100 µM) of 
DGLA or AA for 48 h. Data represent the mean ± SD derived from three separate experiments 
with triplicate wells per condition. 
It was the increased ratio between [DGLA-derived free radical metabolites] vs. [AA-
derived free radical metabolites] that resulted in the anti-proliferation effect of the double doses 
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of DGLA compared to AA as observed in the MTS assay (Fig. 22). Our results suggest that the 
double dose DGLA treatment controlled the conversion of DGLA to AA. When DGLA was 
increased, cells benefited from the elevated ratio of [DGLA-derived free radical 
metabolites]/[AA-derived free radical metabolites], which exerted an anti-proliferation effect on 
HCA-7 colony 29 cells. However, this increased ratio was due only to the increase of DGLA-
derived free radical metabolites (Fig. 18B), as the AA-derived free radical metabolites 
maintained the same level (Fig. 18B) after the second dose of DGLA was introduced. 
In this chapter, common and exclusive free radicals as the reduced forms were profiled 
for up to 48 h in COX-catalyzed AA vs. DGLA peroxidation in cells. AA, DGLA, free radical 
derivatives and prostaglandins were tested for their effects on the cellular growth response. 
Among the tested compounds, rather than PGE1, the derivative corresponding to a DGLA-
derived exclusive free radical (8-hydroxyoctanoic acid) showed the most inhibitory effect on cell 
growth. Thus, the anti-proliferative effect of DGLA was associated with the DGLA-derived 
exclusive free radicals metabolites. 
To increase the level of the anti-proliferative DGLA-derived free radical metabolites, 
double doses of DGLA were used to increase the level of DGLA in cells to compete with AA for 
COX. However, as shown in Fig. 22, although the double doses of DGLA treatment decreased 
cell proliferation compared to the single dose treatment, the cell growth was still not inhibited 
compared to the control group (0.1% ethanol). Thus, the approach of increasing the DGLA 
concentration in cells was not enough to fully restore the anti-proliferative effect of DGLA. Thus, 
other options that can reciprocally regulate the level of DGLA and AA in cells should be 
considered. 
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CHAPTER 5. INHIBITION OF THE CONVERSION FROM DGLA TO AA 
ATTENUATED CANCER CELL GROWTH AND ENHANCED THE EFFICACY OF A 
CHEMOTHERAPY DRUG 
5.1. Introduction 
Identification of factors that modulate tumorigenesis is crucial in cancer prevention and 
treatment. Most cancer drug discovery studies have tried to target cell proliferation, using cell-
based screening systems to identify anti-cancer compounds. However, the translation of such 
discoveries into cancer therapy has had limited success [206, 207]. Current research shows that 
targeting lipid metabolism or related factors that modulate the tumor microenvironment may also 
be a promising approach for cancer therapy [208, 209]. 
AA is the major ω-6 PUFA in tissues and is converted from DGLA in our body by D5D 
(Scheme 1). It is generally accepted that of the COX metabolism products, AA-derived 
eicosanoids such as PGs2 promote cancer growth by activating the down-stream pro-
carcinogenic signaling pathways [181-183]. Given the importance of AA metabolites in cancer 
biology, many studies have focused on the biosynthesis and degradation enzymes to suppress the 
tumorigenic effects of AA-derived eicosanoids [210]. COX-2 has been considered to be a target 
enzyme in cancer therapy, and several COX inhibitors have been developed and used in 
treatments for colon cancer [211, 212]. Although some of these drugs targeting eicosanoid 
signaling, such as aspirin and celecoxib, have shown efficacy in suppressing cancer, they have 
also been associated with severe toxicity during the treatment of cancer [210, 213]; thus, other 
strategies must be identified to target AA metabolism. The role in tumorigenesis of endogenous 
AA production, which occurs upstream of the COX pathway (Scheme 1), remains unexplored. 
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One way of modulating PG biosynthesis and tumor development may be decreasing AA levels 
via inhibiting its biosynthesis from its upstream fatty acids (DGLA) . 
D5D is one of the rate-limiting enzymes responsible for the synthesis of AA. Decreased 
D5D activity can lead to reduced AA production. For example, CP-24879 (p-isopentoxyaniline), 
an aniline derivative, was identified as a mixed D5D/D6D inhibitor during the screening of 
chemical and natural product libraries [214]. In mouse mastocytoma ABMC-7 cells cultured 
chronically with CP-24879, the desaturase activity was inhibited in a concentration-dependent 
manner that correlated with decreases in AA and its metabolite, LTC4 [214]. In the livers of mice 
treated chronically with the maximally tolerated dose of CP-24879 (3.0 mg/kg, t.i.d.), the 
activities of D5D/D6D were inhibited by approximately 80%, and thus AA was depleted by 
nearly 50% compared to control [214]. These results suggest that D5D/D6D inhibitors may play 
a role in regulating an anti-inflammatory and anti-cancer response by decreasing the level of AA 
and the production of AA-derived metabolites. Sesamin and curcumin are potential D5D 
inhibitors which could interfere with the desaturation of PUFAs [215, 216]. Between sesamin 
and curcumin, the latter was more effective at increasing the ratio of DGLA to AA in cultured rat 
hepatocytes [215]. Kinetic studies of the inhibitory properties of sesamin and curcumin using rat 
liver microsome D5D showed that rat liver microsome D5D was noncompetitively inhibited by 
sesamin (ki=155 µM) and curcumin (ki=36 µM) [215, 216]. 
Our previous results (Chapter 4) have shown that the free radical metabolites generated 
from AA and DGLA peroxidation through COX might correspond to their contrasting 
bioactivities, i.e., their pro- and anti-inflammatory effects. Increasing the anti-proliferative 
DGLA-derived exclusive free radical metabolites by increasing the level of DGLA in cells (i.e., 
101 
double doses of DGLA treatment vs. a single dose of DGLA treatment) was able to attenuate 
colon cancer cell growth. 
We proposed that inhibiting the conversion from DGLA to AA could enhance the 
formation of DGLA-derived free radicals; while greatly limiting the formation of exclusive AA-
derived free radicals may more effectively slow down the cancer cell growth. In this study, cells 
were co-treated with DGLA and D5D inhibitors. Hydroxylamines, PUFAs and PGEs were 
profiled and a cell proliferation assay was performed. Among the three tested D5D inhibitors, 
including CP-24879, sesamin and curcumin (Scheme 3), the most effective was CP-24879. Our 
results showed that CP-24879 partially suppressed the activity of D5D. The formation of 
exclusive AA-derived exclusive free radical metabolites and PGE2 was significantly delayed and 
decreased after co-treatment with DGLA and CP-24879. However, these cells still exhibited 
some accumulation of AA-derived COX metabolites. 
In order to completely block the conversion from DGLA to AA, HCA-7 colony 29 cells 
were also transfected with siRNA. D5D knockdown cells restored the anti-proliferative effect of 
DGLA. Decreased colon cancer cell growth was observed as decreasing the AA-derived free 
radical metabolites and simultaneously increasing the DGLA-derived free radical metabolites by 
D5D inhibition (CP-24879) or D5D knockdown (transfection with siRNA). 
5-fluorouracil (5-FU), a fluorinated pyrimidine analog, has been used against cancer for 
more than 50 years. It is still one of the most widely applied drugs in the therapy of patients with 
colon cancer [217]. It is a suicide inhibitor of thymidylate synthase, acting through irreversible 
inhibition [217]. Since COX-2 was overexpressed in colon cancer, it was suggested that a 
combination treatment with a COX-2 inhibitor and anti-cancer agents such as 5-FU might result 
in synergistic apoptosis in colon cancer cells [217-219]. Increasing evidence showed that several 
102 
COX inhibitors, such as NDAIDs, increased the susceptibility of colon cancer cells to 
chemotherapy drugs, e.g. 5-FU, and influenced the mRNA expression of apoptosis-related genes 
p53, p21 and BAX [220-222]. This synergism was associated with decreased COX-2 expression 
and reduced formation of AA-derived eicosanoids [217]. 
 
Scheme 13. Proposed mechanism of the synergistic effect of DGLA and 5-FU. 
We hypothesized that instead of interfering with the COX pathway, we could greatly 
enhance the cytotoxicity of 5-FU in colon cancer cells by targeting D5D (Scheme 13). Our 
results showed that targeting D5D could decrease the conversion from DGLA to AA, thus 
leading to decreased formation of AA-derived metabolites. In addition, the DGLA-derived 
metabolites, especially the exclusive free radical metabolites, could inhibit colon cancer cell 
growth. The cytotoxicity effect was evaluated via MTS assay. Our results showed that HCA-7 
colony 29 is not sensitive to treatment with 5-FU (IC50 > 1mM). However, co-treatment with 
DGLA and CP-24879 sensitized HCA-7 colony 29 cells to 5-FU. In D5D knockdown cells, the 
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synergistic effect of DGLA and 5-FU on cell cytotoxicity was more significant. The increased 
susceptibility of colon cancer cells to 5-FU may be attributed to the DGLA-derived free radical 
metabolite-induced DNA damage. 
5.2. Results and Discussion 
5.2.1. Hydroxylamines, PUFAs and PGEs in co-treatment with DGLA and CP-24879 
Hydroxylamines in cells co-treated with DGLA and CP-24879: To investigate whether 
the D5D inhibitor CP-24879 could decrease the production of AA-derived free radical products 
by inhibiting the biosynthesis of AA, hydroxylamines (especially those that are exclusive in AA 
and DGLA) were profiled after a combined treatment with DGLA and CP-24879 at 8, 12, 24 and 
48 h (Fig. 23). The production of the m/z 297 ion (the radical produced in common by AA and 
DGLA), as the reduced adduct of POBN/●C6H13O, reached a peak concentration of ~82.7 nM at 
12 h and then decreased to ~ 76.5 nM at 24 h and to ~ 63.1 nM 48 h (Fig. 23A). 
The exclusive ions of m/z 325 and m/z 355 from COX/DGLA as the reduced adducts of 
POBN/●C7H13O2 and POBN/●C8H15O3, respectively, were observed in the combined treatment of 
DGLA and CP-24879 at 8, 12, 24 and 48 h (Fig. 23B). The concentrations of the m/z 325 ion 
were about 2.1 nM at 8 h, and increased to a peak of ~7.0 nM at 24 h followed by a decrease to 
5.8 nM at 48 h (Fig. 23B). A similar trend was observed in the formation of the m/z 355 ion. The 
concentration was ~ 2.0 nM at 8 h, increasing to a peak of 10.5 nM at 24 h and maintaining the 
same level of 10.4 nM at 48 h (Fig. 23B). The exclusive AA-derived free radical product, the 
m/z 449 ion, as the reduced adduct of POBN/●C14H21O4, was not observed at 8 or 12 h, and the 
concentrations at 24 and 48 h were around 0.2 nM and 0.9 nM, respectively (Fig. 23B). 
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Fig. 23. Profiles of hydroxylamines with co-treatment of DGLA and CP-24879. 
HCA-7 colony 29 cells were treated with 100 µM DGLA and 5 µM CP-24879, and the 
hydroxylamines were profiled at 12, 24, 36 and 48 h. (A) Profile of the common radical product 
(m/z 297) in cells treated with DGLA and CP-24879. (B) Profile of the exclusive radical 
products in cells treated with DGLA and CP-24879. The exclusive radical products in 
COX/DGLA peroxidation were m/z 325 and m/z 355. Hydroxylamines were quantified with d9-
POBN. (*) m/z 449 was the hydroxylamine generated from COX/AA peroxidation. Data are 
expressed as means ± SD from n≥3. 
The m/z 297 ion was the only hydroxylamine observed after co-treatment with DGLA 
and CP-24879 for 4 h. The concentration of the m/z 297 ion was at almost the same level as the 
one we observed in the DGLA treatment (data not shown). Compared to what we observed in 
cells treated with DGLA alone (Fig. 12), the concentrations of the m/z 297 ions were at about the 
same level at 12 h and 48 h; however, they increased by about 16% at 24 h. For the exclusively 
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DGLA-derived free radical products, the m/z 325 and m/z 355 ion concentrations increased at all 
tested time points, and the most noticeable increase occurred at 8 h. In DGLA-treated cells, only 
trace amounts of both ions were observed (Fig. 12B); with the co-treatment with CP-24879 and 
DGLA, the concentrations of m/z 325 and m/z 355 increased to ~ 2.1 nM. On the other hand, the 
formation of the exclusive AA-derived free radical product, the m/z 449 ion, was significantly 
delayed as well as decreased in the co-treatment with DGLA and CP-24879. It was under the 
detection limit at 8 and 12 h, while a trace amount of the m/z 449 ion was detected at 24 h. The 
concentration at 48 h was decreased to 15% compared to that in the DGLA-only treatment (Fig. 
12B). 
The significant decrease in the accumulation of the AA-derived exclusive free radical 
product suggests that the biosynthesis of AA from DGLA in cells was inhibited by CP-34879. In 
the meantime, the increasing formation of free radical products, especially the m/z 325 and m/z 
355 ions (e.g. DGLA-derived exclusive free radicals products) as shown in Fig. 23B, indicates 
that without AA as a competitor, the metabolism of DGLA through COX greatly increased. 
Because DGLA is the substrate for D5D, the inhibition of D5D also contributed to the increase 
of DGLA in cells. 
PUFAs and PGEs in cells co-treated with DGLA and CP-24879: The formation of 
hydroxylamines showed that the biosynthesis of AA was inhibited by the co-treatment with CP-
24879; we also measured PUFAs and PGEs to confirm these results. The profiles of PUFAs and 
PGEs in cell culture medium with the co-treatment with DGLA and CP-24879 are shown in Fig. 
24. The concentrations of DGLA were ~36.2, 7.7, 6.2 and 2.9 µM at 8, 12, 24 and 48 h, 
respectively (Fig. 24A). The highest concentration of PGE1 (~ 92 nM) was observed at 8 h and 
gradually decreased to 64.0 nM at 48 h (Fig. 24B). 
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Even when the D5D inhibitor CP-24879 was applied, AA and PGE2 were also observed 
(Fig. 24). Within the tested time points, the peak concentration of AA (~ 1.2 µM) was observed 
at 8 h, followed by a decrease to 0.2 µM at 48 h (Fig. 24A). On the other hand, the production of 
PGE2 increased from 8 h (~ 6.9 nM) to 48 h (14.4 nM) (Fig. 24B). 
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Fig. 24. Profiles of DGLA, AA, PGE1 and PGE2 with co-treatment of DGLA and CP-24879. 
HCA-7 colony 29 cells were cultured under normal cell growth conditions for 8, 12, 24 and 48 h 
with a supplement of 100 µM of DGLA and 5 µM of CP-24879. (A) Profiles of DGLA and AA 
in cell culture medium, (B) Profiles of PGE1 and PGE2 in cell culture medium. DGLA, AA, 
PGE1 and PGE2 were quantified with the internal standards DGLA-d6, AA-d8, PGE1-d4 and 
PGE2-d9, respectively. Data are expressed as means ± SD from n≥3. 
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Compared to treatment with DGLA alone, the concentration of DGLA in the cell culture 
medium increased in the co-treatment of DGLA with CP-24879. At 48 h, the ratio of the free 
DGLA to AA was around 4 to 1. At the same time, AA was significantly decreased in the 
presence of CP-24879; the concentration of AA was only 30% of what we had seen in the DGLA 
treatment at 8 h (Fig. 14A) and was less than 50% at 12, 24 and 48 h. The concentrations of 
PGE1 at each time point increased in the co-treatment with DGLA and CP-24879 compared to 
the treatment with DGLA. Due to the decrease in its precursor AA, the concentration of PGE2 
dramatically dropped. The ratio of [PGE1]:[PGE2] increased from ~ 1:1 (DGLA treatment) to 
4.4:1 (co-treatment of DGLA and CP-24879) at 48 h. Similarly, at 8, 12 and 24 h, the ratio was 
also increased. 
The formation of PGEs was consistent with the formation of the free radical metabolites 
in the combined treatment with DGLA and CP-24879. The more PGE1 was observed, the more 
of the exclusive free radical products of ●C7H13O2 and ●C8H15O3 from COX/DGLA were formed. 
On the other hand, when the concentration of PGE2 was very low at 8 and 12 h, the free radical 
product of ●C14H21O4 from COX/AA was not observed. As PGE2 accumulated and its 
concentration increased, the free radical product of ●C14H21O4 started to show up. 
The profiles of the AA-derived exclusive free radical product (m/z 449 ion) and PGE2 
suggest that although CP-24879 delayed as well as decreased the formation of AA-derived 
metabolites, it did not completely block the biosynthesis of AA from DGLA. However, when we 
increased the concentration of the inhibitors in hope of achieving a more extensive suppression 
of the D5D activity, the COX activity was also affected in a dose-dependent manner. We 
observed that both PGE1 and PGE2 formation were significantly decreased when we increased 
the concentration of CP-24879 to a higher level (in the range of 10 to 50 µM) (data not shown). 
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Therefore, we concluded that to maintain the COX activity as well as to effectively control the 
formation of AA, a concentration of 5 µM for CP-24879 is appropriate. 
5.2.2. Effects of DGLA and CP-24879 on cell proliferation and cell cycle distribution 
In order to study the effect of co-treatment with DGLA and CP-24879 on colon cancer 
cell growth, we performed the MTS assay and PI staining (Table 5). In cells co-treated with 
DGLA and CP-24879 for 48 h, cell viability was ~109.1% compared to ~98.3% in the DGLA 
treatment (Table 3). The cells in the G2/M phase were ~26.3%, which was increased by more 
than 10% in both of these two treatments (DGLA+CP-24879 and DGLA) compared to the 
control group at 8 h (Table 5, Figs. 25A, 25C and 25E). The G2/M phase cell cycle arrest was 
accompanied by an increase in G1 phase cells (Table 5). 
Table 5. Effect of DGLA and CP-24879 on cell cycle distribution and proliferation. 
HCA-7 
Colony 29 
treated w/ 
Cell Cycle Distribution Cell Proliferation 
% in G1 Phase % in G2/M Phase % viability 
8 h 24 h 8 h 24 h 48 h 
Control 
(0.1 % ethanol) 
37.4 
± 2.4 
22.1 
± 1.2 
29.7 
± 2.3 
20.9 
± 0.9 100 
DGLA 
(100 µM) 
43.6 
± 9.6 
29.4 
± 2.1 
41.3* 
± 2.5 
23.6 
± 1.6 
109.1* 
± 5.7 
DGLA w/ 
5 µM CP 
42.8* 
± 6.3 
29.4 
± 3.0 
42.4* 
± 1.8 
26.3* 
± 1.8 
98.3* 
± 5.0 
HCA-7 colony 29 cells treated with 100 µM DGLA and a combined treatment of 100 µM DGLA 
and 5 µM CP-24879. Data represent the mean ± SD derived from three separate experiments 
with triplicate wells per condition. (a) % cell viability was compared with control group. Note, 
control cells were incubated with 0.1% DMSO and 0.1% ethanol (final concentrations). (*) 
P˂0.01, significantly different from control. 
That no significant difference was observed between these two treatments is probably 
because at 8 h, DGLA was still the dominant fatty acid in the cells. As our data in Fig. 14 
showed, the level of AA converted from DGLA through D5D in the cells was not high enough to 
compete with DGLA for COX. In other words, the DGLA-derived free radical metabolites 
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overwhelmed the AA-derived free radical metabolites and the anti-proliferative effect of DGLA 
was dominant at the 8 h time point. 
 
Fig. 25. Effects of co-treatment of DGLA and CP-24879 on cell cycle distribution. 
(A-B) HCA-7 colony 29 cells were treated with 0.1% ethanol for 8 and 24 h, respectively, (C-D) 
HCA-7 colony 29 cells were treated with 100 µM DGLA for 8 and 24 h, respectively, (A-B) 
HCA-7 colony 29 cells were co-treated with 100 µM DGLA and 5 µM CP-24879 for 8 and 24 h, 
respectively. 
When the incubation time was increased to 24 h, as the formation of AA and its derived 
free radical metabolites increased, the anti-proliferative effect of DGLA was abolished. The 
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percentage of cells in the G2 phase was similar to that in the control group (Table 5, Figs. 25B 
and 25D). The DGLA-induced cell G2/M arrest was attenuated by the action of CP-24879 at 24 
h. In the co-treatment with DGLA and CP-24879, the percentage of cells in the G2/M phase was 
~26.3%, which was 10% more than in the control and DGLA groups (Table 5, Figs. 25D and 
25F). However, CP-24879 did not completely restore the anti-proliferative effect of DGLA. This 
failure may be due to the partial but not complete suppression of D5D, which was shown by the 
increasing formation of AA-derived free radical metabolites and PGE2 as the incubation time 
increased (Figs. 22B and 23B). 
Compared to the single dose and double dose DGLA treatments (Table 5 and Fig. 22), 
the co-treatment with CP-24879 significantly decreased cell proliferation. Our data suggested 
that DGLA indeed has a potentially inhibitory effect on the growth of HCA-7 colony 29 cells if 
its conversion to AA is limited. Targeting D5D is a promising approach to manifesting an anti-
inflammatory and anti-cancer response by simultaneously increasing the anti-proliferative 
DGLA-derived free radical metabolites and decreasing the ensuing production of AA-derived 
pro-proliferation metabolites. 
5.2.3. Possible inhibition mechanism of CP-24879 
CP-24879 was identified as a mixed D5D/D6D inhibitor during the screening of chemical 
and natural product libraries [214]. However, the inhibitory mechanism was still unknown. In 
order to gain more insight into the inhibitory action of CP-24879, we used Western blot analysis 
to check the expression of D5D with different treatments. Cells were treated with 100 µM of 
DGLA alone, 5 µM CP-24879 alone, and 100 µM DGLA with 5 µM CP-24879. No significant 
difference in expression of D5D was observed (Fig. 26) between the different treatments. 
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Fig. 26. Western blot analysis of D5D expression with co-treatment of DGLA and CP-24879. 
Cells were treated with DGLA ± CP-24879 for 24 h. Forty micrograms of protein per sample 
was separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted using a D5D-
specific antibody. Beta-actin served as the loading control. 
Our data suggest that CP-24879 inhibits the enzymatic activity of D5D without affecting 
its protein expression. Thus, CP-24879 did not inhibit D5D via regulating gene expression. 
Although D5D has been cloned and expressed in cells [14], the crystal structure of D5D remains 
unsolved. Thus, the exact inhibitory mechanism is not clear at this stage. In general, the 
competitive enzyme inhibitor is a compound whose structure and molecular geometry closely 
resemble that of the substrate. It is possible that CP-24879 inhibits D5D through uncompetitive 
or noncompetitive action, because CP-24879 is not structurally close to a fatty acid (Scheme 3). 
The details of the inhibitory mechanism need to be further investigated. 
5.2.4. Study of other D5D inhibitors 
Our previous data showed that CP-24879 suppressed D5D activity and attenuated the 
conversion from DGLA to AA. However, the exclusive AA-derived free radical product (the m/z 
449 ion) as well as PGE2 was still observed after 48 h (Figs. 23B and 24B). Although the 
combined treatment of DGLA and CP-24879 has an anti-proliferative effect compared to the 
DGLA treatment, the cell growth was not inhibited compared to the control group. Therefore, we 
D5D (50 KD) 
Beta-actin 
DGLA ± Inhibitor (24 h)  
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also tested the other commercial available D5D inhibitors. Besides the synthetic CP-24879, it has 
been reported that sesamin and curcumin obtained from natural sources are also potential D5D 
inhibitors [214, 215]. 
Co-treatment with sesamin and DGLA: hydroxylamine, PUFA and PGEs: First of all, we 
tested the effect of sesamin as the D5D inhibitor. Hydroxylamines were measured at 8, 12, 24 
and 48 h after co-treatment with DGLA and sesamin (Fig. 27). For the common free radical 
product, m/z 297 as the reduced adduct of POBN/●C6H13O, the peak concentration of ~8.1 nM 
was observed at 24 h (Fig. 27A). The concentrations from 12 h to 48 h were within the range of 
60.7 to 68.1 nM. 
The exclusive ions of m/z 325 and m/z 355 from COX/DGLA as the reduced adducts of 
POBN/●C7H13O2 and POBN/● C8H15O3, respectively, were observed in the combined treatment 
with DGLA and sesamin at 8, 12, 24 and 48 h (Fig. 27B). Trace levels of both ions (~0.2 nM) 
were detected at 8 h. The concentrations of the m/z 325 ion were around 6.4 nM at 12 h and 6.2 
nM at 24 h, followed by a decrease to 5.5 nM at 48 h. For the formation of the m/z 355 ion, the 
concentration was ~6.7 nM at 12 h, increasing to ~7.6 nM at 24 h and maintaining a similar level 
(~7.3 nM) up to 48 h. The exclusive AA-derived free radical product, the m/z 449 ion as the 
reduced product of POBN/●C14H21O4, was also observed. It was detected at 8, 12 and 48 h, with 
concentrations of 3.5, 6.0 and 4.4 nM, respectively (Fig 27B). 
The profiles of all the free radical products in the combined treatment of DGLA with 
sesamin were similar to those we observed in the DGLA-alone treatment (Fig. 12). In particular, 
the high concentration of the AA-derived free radical product m/z 449 ion suggests that sesamin 
did not inhibit the conversion from DGLA to AA. This may be due to the poor solubility of 
sesamin in the cell culture medium. It was reported that sesamin inhibits the conversion of 
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Fig. 27. Profiles of hydroxylamines with co-treatment of DGLA and sesamin. 
HCA-7 colony 29 cells were co-treated with 100 µM DGLA and 100 µM sesamin in the 
presence of 20 mM POBN, and the hydroxylamines were profiled at 12, 24, 36 and 48 h. (A) 
Profile of common radical product (m/z 297) in cells treated with DGLA and sesamin. (B) 
Profiles of exclusive radical products in cells treated with DGLA and sesamin. The exclusive 
radical products in COX/DGLA peroxidation were m/z 325 and m/z 355, Hydroxylamines were 
quantified with d9-POBN. (*) m/z 449 was the hydroxylamine generated from COX/AA 
peroxidation. Data are expressed as means ± SD from n≥3. 
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Fig. 28. Profiles of DGLA, AA, PGE1 and PGE2 with co-treatment of DGLA and sesamin. 
HCA-7 colony 29 cells were co-treated with 100 µM DGLA and 100 µM sesamin. PUFAs and 
PGEs were profiled at 12, 24, 36 and 48 h. (A) Profiles of DGLA and AA in cell culture medium, 
(B) Profiles of PGE1 and PGE2 in cell culture medium. DGLA, AA, PGE1 and PGE2 were 
quantified with the internal standards DGLA-d6, AA-d8, PGE1-d4 and PGE2-d9, respectively. 
Data are expressed as means ± SD from n≥3. 
DGLA to AA with a Ki value of 155 µM in rat liver microsomes [216]. However, the highest 
final concentration that sesamin was able to achieve in the cell culture medium was 100 µM. 
Higher concentrations, e.g., 150 and 200 µM, were also tested; however, the excess sesamin 
formed crystals in the medium. 
PUFA and PGE formation in co-treatment with DGLA and sesamin was also measured at 
8, 12, 24 and 48 h (Fig. 28). The results were also similar to what we observed in the DGLA-
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only treatment (Fig. 14). As the DGLA continuously converted to AA, the ratio between [DGLA] 
and [AA] decreased (Fig. 28A). It was clearer in the profile of PGEs: the concentration of 
PGE1:PGE2 increased to about 1:1 at 48 h (Fig. 28B). The results confirmed that sesamin at the 
concentration of 100 µM did not exert an inhibitory effect on D5D activity. 
Co-treatment with curcumin and DGLA: Hydroxylamine, PUFA and PGEs: Another 
reported D5D inhibitor we tested was curcumin. The formation of hydroxylamines was profiled 
at 8, 12, 24 and 48 h (Fig. 29). For the common radical product, the m/z 297 ion as the reduced 
adduct of POBN/●C6H13O, the peak concentration of ~ 25.1 nM was observed at 24 h (Fig. 29A). 
The concentrations at 8, 24 and 48 h were ~14.8, 21.1 and 24.6 nM, respectively. 
The exclusive ions of m/z 325 and m/z 355 from COX/DGLA as the reduced adducts of 
POBN/●C7H13O2 and POBN/● C8H15O3, respectively, were observed in the combined treatment 
with DGLA and curcumin at 12, 24 and 48 h (Fig. 29B). The concentrations of the m/z 325 ion 
were ~ 1.5, 2.7 and 2.0 nM at 12, 24 and 48 h; the concentrations of m/z 355 were about 2.9, 3.3 
and 3.0 at 12, 24 and 48 h. The exclusive AA-derived free radical product, the m/z 449 ion as the 
reduced product of POBN/●C14H21O4, was also observed. It was detected at 8, 12 and 48 h, with 
concentrations of 0.5, 1.0 and 0.8 nM, respectively (Fig. 29B). 
The formation of all the free radical products (including the common and exclusive free 
radical products) in the combined treatment of DGLA with curcumin was significantly decreased 
(more than a 60% decrease) compared to that in the DGLA alone treatment (Fig. 12). Because 
both the AA-derived exclusive free radical products and the DGLA-derived exclusive free 
radical products decreased at the same time, it was hard to tell whether the curcumin inhibited 
the conversion from DGLA to AA from the profiles of AA and DGLA. However, the decreased 
116 
formation of the free radical products suggests that curcumin significantly decreases the activity 
of COX. 
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Fig. 29. Profiles of hydroxylamines with co-treatment of DGLA and curcumin. 
HCA-7 colony 29 cells were co-treated with 100 µM DGLA and 20 µM curcumin in the 
presence of 20 mM POBN, and the hydroxylamines were profiled at 12, 24, 36 and 48 h. (A) 
Profile of common radical product (m/z 297) in cells treated with DGLA and curcumin. (B) 
Profile of exclusive radical products in cells treated with DGLA and curcumin. The exclusive 
radical products in COX/DGLA peroxidation were m/z 325 and m/z 355. Hydroxylamines were 
quantified with d9-POBN. (*) m/z 449 was the hydroxylamine generated from COX/AA 
peroxidation. Data are expressed as means ± SD from n≥3. 
PUFAs and PGEs produced in the co-treatment with DGLA and curcumin were profiled 
at 8, 12, 24 and 48 h. As shown in Fig. 30, the level of DGLA in the cell medium was ~ 48.6 µM 
at 8 h and decreased to 24.5 µM at 12 h, 15.1 µM at 24 h and 8.0 µM at 48 h (Fig. 30A). The 
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highest concentration of PGE1 (~ 33.1 nM) was observed at 8 h, after which it decreased to 26.4, 
25.0 and 23.7 nM at 12, 24 and 48 h, respectively (Fig. 30B). 
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Fig. 30. Profiles of DGLA, AA, PGE1 and PGE2 with co-treatment of DGLA and curcumin. 
HCA-7 colony 29 cells were co-treated with 100 µM DGLA and 20 µM curcumin. PUFAs and 
PGEs were profiled at 12, 24, 36 and 48 h. (A) Profiles of DGLA and AA in cell culture medium, 
(B) Profiles of PGE1 and PGE2 in cell culture medium. DGLA, AA, PGE1 and PGE2 were 
quantified with the internal standards DGLA-d6, AA-d8, PGE1-d4 and PGE2-d9, respectively. 
Data are expressed as means ± SD from n≥3. 
The profiles of PUFA and PGEs in the co-treatment with DGLA and curcumin were 
consistent with the results from the free radical products. Compared to the treatment with DGLA 
alone (Fig. 14), the concentration of DGLA significantly increased at all tested time points for 
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the co-treatment with DGLA and curcumin. For example, the level of DGLA at 8 h increased by 
70%. Conversely, the formation of PGEs significantly decreased at all tested time points (more 
than a 50% decrease). The ratio of [DGLA] to [AA], and especially [PGE1] vs. [PGE2], suggests 
that curcumin inhibits the D5D activity to some extent. The ratio of [PGE1]:[PGE2] was close to 
1:2. 
When the concentration of curcumin was varied from 5 to 50 µM in the curcumin-DGLA 
treatment, the lowest tested concentration (5 µM) did not affect D5D activity in cells, while it did 
inhibit PGE biosynthesis (data not shown). These results suggest that curcumin is not a specific 
inhibitor for D5D. 
Cell proliferation study of D5D inhibitors: The effects of sesamin and curcumin together 
with DGLA on cell proliferation were evaluated via the MTS assay (Fig. 31). As expected, 
sesamin failed to restore the anti-proliferative effect of DGLA, and co-treatment with DGLA and 
sesamin promoted cell growth compared to the control group, which showed an effect similar to 
the ones for the DGLA-alone treatment (Fig. 31). On the other hand, curcumin with DGLA 
exerted a significant anti-proliferative effect, which decreased cell proliferation by ~24% 
compared to the control group (Fig. 31). However, this anti-proliferative effect was induced by 
curcumin rather than DGLA, because treatment with curcumin alone, without DGLA, showed a 
similar effect (data not shown). Curcumin is the principal curcuminoid of the popular Indian 
spice turmeric, which is a member of the ginger family. Increasing evidence has shown that 
curcumin has multiple roles in the treatment of cancer; e.g., it exerts a potential anti-
inflammatory and anti-cancer effect by down-regulating the oncogene Mdm2 [223], down-
regulating the peroxidizing enzymes COX and LOX [224], and scavenging free radicals as an 
antioxidant [224]. 
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Fig. 31. Effect of DGLA with sesamin or curcumin on cell proliferation. 
HCA-7 colony 29 cells were treated with 100 µM DGLA or a combined treatment of 100 µM 
DGLA with 100 µM sesamin or 100 µM DGLA with 20 µM curcumin. Data represent the mean 
± SD derived from three separate experiments with triplicate wells per condition. Note, % cell 
viability was compared with the control group. Control cells were incubated with 0.1% 
dimethylsulfoxide and 0.1% ethanol (final concentration). (*) P˂0.01, significantly different 
from control. 
By far, among all the tested inhibitors, CP-24879 was the most effective; it exerts the 
greatest inhibitory effect on the biosynthesis of AA by suppressing D5D activity while not 
affecting the activity of COX. The combined treatment of DGLA and CP-24879 delayed and 
decreased the formation of AA-derived free radical metabolites, while concurrently increasing 
the formation of DGLA-derived free radical metabolites, which resulted in the partial restoration 
of the anti-proliferative effect of DGLA. 
5.2.5. DGLA enhanced the efficacy of the chemotherapy drug 5-FU 
5-FU, a fluorinated pyrimidine analog, is one of the most widely applied drugs in the 
therapy of patients with colon cancer. Due to the high expression of COX-2 in colon cancer, 
research has shown that COX inhibitors sensitize colon cancer cells to chemotherapy drugs [210, 
213]. This synergism was linked with decreased expression of COX-2 and reduced formation of 
AA-derived eicosanoids [210, 213]. 
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Targeting D5D to decrease the biosynthesis of AA from DGLA could also reduce the 
formation of AA-derived eicosanoids. In addition, our previous data suggested that the exclusive 
free radical metabolites derived from DGLA could inhibit cell growth, and DGLA could induce 
cell arrest at the G2/M phase. Here, for the first time, we have investigated whether DGLA could 
increase the susceptibility of HCA-7 colony 29 (with a high expression of COX-2) to 5-FU. 
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Fig. 32. Co-treatment of DGLA and CP-24879 enhanced the efficacy of 5-FU. 
HCA-7 colony 29 cells were treated with various concentrations of 5-FU, 5-FU with 5 µM CP-
24879, 5-FU with100 µM DGLA, and the combined treatment of 5-FU and 100 µM DGLA with 
5 µM CP-24879. Data represent the mean ± SD derived from three separate experiments with 
triplicate wells per condition. Note that % cell viability was compared with the control group. 
Control cells were incubated with 0.1% dimethylsulfoxide and 0.1% ethanol (final 
concentration). (*) P˂0.01, significantly different from control. 
Four different treatments, including 5-FU, 5-FU+CP-24879, 5-FU+DGLA, and 5-
FU+CP-24879+DGLA, were designed, and for each group, a series of concentrations of 5-FU 
(ranging from 0.02 to 1 mM) were applied. Cell proliferation after a 48 h treatment was 
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measured via the MTS assay as shown in Fig. 32. HCA-7 colony 29 was not sensitive to low 
concentrations of 5-FU alone (IC50>1mM). 5-FU only inhibited colon cancer cell growth at 
concentrations higher than 0.4 mM (Fig. 32). CP-24879 did not alter the effect of 5-FU on cell 
growth. DGLA decreased the sensitivity of HCA-7 colony 29 cells to 5-FU; the cell proliferation 
increased compared to the 5-FU-only treatment. With the addition of both DGLA and CP-24879, 
the sensitivity of cells to 5-FU increased. The cell viability decreased by more than 10% with 0.4 
mM 5-FU and decreased by more than 15% with 1 mM 5-FU (Fig. 32). 
When cells were co-treated with DGLA and 5-FU, the increase in cell proliferation was 
expected due to the rapid conversion from DGLA to AA through D5D. As shown in Fig. 14B, 
after 48 h, the formation of PGE1 was almost equal to PGE2, indicating that AA was competing 
with DGLA for COX. And this competition also resulted in the formation of excess AA-derived 
free radical metabolites (Fig. 12B). The presence of AA-derived free radical metabolites may 
abolish the anti-proliferative effect of DGLA-derived free radical metabolites. In this case, it 
protects the cells from undergoing apoptosis. When the D5D inhibitor was introduced, formation 
of the AA-derived free radical metabolites was delayed and reduced (Fig. 23B), thus the DGLA-
derived free radical metabolites exhibited anti-proliferation effects that synergized the apoptosis 
induced by 5-FU in colon cancer cells. 
5-FU induced anti-cancer effects and toxicity, including blocking DNA synthesis, 
inducing translational errors, and regulating the pro-apoptosis genes p53, p21 and BAX [220-
222]. Treatment with both CP-24879 and DGLA restored the anti-proliferative effect of DGLA, 
enhancing the DGLA-derived free radical metabolites that may have an anti-carcinogenic effect 
through causing DNA lesions and activating tumor suppressors such as p53. Thus, the 
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synergistic effect of DGLA with 5-FU might be due to their co-effect in causing DNA damage 
and activating pro-apoptosis genes. 
5.2.6. Effect of DGLA in D5D knockdown cells 
Although the CP-24879 was able to partially restore DGLA’s anti-carcinogenic effect, 
nevertheless, the inhibition of D5D activity was not complete. As we observed from Table 5, 
DGLA with CP-24879 decreased cell proliferation compared to DGLA treatment, but was not 
significantly different than the control treatment. Another approach to inhibiting the conversion 
from DGLA to AA was to use RNA interference to suppress D5D gene expression. D5D was 
silenced in HCA-7 colony 29 cells via siRNA transfection. 
D5D expression was measured after transfecting HCA-7 colony 29 with negative control 
siRNA or the D5D siRNA for 48 h by Western blot analysis (Fig. 33). The expression of D5D 
decreased as the siRNA concentration increased. D5D expression was completely silenced with 
150 nM D5D siRNA (Fig. 33). 
 
Fig. 33. Western blot analysis of D5D knockdown. 
Cells were transfected with negative control siRNA (150 nM) and D5D siRNA (50 to 150 nM). 
Western blot analysis was performed after 48 h. Forty micrograms of protein per sample was 
separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted using a D5D-
specific antibody. Beta-actin served as the loading control. 
After D5D was successfully knocked down in HCA-7 colony 29 cells, the formation of 
hydroxylamines was profiled after treating the cells with DGLA for 48 h (Fig. 34). The 
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concentration of the m/z 297 ion (common radical product) as the reduced adduct of 
POBN/●C6H13O was ~56.8 nM in the control cells (transfected with negative control siRNA) and 
~ 70.3 nM in the D5D knockdown cells (Fig. 34A). The exclusive ions of m/z 325 and m/z 355 
from COX/DGLA, as the reduced adducts of POBN/●C7H13O2 and POBN/● C8H15O3, 
respectively, were observed after 48 h (Fig. 34B). The concentrations of the m/z 325 ion were ~ 
4.9 nM in the control cells and ~9.2 nM in the D5D knockdown cells (Fig. 34B). For the m/z 355 
ion, the concentration was ~ 8.9 nM in control cells and ~12.5 nM in the D5D knockdown cells 
(Fig. 34B). The exclusive AA-derived free radical product, the m/z 449 ion as the reduced adduct 
of POBN/●C14H21O4, was not observed at 8 or 12 h, and the concentrations at 24 and 48 h were 
around 4.0 nM in the control and not detectable in the D5D knockdown cells. 
Compared to the control cells, the formation of all the free radical products, including the 
m/z 297, m/z 325 and m/z 355 ions, increased in the D5D knockdown cells, especially the 
DGLA-derived exclusive free radical products (Fig. 34). The concentration of the m/z 325 ion 
increased by ~80% and that of the m/z 325 ion increased by ~40%. Conversely, due to the 
silencing of D5D expression, the exclusive AA-derived free radical product, the m/z 449 ion, 
was not observed. Compared to the formation of hydroxylamines in the cells co-treated with CP-
24879 and DGLA at 48 h (Fig. 23B), the concentrations of m/z 325 and m/z 355 increased and 
the formation of the exclusive AA-derived free radical product, the m/z 449 ion, decreased. 
PUFAs and PGEs in the cell culture medium were also measured after 48 h and the 
results were consistent with the formation of hydroxylamines (Fig. 35). The concentration of 
DGLA in the control cells was ~1.3 µM and in the D5D knockdown cells was ~3.1 µM (Fig. 
35A). PGE1 in the control cells was ~42.0 nM and in D5D knockdown cells it was ~85.2 nM 
(Fig. 35B). 
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Fig. 34. Profiles of hydroxylamines in D5D knockdown cells with DGLA treatment. 
HCA-7 colony 29 cells were transfected with 150 nM of control siRNA or D5D siRNA, and then 
treated with 100 µM of DGLA for 48 h. (A) Profile of the common radical product (m/z 297) in 
cells treated with DGLA. (B) Profiles of exclusive radical products in cells treated with DGLA. 
The exclusive radical products in COX/DGLA peroxidation were m/z 325 and m/z 355. 
Hydroxylamines were quantified with d9-POBN. (*) m/z 449 was the hydroxylamine generated 
from COX/AA peroxidation. Data are expressed as means ± SD from n≥3. 
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Fig. 35. Profiles of DGLA, AA, PGE1 and PGE2 in D5D knockdown cells with DGLA 
treatment. 
HCA-7 colony 29 cells were transfected with 150 nM of control siRNA or D5D siRNA, and then 
treated with 100 µM of DGLA for 48 h. (A) Profiles of DGLA and AA in cell culture medium, 
(B) Profiles of PGE1 and PGE2 in cell culture medium. DGLA, AA, PGE1 and PGE2 were 
quantified with the internal standards DGLA-d6, AA-d8, PGE1-d4 and PGE2-d9, respectively. 
Data are expressed as means ± SD from n≥3. 
Without the inhibition of D5D expression, in control cells the ratios of both DGLA vs. 
AA and PGE1 vs. PGE2 were close to 1 after 48 h (Fig. 14). In the D5D knockdown cells, the 
amounts of both AA and PGE2 were very low, close to the level that was measured in the cells 
without exogenous DGLA added (data not shown). Compared to the co-treatment with DGLA 
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and CP-24879, the formation of PGE1 was significantly increased and PGE2 was significantly 
decreased in the D5D knockdown cells. 
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Fig. 36. Cell proliferation assays in D5D knockdown cells. 
Cells were transfected with 150 nM of control siRNA and D5D siRNA, respectively, and then 
treated with 100 µM DGLA, 0.2 µM 5-FU and 100 µM DGLA+0.2 µM 5-FU for 48 h. Data 
represent the mean ± SD derived from three separate experiments with triplicate wells per 
condition. Note that % cell viability was compared with the control group. The transfection 
procedure was described in Materials and Methods. (*) P˂0.01, significantly different from 
control. 
The synergistic effect of DGLA and 5-FU on cytotoxicity in D5D knockdown cells was 
also evaluated (Fig. 36). The transfected cells were treated with DGLA, 5-FU, or DGLA+5-FU 
for 48 h and the cell proliferation was examined via the MTS assay. In D5D knockdown cells, 
DGLA alone was able to exert significant inhibition on cell growth, and it increased the 
cytotoxicity of 5-FU in the combined treatment (Fig. 36). No inhibitory effect was observed in 
the control cells. The concentration of 5-FU used in this study was 0.2 mM. The combination of 
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5-FU and DGLA in D5D knockdown cells decreased cell viability more than the combined 
treatment of DGLA, CP-24879 and 5-FU at the same concentrations (Fig. 32). 
In D5D knockdown cells, the biosynthesis of AA was completely blocked. AA-derived 
free radical metabolites were not detectable, and the DGLA-derived free radical metabolites 
increased significantly. Compared to the results showed in Fig. 32, siRNA transfection was 
better at suppressing the expression of D5D, which resulted in the anti-proliferative effect of 
DGLA. 
In summary, when the conversion from DGLA to AA was inhibited, DGLA exhibited an 
anti-proliferative effect which was associated with the enhancement of the formation of DGLA-
derived free radicals and reduction of the formation of AA-derived free radicals. Thus, targeting 
D5D instead of COX-2 is a new approach which could be used in the control of colon cancer 
growth and progression. 
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CHAPTER 6. SUMMARY, DICUSSION AND FUTURE DIRECTIONS 
6.1. Introduction 
The typical western diet enriched in ω-6 PUFAs (mainly LA) is associated with an 
increased risk of cancer and other inflammation-related diseases. LA in the diet is converted to 
DGLA and then AA through a series of desaturation and elongation actions in the body (Scheme 
1). As the most abundant ω-6 PUFA in mammalian cells, AA is metabolized to the pro-
inflammatory PGE2 through COX. DGLA, the upstream fatty acid of AA, is also a substrate for 
COX and is converted to the anti-inflammatory PGE1 (Scheme 2). PGE2 and PGE1 are well-
known lipid signaling molecules that participate in various physiological and pathological 
actions by activating the PKA signaling pathway through EP receptors. In general, PGE2 and 
PGE1 were believed to be corresponded to the opposing effects of AA vs. DGLA. However, the 
structures of PGE2 and PGE1 are similar (PGE1 only missing one double bond in the structure). 
Thus, it could be problematic for them to exert opposing activities if they bind to the same 
receptor(s). 
COX catalyzes PUFA peroxidation through a series of free radical reactions. In COX-
catalyzed PUFA peroxidation, in addition to PGEs and other type of PGs, several free radicals, 
the most reactive intermediate metabolites, were also formed. However, due to their highly 
reactive nature, AA and DGLA derived individual free radicals had not been characterized in 
cells, therefore, their possible role in cancer progression and prevention still remained a mystery. 
In order to understand the possible association between those free radicals and colon cancer 
growth, for the first time we successfully characterized free radicals formed from cellular COX-
catalyzed AA and DGLA peroxidation via refined LC/MS method along with SPE using the 
human colon cancer cell line HCA-7 colony 29, a cell line with high COX-2 expression. This 
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new technique allowed us to profile free radicals (as hydroxylamines) for the first time to 
characterize free radicals in cells under normal growth conditions in which other biological 
parameter could also be assessed. 
6.2. Summary of Research Data 
6.2.1. Summary of chapter 3: detection and characterization of free radicals from COX/AA and 
COX/DGLA in cells 
Common and exclusive free radicals as the reduced forms were identified and 
characterized in COX-catalyzed AA vs. DGLA peroxidation in cells (Table 6). The ●C6H13O 
radical was the free radical generated in common from both COX/AA and COX/DGLA 
peroxidation. The ●C14H21O4 radical was the exclusive free radical from COX/AA, and the 
●C7H13O2 and ●C8H14O3 radicals were the exclusive free radicals from COX/DGLA. 
Table 6. Common and exclusive free radicals in COX/AA vs. COX/DGLA 
 Common Radicals Exclusive Radicals 
COX/AA ●C6H13O ●C14H21O4 
COX/DGLA ●C6H13O ●C7H13O2 and ●C8H14O3 
 
6.2.2. Summary of chapter 4: assessment of the association between AA-/DGLA-derived free 
radicals and colon cancer cell growth 
According to our data (Table 3 and Fig. 22), AA clearly promoted the growth of HCA-7 
colony 29 cells, while DGLA may have the opposite effect depend on the way to treat cells. 
However, due to the rapid conversion from DGLA to AA by D5D in cells, the anti-proliferative 
effect of DGLA could be abolished, and the generated AA (from DGLA) exerts pro-tumorigenic 
effect. A close correlation between free radicals and cell growth was revealed for the first time 
with our refined method. 
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Because PUFA-derived free radicals cannot be synthesized to test them on cells due to 
their very short lifetimes, the related free radical derivatives (Table 4) were selected and used to 
test for individual bioactivity. Among the tested free radical derivatives, the derivatives 
corresponding to the DGLA-derived exclusive free radical (8-hydroxyoctanoic acid) showed the 
most inhibitory effect on cell growth comparing with those effects from other tested radical 
derivatives and PGEs. PGE1 did not show an anti-proliferative effect on cell growth at the tested 
concentration. Thus, the anti-proliferative effect of DGLA may associate with the DGLA-
derived exclusive free radicals metabolites. 
Due to the lack of commercially available derivatives, the exclusive radical ●C=C 
(●C14H21O4) from COX/AA peroxidation was not yet to be tested for the effect on cell growth. 
We anticipate that this special radical may be closely corresponded to the pro-carcinogenic effect 
of AA and future studies will be conducted. 
6.2.3. Summary of chapter 4: double dose of DGLA attenuates colon cancer cell growth 
In order to increase the level of the anti-proliferative DGLA-derived free radical 
metabolites, double doses of DGLA were used to raise the level of DGLA in cells to compete 
with its downstream fatty acid, AA, for COX. Double doses of DGLA inhibited cell proliferation 
compared to the cells treated with a single dose of DGLA after 48 h (Fig. 22). 
However, no significant difference was observed compared to the control treatment (0.01% 
ethanol, Fig. 22), probably due to the presence of the AA-derived exclusive free radical 
metabolites. In addition, although in double doses of DGLA treatment the ratio between DGLA-
derived exclusive free radical metabolites vs. AA-derived exclusive free radical metabolites 
decreased compared to the single dose DGLA treatment, the decrease of AA-derived radical was 
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not enough to fully restore the anti-proliferative effect of DGLA. Thus, other options that could 
reciprocally regulate the level of DGLA and AA in cells should be considered. 
6.2.4. Summary of chapter 5: blocking D5D activity inhibits cell proliferation and sensitizes 
cells to chemotherapy drugs 
To raise the ratio between the anti-proliferative DGLA- vs. pro-proliferative AA-derived 
free radical metabolites, we also inhibit the biosynthesis of AA from DGLA treatment, including 
decreasing D5D activity with enzyme inhibitors and silencing D5D gene expression by siRNA 
transfection. Among the tested D5D inhibitors, e.g. sesamin, curcumin and CP-24879, CP-24879 
was the most effective: 1) it decreased the AA-derived free radical metabolites and concurrently 
increased the DGLA-derived free radical metabolites; 2) DGLA combined with CP-24879 
decreased cell proliferation compared to the DGLA alone and double dose-DGLA treatments; 
and 3) however, CP-24879 did not completely block the biosynthesis of AA, although it delayed 
and decreased the production of AA-derived free radical. 
Transfecting HCA-7 colony 29 with siRNA diminished the expression of D5D, which 
resulted in the full recovery of the anti-proliferative effect of DGLA. In D5D knockdown cells, 
the biosynthesis of AA was completely blocked. AA-derived free radical metabolites were not 
detectable, and the DGLA-derived free radical metabolites increased significantly. 
Targeting D5D was able to decrease the pro-proliferative AA-derived free radical 
metabolites and simultaneously increased anti-proliferative DGLA-derived free radical 
metabolites. The combined treatment with DGLA and D5D inhibitors also increased the 
susceptibility of colon cancer cells to the chemotherapy drug 5-FU. In the D5D knockdown cells, 
the synergistic effects of DGLA and 5-FU are more significant for cell growth inhibition and 
cytotoxicity probably through the activation of the pro-apoptosis signaling pathway, e.g. p53. 
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In conclusion, our refined spin-trapping, LC/MS method along with SPE allowed us to 
detect and profile the free radicals in the same experimental setting in which the cell proliferation 
and cell cycle distribution could also be assessed. The opposite effects of DGLA and AA were 
associated with their exclusive free radical metabolites, rather than the PGEs. Suppressing D5D 
activity with D5D inhibitors or silencing the D5D expression by siRNA knockdown increased 
the content of DGLA-derived metabolites vs. AA-derived metabolites, thus inhibiting cell 
proliferation. Our data could be used to guide that DGLA is a beneficial ω-6 fatty acid, and an 
appropriate dietary intervention with a balanced ratio of cellular DGLA vs. AA could control 
colon cancer growth and progression. 
6.3. Discussion 
In order to investigate the association between cancer cell growth and free radicals 
generated from COX-catalyzed AA vs. DGLA peroxidation, we have for the first time 
characterized free radicals formed from HCA-7 colony 29 cells under normal growing conditions. 
Unlike the cell-PBS system (Figs. 2 and 3), in which large doses of POBN and PUFAs must be 
introduced to generate enough free radicals to be trapped and measured, our refined spin-
trapping experiment grew cells in a normal culture medium with a much lower concentration of 
POBN and PUFAs. In addition, instead of measuring ESR-active radical adducts, we actually 
measured a reduced form (hydroxylamines, Scheme 12) of the POBN adducts using LC/MS and 
LC/MS2, since hydroxylamines are much more stable redox forms of spin adducts than ESR-
active POBN adducts, especially in cell culture media. 
Our data suggested that in both COX-catalyzed DGLA and AA systems, 8 h and 12 h 
incubation seem to be the critical time points for free radical formation. The overall radical 
production in both peroxidation systems accumulated and approached a peak at about 12 h (Figs. 
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11 and 12). Considering POBN’s decreased trapping ability in culture media, in reality the 
radical production would be at a plateau after 12 h. The exclusive radical products, i.e., the m/z 
449 hydroxylamine as the reduced product of POBN/●C14H21O4, and the m/z 355 and m/z 325 
hydroxylamines as reduced products of POBN/●C8H15O3 and POBN/●C7H13O2, generated from 
COX-catalyzed AA and DGLA, respectively, started to show up at 8 h. The appearance of the 
hydroxylamine of m/z 449 (referring to ●C14H21O4) was much delayed (with much less produced 
as well) compared to the hydroxylamine of m/z 297 (referring to ●C6H13O). These two free 
radicals were expected to form at the same time points and in similar quantities since they are 
two co-metabolites fragmenting from the same product through β’-scission of PGF2-alkoxyl 
radicals as proposed elsewhere ([171], Scheme 10). The delayed appearance of m/z 449 
suggested that β’-scission could also occur on alkoxyl radicals derived from other types of PGs 
(PGH2 etc.) during COX-catalyzed AA peroxidation, instead of taking place at the PGF2 stage 
[171] in which the ●C=C radical, whose adduct was reduced to the m/z 449 hydroxylamine, was 
formed at the same time as the hydroxylamine of m/z 297. Again, β’-scission of a PGH1-type 
alkoxyl radical did not result in a ●C=C radical from DGLA ([173], Scheme 11) that could form 
●C14H21O4 as in AA peroxidation. 
In addition, the formation of a similar amount of the hydroxylamine of m/z 449 
(asterisked in Fig. 12B), as the hydroxylamines of m/z 355 and m/z 325 during COX-catalyzed 
peroxidation in cells treated by DGLA (12 h to 48 h), suggested that once formed (converted 
from DGLA by D5D), AA is a more favored substrate than DGLA for COX peroxidation. The 
formation peak of AA (from DGLA) was found at 8 h, although the concentration of DGLA was 
still much higher than AA (~5-6 fold, Fig. 14A). DGLA can be very effectively converted to AA; 
in turn both fatty acids competitively compete with each other for COX peroxidation. When cells 
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were incubated with AA, neither DGLA nor the DGLA-exclusive hydroxylamines of m/z 355 
and m/z 325 were detected. However, a considerable amount of m/z 449 was detected as early as 
8 h (Fig. 12B). 
The formation of the hydroxylamine of m/z 449 was generally associated with cell 
growth promotion. The sustained G2 phase cell cycle arrests were observed at the time points and 
the treatments in which the hydroxylamine of m/z 449 was barely measurable. For example, 
treatment of DGLA ~ 8 h was correlated with sustained G2 phase cell cycle arrest, while the 
combined treatment with DGLA and CP-24879 was correlated with sustained G2 phase cell cycle 
arrest within one day. The considerable abundance of the hydroxylamine of m/z 449 formed in 
cells after treatment with AA (8 h to 24 h, Fig. 11B) and the one-day DGLA treatment was 
correlated with a lack of any difference in G2 phase cell cycle distribution vs. the control. 
The two series of prostaglandins, PGs1 and PGs2, are well-known bioactive metabolites. 
Unlike PGs2s, which are generally viewed as pro-inflammatory and pro-carcinogenic PGs, 
PGs1s may possess anti-inflammatory and anti-cancer activity. However, some research studies 
of PGs on cell growth were considered somewhat unrealistic since much higher concentrations 
of PGs (particularly PGE1) were used than the concentrations that could form under normal cell 
culture conditions with fatty acid supplementation. It was reported that no more than 13 nM of 
PGEs could form from cultured cells without a fatty acid supplement [225-228]. The colon 
cancer cell (HT-29) growth could be stimulated by up to 45% by PGE2 at a range of 
concentrations from 0.5 µM to 10 µM [204]. At a similar concentration, PGE2 could also induce 
the expression of vascular endothelial growth factor, one of the major regulators for LS-174T 
cell angiogenesis, thus exerting pro-oncogenic actions in colorectal carcinogenesis [205]. On the 
other hand, a dose of PGE1 (30 µg/mL) was reported to inhibit the proliferation of HeLa cells 
135 
[185] and B16-F10 cells [70]. However, at lower doses (3.0 µg/mL), PGE1 could not inhibit cell 
proliferation, and even increased cell growth [185]. 
In our experiments, no more than 0.12 µM of PGEs (2×106 cells, Figs. 13 and 14) could 
actually be detected from the 100 µM PUFA treatments. However, when a range of 0.01 µM to 
1.0 µM PGE (~ 40 to 4000 fold higher than the PGEs per number of cells actually formed and 
measured in our experiments) was used to directly treat an HCA-7 colony with 29 cells (5×103 
cells) in our study, neither PGE1 nor PGE2 showed much effect on cell proliferation (Fig. 16). 
The inconsistent cell growth responses from the PUFA treatment (Table 3) and the PGEs used to 
directly treat cells (Fig. 16) suggested that rather than PGEs, free radicals and derivatives should 
be considered for their possible bioactivities. Interestingly, inhibited cell proliferation effects 
were observed from some of the tested free radical derivatives (Fig. 17) at the same 
concentrations as the PGEs in Fig. 16. The 8-hydroxyoctanoic acid (a derivative of ●C8H15O3 as 
an exclusive product from 8-C oxygenation in COX catalyzed DGLA peroxidation) showed 
some anti-proliferation effects, while another exclusive radical (●C7H13O2), a derivative from the 
8-C oxygenation of DGLA (heptanoic acid), did not affect cell proliferation. However, as the 
common and major product from 15-C oxygenation of both AA and DGLA, 1-hexanol (a 
derivative of ●C6H13O) was also correlated with inhibition of cell proliferation. 
Although no mechanism has so far been defined for the tested exclusive free radical 
derivatives, our results suggest that the radical metabolites derived from C-8 oxygenation of 
DGLA had an inhibitory effect on colon cancer cell growth. In addition, based on the time course 
of ●C=C radical generation and the related cell growth response (Fig. 11B and Table 3), it is 
logical to propose that ●C14H21O4 or its derivative corresponds with AA-promoted cell growth. A 
future goal is to study the effect of the ●C14H21O4 radical on cell growth by selecting or 
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synthesizing similar compounds and their derivatives to further explore COX peroxidation and 
AA bioactivity. Finally, the data in this study indicate that the novel free radicals as well as the 
related radical derivatives formed from COX peroxidation should be the new targets to be tested 
for their promoting or inhibiting effect on cancer cell growth. Understanding these radicals and 
their related radical reactions may allow us to advance our knowledge of the mechanisms of 
PUFA’s bioactivity in cancer biology. 
Three D5D inhibitors, e.g. sesamin, curcumin and CP-24879, were tested for their effect 
on suppressing D5D activity. Our data suggested that sesamin did not inhibit the conversion 
from DGLA to AA (Fig. 31), due to the poor solubility of sesamin in the cell culture medium. It 
was reported that sesamin inhibits the conversion of DGLA to AA with a Ki value of 155 µM in 
rat liver microsomes [215]. However, the highest final concentration that sesamin was able to 
achieve in the cell culture medium was 100 µM. were also tested; however, the excess sesamin 
formed crystals in the medium, e.g., 150 and 200 µM. 
In the case of curcumin, when the concentration of curcumin was varied from 5 to 50 µM 
in the curcumin-DGLA treatment, the lowest tested concentration (5 µM) did not affect D5D 
activity in cells, while it did inhibit PGEs biosynthesis (data not shown). These results suggest 
that curcumin is not a specific inhibitor for D5D. 
HCA-7 colony 29 was not sensitive to the chemotherapy drug 5-FU which is widely used 
in the treatment of colon cancer (Fig. 32). 5-FU induced anti-cancer effects and toxicity, 
including blocking DNA synthesis, inducing translational errors, and regulating the pro-
apoptosis genes p53, p21 and BAX [220-222]. Treatment with both CP-24879 and DGLA 
restored the anti-proliferative effect of DGLA, enhancing the DGLA-derived free radical 
metabolites that may have an anti-carcinogenic effect through causing DNA lesions and 
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activating tumor suppressors such as p53. Thus, the synergistic effects of DGLA with 5-FU 
might be due to their co-effect in causing DNA damage and activating pro-apoptosis genes. 
6.4. Future Directions 
6.4.1. Study of the association between the AA-derived exclusive free radical and colon cancer 
cell growth 
Among the four free radicals detected in cellular COX-catalyzed AA and DGLA 
peroxidation, the corresponding derivatives (in alcohol form) of ●C6H13O (the common free 
radical generated from both COX/AA and COX/DGLA peroxidation), ●C7H13O2 and ●C8H14O3 
(two exclusive free radicals from COX/DGLA) were used to test the effects of the parent free 
radicals on the growth of HCA-7 colony 29. Our results (Fig. 17) showed that the derivatives 
corresponding to one DGLA-derived exclusive free radical (8-hydroxyoctanoic acid) had the 
most inhibitory effect on cell growth. We also expected that the AA-derived exclusive free 
radical (●C14H21O4) should have a pro-proliferative effect. However, the derivative of this 
particular free radical was not commercially available, thus its role in regulating colon cancer 
cell growth is not yet clear. In the future, we will synthesis a compound structurally close to 
●C14H21O4 and test its effect on cell growth. The results will help us get a better understanding of 
the pro-tumorigenic role of AA in cancer biology. 
6.4.2. Study of the roles of AA-and DGLA-derived free radicals’ metabolism in signal 
transduction 
AA and DGLA have opposing effects on colon cancer cell growth. AA promotes cell 
proliferation while DGLA inhibits cell growth. Since our results showed that the PGEs at 
physiological concentration were not responsible for the contrasting effects of AA vs. DGLA, we 
concluded that that was associated with their exclusive free radical metabolites. The role of free 
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radicals in carcinogenesis is complex. Most cancer types have increased generation of free 
radicals, which can react with DNA, proteins and lipids in the body and cause extensive 
oxidative damage. The increased free radicals can lead to DNA strand breaks, point mutations 
and aberrant DNA crossing-linking, contributing to carcinogenesis by mutating proto-oncogenes 
and suppress tumor suppressor genes.  
We proposed that the newly characterized lipid mediators, AA-derived exclusive free 
radical metabolites and DGLA-derived exclusive free radical metabolites, may act through 
different mechanisms. AA-derived free radical metabolites may provoke the pro-tumorigenic 
pathway by activate the oncogene, e.g. epidermal growth factor receptor (EGFR) and Human 
Epidermal Growth Factor Receptor 2 (HER2); while DGLA-derived free radical metabolites 
may induce the pro-apoptotic pathway activate the apoptotic genes such as p53, p21 and BAX. 
The underlying mechanism will be further studied using the free radical derivatives. The results 
will make a clear association between the exclusive free radical metabolites from COX/AA and 
COX/DGLA and the contrasting bioactivities of AA vs. DGLA, and ultimately reveal the full 
role of COX/DGLA in cancer biology. 
6.4.3. Study of the inhibitory mechanism of D5D and search for new inhibitors 
D5D is the rate-limiting enzyme responsible for the biosynthesis of AA from DGLA. 
Suppressing D5D expression was seen to decrease cell proliferation. Accordingly, the content of 
AA and AA-derived pro-proliferative metabolites significantly decreased. In the meantime, 
DGLA and DGLA-derived anti-proliferative metabolites increased. Our results indicated that 
D5D is a potentially critical factor for tumorigenesis, and that targeting this enzyme could be 
effective in suppressing tumor growth. So far, there have been only very limited studies targeting 
D5D, and only a few inhibitors have been identified. None of them are very specific inhibitors 
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and the inhibitory mechanism was not clear. There is an increasing need for developing new 
D5D inhibitors and elucidating the mechanism of their action. An effective D5D inhibitor has a 
potential use as an anti-cancer drug to reduce cancer growth. 
6.4.4. Investigation of the effect of normal diet in a D5D knockout mouse model 
LA is the most abundant ω-6 PUFA in normal diet which was enriched with corn oil. LA 
was converted to DGLA first, and then covert to AA via D5D in our body. We found that inhibit 
the conversion form DGLA to AA in cells could attenuate colon cancer cell growth. Thus, the 
use of D5D inhibitors or D5D knockdown may be useful for study the role of DGLA in cancer 
development. An animal model could be used to investigate whether a supplement of ω-6 rich 
diet with D5D inhibitors could control tumor growth. Furthermore, a novel D5D knockout 
mouse model has recently been generated and characterized [229]. The D5D knockout resulted 
in the depletion of AA and massive enhancement of DGLA, which is consisted with the 
reduction in intestinal crypt proliferation [229]. Hence, in future studies, this AA-deficient 
mouse model will be used to investigate the mechanism of the protective and therapeutic role of 
DGLA in cancer development. 
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